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Schizophrenia is a debilitating neuropsychiatric disorder affecting approximately 1% of the global population. 
Unfortunately, antipsychotic treatment is ineffective in 50% of patients. The complex, heterogeneous and 
multifactorial nature of antipsychotic response presents a challenge with respect to elucidating the underlying 
mechanisms. Although genetic, neuroimaging, and clinical studies of antipsychotic response have shown 
much progress and potential, clinically actionable findings remain incredibly limited. This has hindered the 
progress toward more personalised treatment approaches, highlighting the necessity of implementing larger 
cohorts and more integrated approaches in antipsychotic treatment response studies. Genetic and brain 
structural variation has been widely implicated in antipsychotic response, and there is emerging evidence for 
a role of childhood trauma in differential treatment outcomes. Although imaging genetics and gene-
environment interaction (GxE) studies have begun to disentangle the underlying relationships between these 
variables, studies of this nature in antipsychotic response remain scarce. 
This study aimed to investigate the interplay between genetics, brain structure, childhood trauma, and 
antipsychotic response, using an integrative approach. This was done with a cohort of 103 first-episode 
schizophrenia patients treated with a long-acting injectable antipsychotic. Data was available for genome-wide 
variants, baseline regional brain volumes, childhood trauma severity, and treatment response. Candidate 
genes previously associated with both brain structure and antipsychotic response were selected from 
literature. From the available genotype data, variants within these genes were extracted and prioritised using 
a bioinformatics pipeline. Next, based on previous associations with antipsychotic response in literature, brain 
regions of interest (ROIs) were identified in the available neuroimaging data. Linear regression was used to 
conduct association analyses exploring the roles of ROIs in treatment response, childhood trauma in 
antipsychotic response/brain structure, imaging genetics in antipsychotic response, and imaging gene-
environment interactions in antipsychotic response. 
Ten genetic variants in CACNA1C, NRG1, and OXTR were significantly associated with antipsychotic 
response, after correction for multiple testing; ⍺=6.720×10-5 (additive model), ⍺=9.470×10-5 (genotypic model). 
Thirty-four significant associations with antipsychotic response were identified for GxE with childhood trauma 
and variants in CACNA1C, COMT, DISC1, DRD3, NRG1, and OXTR; ⍺=1.120×10-5 (additive model), 
⍺=1.578×10-5 (genotypic model). None of the remaining association analyses yielded significant results, so an 
unadjusted threshold (⍺=0.05) was considered for the exploratory observation of imaging genetic and imaging 
gene-environment interaction trends of interest. Five GxE significantly associated with improved response to 
antipsychotics showed tentative trends for increased putamen and hippocampal volumes. Conversely, six GxE 
significantly associated with poorer treatment response showed trends for reduced volumes of the caudate, 
cortex, pallidum, putamen, subcortical grey matter, and total grey matter. These findings highlighted a trend-
level positive correlation between baseline ROI volumes and treatment response (i.e. larger ROI volumes and 
improved antipsychotic response, and vice versa). 
The tentative positive correlation between ROI volumes and antipsychotic response in the context of GxE 
suggests a mechanism through which the relationship between brain structure and antipsychotic response 
may be mediated. Overall, the novel significant associations, and trends of interest, provide support for the 
utility of integrated research approaches to more effectively disentangle relationships between underlying 




Skisofrenie is 'n verswakkende neuropsigiatriese versteuring wat ongeveer 1% van die wêreldbevolking 
aantas. Ongelukkig is antipsigotiese behandeling oneffektief in ongeveer 50% van pasiënte. Die komplekse, 
heterogene en multifaktoriale aard van antipsigotiese reaksie bied 'n uitdaging met betrekking tot die toeligting 
van die onderliggende meganismes. Alhoewel genetiese, brein beelding en kliniese studies van antipsigotiese 
reaksie baie vooruitgang en potensiaal getoon het, bly kliniese werkbare bevindings ongelooflik beperk. Dit 
het die vordering na meer verpersoonlikte behandelingsbenaderings belemmer, en dit het die noodsaaklikheid 
van die implementering van groter kohorte en meer geïntegreerde benaderings in antipsigotiese 
behandelingsresponse uitgelig. Genetiese en breinstruktuurvariasie is bekend om betrokke te wees by 
antipsigotiese reaksie, en daar is opkomende bewyse vir die rol van kindertyd trauma in die differensiële 
uitkoms van behandeling. Alhoewel die beeldings genetika en gene-omgewing interaksie (GxE) studies begin 
het om die onderliggende verwantskappe tussen hierdie veranderlikes te ontrafel, bly studies van hierdie aard 
in antipsigotiese reaksie skaars. 
Hierdie studie mik om die wisselwerking tussen genetika, breinstruktuur, kindertyd trauma en antipsigotiese 
respons met behulp van 'n geïntegreerde benadering te ondersoek.  'n Groep van 103 pasiënte met die eerste 
episode van skisofrenie wat behandel is met 'n langwerkende inspuitbare antipsigotiese middle is gebruik vir 
hierdie studie. Data was beskikbaar vir genoomwye variante, basislyn streeksbreinvolumes, erns van kindertyd 
trauma en die respons van behandeling. Kandidaatgene wat voorheen met beide breinstruktuur en 
antipsigotiese respons geassosieer is, is uit die literatuur gekies. Uit die beskikbare genotipe-data is variante 
binne hierdie gene onttrek en geprioritiseer met behulp van 'n bioinformatika-pyplyn. Volgende, op grond van 
vorige assosiasies met antipsigotiese respons in die literatuur, is breinstreke van belang (ROIs) geïdentifiseer 
in die beskikbare brein beeld data. Lineêre regressie is gebruik om assosiasieanalises te doen om die rolle 
van ROIs in behandelingsrespons, kindertyd trauma in antipsigotiese reaksies/breinstruktuur te ondersoek, 
genetiese beeldvorming in antipsigotiese reaksies te ondersoek, en geen-omgewing interaksies in 
antipsigotiese respons te beeld. 
Tien genetiese variante in CACNA1C, NRG1 en OXTR het betekenisvolle assosiasie met antipsigotiese 
respons, na regstelling vir veelvoudige toetsing; ⍺=6.720×10-5 (toevoegingsmodel), ⍺=9.470×10-5 (genotipiese 
model). Vier-en-dertig betekenisvolle assosiasies met antipsigotiese respons is geïdentifiseer vir GxE met 
kindertyd trauma en variëteite in CACNA1C, COMT, DISC1, DRD3, NRG1 en OXTR; ⍺=1.120×10-5 
(aanvullende model), ⍺=1.578×10-5 (genotipiese model). Nie een van die oorblywende assosiasie-ontledings 
het beduidende resultate opgelewer nie, en 'n onaangepaste drempel (⍺=0,05) is oorweeg vir die 
ondersoekende waarneming van genetiese beeldvorming en interaksie-neigings in gene-omgewing interaksie. 
Vyf GxE wat aansienlik geassosieer is met 'n verbeterde reaksie op antipsigotiese middels, toon tentatiewe 
neigings vir verhoogde putamen en hippocampus volumes. Aan die ander kant het ses GxE wat aansienlik 
geassosieer is met 'n swakker behandelingsrespons, neigings getoon vir verminderde volumes van die 
caudaat, korteks, pallidum, putamen, subkortikale grysstof en totale grysstof. Hierdie bevindings het 'n 
positiewe korrelasie op tendensvlak uitgelig tussen basislyn ROI volumes en behandelingsrespons (d.w.s. 




Die tentatiewe positiewe korrelasie tussen ROI volumes en antipsigotiese respons in die konteks van GxE dui 
op 'n meganisme waardeur die verhouding tussen breinstruktuur en antipsigotiese respons bemiddel kan word. 
In die geheel bied die nuwe betekenisvolle assosiasies, en tendense van belang, die nut van geïntegreerde 
navorsingsbenaderings om die verhoudings tussen onderliggende molekulêre meganismes en heterogene 
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1.1. Schizophrenia  
 
1.1.1. Symptoms and diagnosis 
 
Schizophrenia is a chronic and debilitating neuropsychiatric disorder affecting more than 21 million individuals 
globally (Charlson et al., 2018). The majority of affected individuals reside in low- and middle-income countries, 
yet these countries represent the highest proportions of untreated individuals (Demyttenaere et al., 2004), with 
only 31% of affected individuals having access to treatment (Lora et al., 2012). Schizophrenia is a leading 
contributor to the global disease burden and was reported to be the 12th most disabling disorder among 310 
diseases and injuries according to the Global Burden of Disease study in 2016 (Charlson et al., 2018). In 
addition to the severe negative impact on patients’ quality of life, schizophrenia poses a tremendous 
socioeconomic burden (Chong et al., 2016). 
 
Schizophrenia is complex and pervasive, manifesting as a broad range of symptoms (Owen et al., 2016). The 
diverse psychopathology of the disorder includes core features which are categorised as positive or psychotic 
symptoms (i.e. delusions and hallucinations), negative symptoms (i.e. speech impairments and emotional 
withdrawal), and general or cognitive symptoms (i.e. mood and cognitive impairments; Owen et al., 2016). 
Several clinical measurement tools have been developed to quantify these symptoms, including the Positive 
and Negative Syndrome Scale (PANSS; Kay et al., 1987), the Scales for the Assessment of Negative and 
Positive Symptoms (SANS and SAPS; Andreasen, 1983; 1984), and the Brief Psychiatric Rating Scale (BPRS; 
Overall and Gorham, 1962). The most common of these is the PANSS, which is a 30-item rating scale divided 
into positive (seven items), negative (seven items) and general symptom domains (16 items), as shown in 
Table 1.1. Each of these items is scored according to severity from 1 (absent) to 7 (extreme), conferring a 
baseline score of 30, and a maximum possible score of 210. Aside from measuring symptom severity, the 
PANSS is widely used to monitor response to treatment (Levine et al., 2011).  
 
Table 1.1. The symptoms of schizophrenia as measured by the PANSS (Kay et al., 1987). 
 









Difficulty in abstract thinking 
Emotional withdrawal 
Lack of spontaneity  
Poor rapport 
Social withdrawal 
Stereotyped thinking  




Disturbance of volition 
Guilt feelings 
Lack of judgment and insight 
Mannerisms and posturing  
Motor retardation  
Poor attention  





Unusual thought content 
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The diagnosis of schizophrenia involves the assessment of patient-specific signs and symptoms as described 
by the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5; American Psychiatric 
Association, 2013). Here, it is proposed that for an individual to be diagnosed with schizophrenia, two or more 
of the following active-phase symptoms need to be present for a minimum of one month: delusions, 
hallucinations, disorganized speech, grossly disorganized or catatonic behaviour, and negative symptoms 
(American Psychiatric Association, 2013). Furthermore, at least one of these qualifying symptoms must be 
delusions, hallucinations, or disorganized speech (American Psychiatric Association, 2013). In addition to this 
a decreased level of functioning with regard to work, interpersonal relationships, or self-care, should be evident 
(American Psychiatric Association, 2013). Due to the heterogeneity in disorder manifestation, and the 
symptomatic overlap observed among schizophrenia and other psychiatric disorders (Figure 1.1), a 
comprehensive assessment of individuals is necessary to make a definitive diagnosis (Patel et al., 2014). This 
includes careful evaluation of illness duration, the timing of delusions or hallucinations, and severity of manic 
or depressive symptoms (Patel et al., 2014).  
 
 
Figure 1.1. A depiction of the overlapping symptoms in psychiatric disorders (Adam, 2013). Reproduced with permission 




Despite numerous clinical, pharmacological, physiological and brain imaging studies, there is a limited 
understanding of the underlying mechanisms contributing to schizophrenia pathophysiology. That said, there 
is a growing body of evidence suggesting that dysfunctional neurotransmission plays a role in schizophrenia, 
including either an excess or deficiency of dopamine, serotonin, and glutamate neurotransmitters (Patel et al., 
2014). Specifically, there is strong evidence implicating dysfunctional dopaminergic neurotransmission in the 
manifestation of positive symptoms (Owen et al., 2016; Patel et al., 2014). Furthermore, it has been suggested 
that abnormal glutamate signalling may contribute to the underlying pathophysiology of negative and cognitive 
symptoms (Owen et al., 2016; Patel et al., 2014). 
 
A multitude of neuroimaging studies have identified structural and functional brain alterations in individuals 
with schizophrenia, yet none of these abnormalities are exclusively related to this disorder (Linden, 2012). This 
is not unexpected considering the heterogeneity of schizophrenia psychopathology, and the symptomatic 
overlap with other psychiatric conditions (Owen et al., 2016). However, the lack of distinctive biological 
correlates of schizophrenia highlights a clear deficit with respect to the discovery of reliable biomarkers for 
illness diagnosis (Linden, 2012).  Despite these shortcomings, there has been some advancement in terms of 
relating aspects of schizophrenia to specific underlying neurobiology. For example, many studies have 
provided evidence for the involvement of the prefrontal cortex in cognitive deficits relating to working memory 
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and executive control (Barch and Ceaser, 2012; Lewis, 2012; Meyer-Lindenberg and Tost, 2014). Additionally, 
numerous studies have demonstrated reductions in grey matter, and abnormalities in white matter, in many 
areas of the brain (Haijma et al., 2013). In addition to the prefrontal cortex, brain regions repeatedly implicated 
in schizophrenia include, but are not limited to, the hippocampus, anterior cingulate cortex, temporal lobe, 
caudate nucleus, and thalamus (Haijma et al., 2013; Lieberman et al., 2018; Owen et al., 2016; Tamminga 
and Medoff, 2002). 
 
1.1.3. Risk factors and genetics 
 
Despite over a century of research, the aetiology of schizophrenia remains incompletely understood. However, 
it is widely accepted that this disorder may arise from a combination of multiple genetic and environmental 
influences (Stefansson et al., 2009). Environmental factors that have been implicated in increased risk for 
psychosis include prenatal exposures such as stress and infection, perinatal hypoxia, malnutrition, experience 
of traumatic events including childhood maltreatment, male gender, high paternal age, urbanicity, poverty, 
lower socio-economic class, and cannabis use, among others (Bernardo et al., 2013; Clarke et al., 2012). 
Aside from environmental contributors, genetic predisposition remains the strongest risk factor, with the most 
reliable predictor for the development of schizophrenia being a family history of the disorder (Gareeva and 
Khusnutdinova, 2018). 
 
Considering that schizophrenia is the most heritable of the psychiatric disorders, with approximately 81% 
heritability, it is not surprising that there is a wealth of studies aimed at better characterising the genetic 
underpinnings of the disorder (Gareeva and Khusnutdinova, 2018). Despite this, the exact genetic elements 
continue to elude scientists due to the non-Mendelian nature of schizophrenia. However, extensive research 
has unveiled numerous important findings that have contributed to our understanding of disorder risk (Gareeva 
and Khusnutdinova, 2018). These findings have arisen from the earlier linkage studies in families, as well as 
association studies that made use of candidate gene approaches, followed by the implementation of 
hypothesis-free genome-wide association studies (GWAS), genome-wide copy number variation (CNV) 
studies, and whole genome/ exome sequencing studies (WGES; Drögemöller, 2013). These studies have 
shown that disorder risk can be attributed to numerous common genetic variants each contributing very small 
effects in a cumulative fashion, and by a small number of highly penetrant variants with larger effects 
(Henriksen et al., 2017). Overall, the genetic architecture of schizophrenia has proven to be highly complex, 
heterogeneous, and polygenic (Henriksen et al., 2017). In fact, more recently it has been suggested that an 
omnigenic model may be more appropriate to explain the underlying mechanisms of the disorder (Boyle et al., 
2017). This means that all genes expressed in the relevant tissue (e.g. the brain in schizophrenia) may 
contribute to disorder risk (Boyle et al., 2017). This may contribute to the so-called “missing heritability” 
observed, i.e. all significant GWAS hits considered together only account for a modest fraction of the predicted 
genetic variance (Boyle et al., 2017). To date, over 100 genetic loci have been associated with schizophrenia 
(Henriksen et al., 2017; Ripke et al., 2014). However, important to note here is that statistical associations do 
not necessarily imply causal pathways (Henriksen et al., 2017). Furthermore, there is increasing evidence for 
genetic overlap among numerous psychiatric disorders, so many genetic associations identified are not 
specific to schizophrenia (Henriksen et al., 2017; O’Connell et al., 2018). Overall, extensive research is still 
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required to elucidate the aetiology of schizophrenia, and to identify robust biomarkers to enable reliable 
disorder diagnosis (Henriksen et al., 2017).   
 




The treatment of schizophrenia was revolutionised in the 1950s with the serendipitous discovery of the 
antipsychotic drug chlorpromazine (Owen et al., 2016). This led to the development of over 60 different 
antipsychotics, all of which include blockade of the dopamine D2 receptor in their mechanism of action 
(McCutcheon et al., 2019; Tandon, 2011). To this day, antipsychotics remain the only available therapeutic 
agents for the effective treatment of schizophrenia (McCutcheon et al., 2019; Tandon et al., 2010). These 
drugs are traditionally divided into two general categories: the earlier, typical or first-generation antipsychotics 
(FGAs), and atypical or second-generation antipsychotics (SGAs) – the first of which was clozapine that was 
introduced in the late 1960s (Lally and MacCabe, 2015; Tandon, 2011). Although the precise mechanism of 
action of antipsychotic drugs has not been fully characterised, SGAs have a wider range of neurochemical 
targets. In addition to the dopaminergic pathway, these drugs may also involve serotonergic, glutamatergic 
and alpha-adrenergic systems (Correll, 2010; Meltzer, 2013). FGAs commonly involve high dopamine 
antagonism and low serotonin antagonism, and SGAs can be divided into those that demonstrate moderate-
to-high dopamine antagonism along with high serotonin antagonism, and those that have low dopamine 
antagonism along with high serotonin antagonism (Patel et al., 2014). 
 
The most distinguishing characteristic between FGAs and SGAs is the differential incidence of adverse drugs 
reactions (ADRs; Lally and MacCabe, 2015; Meltzer, 2013). Antipsychotics can induce a diverse range of 
ADRs that are severe, and can be long-lasting (Kaar et al., 2019; Tandon, 2011). Treatment with FGAs is most 
often accompanied by motor abnormalities (Meltzer, 2013; Tandon et al., 2010). These include extrapyramidal 
side effects (EPS) which are either reversible (i.e. parkinsonism), or chronic (i.e. tardive dyskinesia; Tandon 
et al., 2010). On the other hand, SGAs are predominantly associated with weight gain and other metabolic 
adverse effects, despite the significantly lower risk of developing EPS (Tandon et al., 2010). 
 
The treatment of schizophrenia is complicated, and each patient requires careful monitoring for the most 
appropriate decisions to be made with regard to the choice and dosage of drugs (Drögemöller, 2013; Pouget 
et al., 2014). In the case of inadequate response to first line treatment, either the dosage can be increased, or 
an alternate antipsychotic can be administered (Drögemöller, 2013). Based on consensus recommendations 
by experts, before altering the treatment, first line treatment should be continued for three to six weeks in the 
case of little to no response, and for four to 10 weeks if partial response is observed (Buckley, 2008). 
Antipsychotics are generally successful in the treatment of positive symptoms of schizophrenia, yet are 
minimally effective for reducing negative and cognitive symptoms. There is no significant evidence for clear 
differences in the efficacy profiles between FGAs and SGAs (Lally and MacCabe, 2015), with the exception of 
clozapine, which demonstrates clear superiority in efficacy and response in treatment refractory patients, along 
with reductions of suicide (Kane et al., 1988; Meltzer et al., 2003; Shah et al., 2019). However, clozapine use 
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may result in agranulocytosis, a severe and potentially life-threatening ADR, therefore clozapine is not 
administered in the first line of treatment in most cases (Chowdhury et al., 2011; McCutcheon et al., 2019). 
 
1.2.2. Treatment response 
 
The goal of antipsychotic treatment is to achieve and maintain remission without relapse. Reviews of treatment 
outcomes in first-episode schizophrenia (FES) patients concluded that up to 22% of patients may achieve 
remission within the first five years without relapse (Altamura et al., 2007; Carbon and Correll, 2014; Ram et 
al., 1992). Unfortunately, 80% to 85% of individuals experience relapse after an initial period of favourable 
response during the first five years of illness (Altamura et al., 2007; Carbon and Correll, 2014; Lang et al., 
2013; Robinson et al., 1999). Furthermore, approximately 50% of treated patients are minimally- or non-
responsive (treatment refractory; Lohoff and Ferraro, 2010). With the observation of the vast variability in 
response to antipsychotics between individuals with schizophrenia, it quickly became apparent that treatment 
response is a highly complex and heterogeneous trait, much like the disorder itself (Drögemöller, 2013). 
 
Treatment regiments have not been standardised, although response is commonly monitored and evaluated 
using symptom severity scales (Leucht et al., 2008). For instance, overall improvement can be determined by 
comparing BPRS or PANSS total scores before and after treatment (Emsley et al., 2006; Remington et al., 
2010). Earlier studies of treatment response considered a less than 20% improvement in BPRS/ PANSS 
scores as an indication of non-response (Emsley et al., 2006). Improvement in specific symptom domains can 
be evaluated by comparing pre- and post-treatment SANS scores, SAPS scores, or PANSS positive, negative, 
and general scores (Remington et al., 2010). The lack of a standardised definition for antipsychotic treatment 
outcome has drastically hindered cross-study comparison. In 2005, the Remission in Schizophrenia Working 
Group recognised this issue and came to a consensus on criteria to define remission across the SAPS, SANS, 
PANSS, and BPRS (Andreasen et al., 2005). According to these criteria, remission is defined by simultaneous 
ratings of mild, or less, for a specific set of symptoms, for a period of six months (Andreasen et al., 2005). The 
proposed symptom items for the PANSS are delusions, unusual thought content, hallucinatory behaviour, 
conceptual disorganisation, mannerisms/ posturing, blunted affect, social withdrawal, and lack of spontaneity 
(Andreasen et al., 2005). Related items were selected across the SAPS, SANS, and BPRS for evaluating 
overall remission (Andreasen et al., 2005). On the other end of the response spectrum, patients are considered 
to be treatment refractory if there is a lack of improvement in symptoms after successive treatments with two 
different antipsychotics for at least six weeks each, with particular reference to positive symptoms (Suzuki et 
al., 2012). In these cases, clozapine is usually prescribed, as it has proven to be the most effective drug for 
the treatment of refractory individuals (Chowdhury et al., 2011; Shah et al., 2019). Clozapine use is therefore 
typically regarded as an indication of treatment resistance (Shah et al., 2019). An overview of concepts (i.e. 
remission, relapse, and refractoriness) that are central to the consideration of treatment response outcomes 
is outlined in Figure 1.2 (Drögemöller, 2013). 
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Figure 1.2. An overview of the core features of antipsychotic treatment response (Drögemöller, 2013). Reproduced from 
the unpublished doctoral dissertation by Drögemöller (2013). 
 
It is widely conceded that effective treatment in the early stages of the illness is essential for optimising long-
term treatment outcome (Amminger et al., 2011; Chiliza et al., 2015). However, this is difficult to achieve as 
schizophrenia is treated on a trial-and-error basis, which means it may take months to find the right 
antipsychotic (Yoshida and Müller, 2018; Zhang and Malhotra, 2018). The early identification of poor and non-
responders to first-line treatments would enable the expeditious implementation of alternative interventions 
that are more likely to succeed, thereby preventing accruing morbidity (Chiliza et al., 2015; Emsley et al., 
2008). The discovery of reliable predictors of treatment outcome therefore remains a necessity (Emsley et al., 
2008; Zhang and Malhotra, 2018). Despite a wealth of large, longitudinal studies dedicated to prognostic 
factors, very few of the identified outcome predictors have the potential for clinical utility (Carbon and Correll, 
2014). Actionable risk factors associated with poor antipsychotic treatment outcomes include longer duration 
of untreated illness, treatment nonadherence, and lack of early antipsychotic response (Carbon and Correll, 
2014; Yildiz et al., 2015). With regard to the first of these, a shorter duration of untreated psychosis (DUP) has 
been correlated with a shorter time to remission, stable remission, fewer positive symptoms, and better social 
functioning (Emsley et al., 2008). Additionally, FES patients have demonstrated 57-67% improved response 
compared to chronic, multi-episode patients (Emsley et al., 2013a). The inverse relationship between DUP 
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and favourable treatment outcome therefore highlights the importance of early intervention (Emsley et al., 
2013a). With regard to treatment adherence, patients whom discontinue their medication have been 
associated with a five-fold increased risk for relapse, compared to adherent patients (Emsley et al., 2013b; 
Robinson et al., 2004). An effective strategy to combat this problem has been the introduction of long-acting 
injectable (LAI) antipsychotics in the place of oral medication (Nasrallah, 2007). Lastly, early treatment 
response (within the first two weeks) is predictive of favourable outcomes in the long-term, whereas lack of 
symptom reduction during early stages of treatment is indicative of treatment refractoriness (Emsley et al., 
2008). Other predictors of non-response include the male sex, earlier age of onset, poor premorbid adjustment, 
increased severity of symptoms at baseline, and a lack of insight (Carbon and Correll, 2014; Chiliza et al., 
2015). 
 
Overall, the discovery and implementation of antipsychotics for the treatment of schizophrenia has led to 
radical improvements in the quality of life for countless patients. However, considering the severe ADRs 
experienced in ~70% of patients (Kahn et al., 2008; Mas et al., 2012), persistence of negative and cognitive 
symptoms despite continuous treatment, and the high percentage of non-responders, there is a clear need for 
the discovery of new drug targets and the development of novel treatments for schizophrenia. Furthermore, 
the heterogeneity observed in antipsychotic treatment response profiles among patients precludes an option 
for standardised treatment designs for all individuals. Therefore, in addition to implementing reliable clinical 
predictors of treatment outcome, this emphasises the necessity for determining the underlying biological 
mechanisms of treatment response in order to develop more individualised treatment strategies. 
 




Pharmacogenetics refers to the study of genetic variation contributing to differential drug responses between 
individuals (Cacabelos et al., 2011; Malhotra et al., 2012). Pharmacogenomics is an expansion of this concept, 
referring to genetic variation across the entire genome potentially influencing drug response (Cacabelos et al., 
2011). With respect to schizophrenia, antipsychotic treatment response is regarded as a complex, 
multifactorial trait, with a strong genetic basis (Arranz et al., 2011). It has been widely suggested that differential 
treatment outcomes arise as a result of numerous common variants across the entire genome, each 
contributing small effect sizes (Arranz et al., 2011). Antipsychotic pharmacogenomics aims to elucidate the 
genetic underpinnings of differential antipsychotic treatment outcomes in schizophrenia, with the goal of 
maximising drug efficacy and minimising drug toxicity (Weinshilboum and Wang, 2004; Zhang and Malhotra, 
2018). 
 
The first antipsychotic pharmacogenetic studies of schizophrenia made use of candidate gene approaches to 
investigate treatment outcomes (Arranz et al., 2011). Candidate genes were selected based on their potential 
involvement in two pharmacological processes, namely pharmacodynamics and pharmacokinetics (Pouget et 
al., 2014). Pharmacodynamic mechanisms involve the interaction between the drug, transporters, and the 
receptors or proteins that serve as drug targets (Sandritter et al., 2017; Wijesinghe, 2016). Simply put, 
pharmacodynamics refers to the effect of the drug on the body. On the other hand, pharmacokinetic processes 
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can be simply referred to as the effect of the body on the drug, and involve the absorption, distribution, 
metabolism, and elimination of the drug (Sandritter et al., 2017; Wijesinghe, 2016). 
 
With respect to pharmacodynamic mechanisms, candidate gene studies have largely focussed on 
dopaminergic and serotonergic neurotransmitter systems (Brandl et al., 2014; Pouget et al., 2014; Yoshida 
and Müller, 2018). This is expected considering the central role of these systems in antipsychotic mechanism 
of action. Strong evidence has accumulated for the involvement of variation in genes encoding the dopamine 
receptors (DRD2, DRD3, and DRD4 in particular) and serotonin receptors (HTR1A and HTR2A) in differential 
treatment outcomes, including drug efficacy and occurrence of ADRs (Brandl et al., 2014; Pouget et al., 2014; 
Zhang and Malhotra, 2018). While a number of antipsychotics act on other systems such as adrenergic, 
muscarinic, and histaminic systems (Correll, 2010), pharmacogenetic studies of these systems have produced 
inconsistent results, or lack independent replication (Pouget et al., 2014). Considering candidate gene studies 
of pharmacokinetic processes, genes encoding the cytochrome P450 (CYP) enzyme family have received the 
most attention (Brandl et al., 2014; Pouget et al., 2014). The CYP enzymes are the most prominent family of 
drug-metabolising enzymes in humans, and variation within CYP genes influences the metabolism of 
antipsychotic drugs (Arranz et al., 2011; Cacabelos et al., 2011). The differences in metabolism profiles of 
individuals based on specific CYP genotypes range from poor to ultra-rapid metabolisers, with intermediate 
and normal metabolisers between (Cacabelos et al., 2011). Individuals who are considered poor metabolisers 
have an increased risk for drug toxicity and developing ADRs, whereas ultra-rapid metabolisers require higher 
drug dosages to achieve the desired efficacy (Kennedy and Voudouris, 2013). Antipsychotics are 
predominantly metabolised by CYP1A2, CYP2D6, and CYP2A4, with CYP2C19 influencing the metabolism of 
clozapine in particular (Pouget et al., 2014). Variation in other CYP genes, such as CYP3A4 and CYP3A5, has 
also been implicated in antipsychotic treatment outcome (Zandi and Judy, 2010). 
 
Early studies of antipsychotic response provided insight with respect to the involvement of numerous candidate 
genes in treatment outcomes (Yoshida and Müller, 2018). However, none of these findings were sufficiently 
informative to improve treatment strategies and overall patient outcome, which emphasises the complexity of 
treatment response. This highlights a necessity for investigating genetic variation in genes beyond those 
already hypothesised to contribute to drug response via characterised pharmacodynamic and pharmacokinetic 
processes. The implementation of GWAS for the investigation of antipsychotic treatment outcomes aimed to 
address this. However, only a handful of antipsychotic response GWAS have been conducted, the majority of 
which have been hindered by their statistical underpowering owing to limited sample sizes (Allen and Bishop, 
2019). Furthermore, there is an overall deficit in the reproducibility of significant findings from these studies. 
For example, a recent systematic review of GWAS in antipsychotic response reported the identification of 15 
genome-wide significant loci across 10 studies, seven of which were replicated in at least one study (Allen and 
Bishop, 2019). However, only three specific variants were replicated (Allen and Bishop, 2019). While the 
replication of significant loci may enable further research and contribute to the identification of novel gene 
targets, the development of pharmacogenetic tests requires extensive replication of specific variants (Allen 
and Bishop, 2019). In addition to this, the majority of significant GWAS results are located in noncoding regions 
of the genome (Barešić et al., 2019; Ovenden et al., 2017). These findings often lack sufficient biological 
interpretation, as most studies tend to focus on the function of adjacent genes without investigating a potential 
regulatory role of these variants (Barešić et al., 2019; Ovenden et al., 2017). Coupled to this, there has been 
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minimal functional validation of significant variants identified in noncoding regions, as coding variants have 
traditionally proven more amenable to functional analyses (Ovenden et al., 2017).  
 
Additional factors that have further hindered cross-study comparisons and replication of findings include 
varying study designs and differing cohort characteristics (Arranz et al., 2011). For example, variability across 
cohorts with respect to ethnicity, illness characteristics, type of antipsychotic, treatment duration and 
adherence, and outcome phenotypes, have restricted interpretation of research findings (Arranz et al., 2011). 
Overall, numerous genetic variants have been associated with antipsychotic response in the treatment of 
schizophrenia. However, further well-designed investigations in large, well-characterised cohorts are required 
to facilitate the progress toward identifying clinically actionable results (Arranz et al., 2011; Yoshida and Müller, 
2018). 
 
1.3.2. The South African context 
 
South Africa represents a wide range of population groups, including the more homogeneous Afrikaans 
speaking Caucasians, the ancient and genetically diverse African populations, and the highly admixed South 
African Mixed-Ancestry population that has ancestry contributions from African, Asian, and European 
populations (Daya et al., 2013; Warnich et al., 2011). In the context of genomic research, these populations 
have unique challenges and advantages, owing to the fact that they harbour the greatest genetic diversity in 
the world (Warnich et al., 2011). Despite a wealth of antipsychotic pharmacogenomic studies, the vast majority 
has been conducted in developed countries with individuals of European and Asian descent. African 
populations therefore remain drastically underrepresented in pharmacogenomic research (Drögemöller et al., 
2014). The consequences of this disparity can be demonstrated with the previously discussed CYP 
metaboliser genes as an example (section 1.3.1). A study by Gaedigk and Coetsee (2008) showed that South 
African Mixed-Ancestry individuals have a unique CYP allele composition and a distinct frequency distribution. 
This was illustrated with the discovery of two novel CYP2D6 alleles, as well as the vastly different allele 
frequencies in characterised CYP variants compared to individuals of European descent (Gaedigk and 
Coetsee, 2008). Another study of CYP variation by Mitchell et al. (2011) identified 26 novel CYP2C9 alleles in 
a cohort of black South Africans. Considering the role of CYP genes in the metabolism of antipsychotic and 
other drugs, fluctuations in enzyme activity arising from differences in CYP allele composition and frequencies 
among population groups has implications in variable treatment response.  
 
With specific reference to antipsychotic pharmacogenomics, Drögemöller et al. (2014) performed exome 
sequencing on 11 FES patients demonstrating phenotypic extremes for antipsychotic treatment response, i.e. 
5 responders and 6 non-responders. The genetic variation was then compared between the two groups to 
prioritise variants for genotyping in a larger FES cohort (N = 103) and an additional Xhosa schizophrenia cohort 
(N = 222). Examination of coding variation uncovered loss-of-function variants, most of which were rare or 
previously unidentified in Asian and European populations (Drögemöller et al., 2014). Furthermore, a potential 
role of rare loss-of-function variation in treatment response was highlighted, emphasising the importance of 
conducting population-specific pharmacogenomic research (Drögemöller et al., 2014). 
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Overall, these studies emphasise the importance of conducting pharmacogenomic research in a South African 
setting, as genetic associations and clinically actionable findings from more homogeneous populations may 
not be applicable (Sirugo et al., 2019). Furthermore, the increased levels of genetic diversity and decreased 
levels of linkage disequilibrium (LD) in South African populations provide a unique and rich resource for better 
disentangling the genetic underpinnings of complex traits (Ramsay, 2012). This highlights an opportunity to 
gain novel insight into antipsychotic pharmacogenomics which will not only be beneficial in the progression 
toward population-specific treatment regimens in a South African context, but in other, less genetically diverse 
population groups as well. 
 




Childhood maltreatment can be defined as acts of commission or omission resulting in harm, potential harm, 
or threat of harm by a parent or caregiver (Sideli et al., 2012). This definition encompasses severe adverse 
experiences such as physical or emotional abuse and neglect, as well as sexual abuse (Kessler et al., 2010). 
Childhood maltreatment is a substantial problem worldwide, with estimates suggesting that about a third of the 
general population may be affected (Kessler et al., 2010). Evidence exists demonstrating that the effects of 
traumatic experiences during early life may carry through to adulthood, correlating to a range of negative social 
outcomes including higher criminality, a lower level of education, and decreased overall health and well-being 
(Varese et al., 2012). Experiences of child maltreatment are highly prevalent among psychosis patients, and 
have been associated with as much as a three-fold increased risk for developing psychosis (Varese et al., 
2012).  
 
Although numerous lines of evidence indicate that childhood trauma may predict an increased risk for the 
development of psychosis, less is known about the way early life adversities may influence antipsychotic 
treatment outcomes (Misiak and Frydecka, 2016). However, there is emerging evidence to support a potential 
role of childhood trauma in treatment response. For example, a study by Hassan and De Luca (2015) reported 
more frequent experiences of emotional abuse, emotional neglect, and sexual abuse, in treatment refractory 
patients compared to antipsychotic responders. Additionally, in 2016, Misiak and Frydecka found a link 
between childhood trauma and early antipsychotic treatment response, suggesting that emotional abuse in 
particular may contribute to early non-response to treatment in first-episode patients. These two studies 
therefore show a trend for less favourable treatment response in patients with a self-reported history of 
childhood trauma. Although, to date, these are the only two studies addressing this issue in schizophrenia, 
there is evidence for a link between childhood trauma and treatment response in depression. A meta-analysis 
of 10 clinical trials (3098 participants) revealed that experiences of childhood maltreatment unequivocally 
predict unfavourable treatment outcome in depression (Nanni et al., 2012). This trend was supported more 
recently in a large antidepressant response study (1008 participants) of major depression, with childhood 
trauma predicting poor treatment response (Williams et al., 2016). 
 
Childhood trauma is usually assessed in terms of abuse (physical, sexual, emotional/ psychological) and 
neglect (physical, emotional/ psychological; Hovdestad et al., 2015). These assessments are done with the 
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use of self-report questionnaires and semi-structured interviews. The Childhood Trauma Questionnaire (CTQ; 
Bernstein et al., 1997) is one of the most frequently used self-report tools in childhood trauma research (Viola 
et al., 2016). The CTQ comprises 28 items to measure the severity of the aforementioned maltreatment 
categories, i.e. emotional, physical, and sexual abuse, and emotional and physical neglect. A three-item 
minimisation/ denial scale is also incorporated to indicate the potential underreporting of maltreatment. Other 
self-report measurement tools, as recently reviewed by Popovic et al. (2019), include the Personal Safety 
Questionnaire (PSQ) which is based on the Conflicts Tactics Scales (Straus and Douglas, 2004), the 
Childhood Sexual Assaults Scale (CSAS; Koss et al., 1987), the Early Trauma Inventory Self Report (ETI-SR; 
Bremner et al., 2007), the Traumatic Life Events Questionnaire (TLEQ; Kubany et al., 2000), and the Adverse 
Childhood Experiences (ACE) questionnaire (Felitti et al., 1998). Semi-structured interviews include the Early 
Trauma Inventory (Bremner et al., 2000) and the Children’s Life Events Scale (CLES), which is an expansion 
of the Source of Stress Inventory (Chandler, 1981). 
 
1.4.2. Gene-environment interactions (GxE) 
 
Although a history of childhood trauma appears to substantially increase the risk for psychosis, childhood 
maltreatment is by no means causal, as it is neither necessary, nor sufficient, to give rise to the onset of 
psychosis (Misiak et al., 2017). Considering the evidence for the substantial heritability of schizophrenia, it is 
probable that the relationship between childhood trauma and schizophrenia is mediated by gene-environment 
interactions (GxE; Misiak et al., 2017). In other words, the effect of childhood trauma on disorder manifestation 
is contingent on differences in genetic factors, and vice versa (Assary et al., 2018). This is supported by several 
studies of the risk or clinical manifestation of schizophrenia, whereby the effects of childhood trauma appear 
to be moderated by differences in genotype for candidate variants (Alemany et al., 2015; Collip et al., 2013; 
Green et al., 2014; 2015; Modinos et al., 2013). One example is the study by Green et al. (2014), where COMT 
Val/Met heterozygotes with a history of physical abuse had more severe positive symptoms, and more severe 
negative symptoms were found in COMT Val/Met heterozygotes that had experienced emotional neglect. 
Additionally, the same study identified a significant interaction whereby emotional neglect was associated with 
increased severity of negative symptoms in COMT Met/Met homozygotes (Green et al., 2014). There is also 
emerging evidence for the role of GxE with childhood trauma in differential response to antipsychotics in 
schizophrenia. McGregor et al. (2018) reported that associations between MMP9 variants and antipsychotic 
treatment response were modified by childhood trauma. For example, the homozygous recessive (AA) 
genotype for MMP9 rs13925 conferred improved response to antipsychotics when childhood trauma was not 
considered (McGregor et al., 2018). However, when the severity of childhood trauma was factored in as an 
interacting variable, poor response to antipsychotic treatment was observed in these individuals in the 
presence of emotional neglect (McGregor et al., 2018). These findings lend support to the role of childhood 
trauma in antipsychotic treatment response, possibly via interactions with genetic factors. Although only one 
such study could be identified for treatment response in schizophrenia, this type of research has shown 
promise for treatment response in depression. Here, studies have shown that interactions between early life 
adversity and polymorphisms in serotonergic, glutamatergic, and GABAergic genes, influence antidepressant 
drug response (Pu et al., 2013; Xu et al., 2012). Altogether, these findings necessitate further investigation of 
GxE with childhood trauma in antipsychotic treatment response, as potentially crucial mechanisms underlying 
treatment outcomes could be uncovered. 
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The complex interaction between genetic and environmental factors is mediated by epigenetic mechanisms 
(Petronis, 2010). These include DNA methylation, histone modifications, and regulation brought about by 
microRNAs (miRNAs) and other noncoding RNA molecules (Kuehner et al., 2019). These mechanisms bring 
about heritable alterations in gene expression and regulation, without modifying the DNA sequence itself 
(Kuehner et al., 2019). Epigenetic regulation is crucial in neurodevelopment, where it has implications in brain 
growth, neuronal and synaptic plasticity, learning, and memory (Fagiolini et al., 2009; Ovenden et al., 2018). 
For these reasons, it is not surprising that epigenetic dysregulation has been implicated in the development of 
neuropsychiatric disorders, including schizophrenia (reviewed by Ptak and Petronis, 2010). Although in its 
infancy, pharmacoepigenomics aims to characterise the influence of epigenetic alterations on differential drug 
response and holds much potential to explain the missing heritability observed in antipsychotic treatment 
outcomes (Ovenden et al., 2018; Zhang and Malhotra, 2018).  
 
Although current research pertaining to childhood trauma in antipsychotic treatment response (including GxE 
and epigenetic alterations) is limited, there is emerging evidence to support the role of childhood trauma as a 
relevant modifier of treatment outcomes in schizophrenia (McGregor et al., 2018). The importance of pursuing 
this line of research is highlighted by the opportunity it presents for additional therapeutic considerations 
(Gianfrancesco et al., 2019). Firstly, considering the potential contributions of childhood trauma to differential 
treatment response phenotypes via interactions with genetic elements, it has been suggested that trauma-
exposed individuals may represent a biologically distinct subtype of patients that require different therapeutic 
interventions to patients not exposed to severe trauma (Teicher and Samson, 2013). Secondly, awareness of 
the effects of childhood trauma will support a movement toward trauma-informed treatment approaches and 
psychological therapy-based interventions (Gianfrancesco et al., 2019). Overall, better characterising the role 
of childhood trauma in antipsychotic treatment response along with the underlying mechanisms mediating this 
relationship may help to guide and improve treatment strategies in the future based on multifaceted patient 
profiles, including information on genetic, epigenetic, and environmental elements.  
 




Existing neuroimaging methods can broadly be divided into those that examine structural aspects and those 
that examine functional aspects of the brain (Kovelman, 2012). Structural imaging methods include computed 
tomography (CT), structural magnetic resonance imaging (MRI) and diffusion tensor imaging (DTI); functional 
imaging methods include functional MRI (fMRI), arterial spin labelling (ASL), positron emission tomography 
(PET), and single photon emission computed tomography (SPECT; Kovelman, 2012). Imaging genetics is a 
relatively new and rapidly progressing field that integrates neuroimaging and genetic data to investigate the 
genetic architecture of varying brain phenotypes, most frequently based on MRI and fMRI measurements 
(Mufford et al., 2017; Turner et al., 2006). Although this in itself encompasses an extensive range of research, 
one of the most important applications of the field is the study of neuropsychiatric disorders (Hashimoto et al., 
2015). The implementation of imaging genetics approaches for the investigation of neuropsychiatric disorders 
is based on the premise that variations in brain structure and function are so-called “intermediate phenotypes”, 
or endophenotypes, that lie closer in the biological trajectory of genes than the psychiatric disorder itself 
Stellenbosch University https://scholar.sun.ac.za
CHAPTER 1                                                                                                                   LITERATURE REVIEW 
13 
 
(Meyer-Lindenberg and Weinberger, 2006). An endophenotype can be broadly defined as a measurable and 
heritable trait that is genetically correlated with a disorder (Gottesman and Gould, 2003). Considering that 
differential phenotypic definitions may result in different genetic associations, the subjective nature of complex 
psychiatric disorder diagnoses may be one of the factors hindering the effective elucidation of these disorders 
(Greenwood et al., 2019). As the measurement of brain imaging phenotypes is more objective, these 
endophenotypes may serve as biological proxies for disorder manifestation, potentially accelerating the 
discovery of important disorder risk variants (Greenwood et al., 2019). Aside from the potential contribution to 
the discovery of genetic variants implicated in psychiatric disorders, imaging genetics will likely provide critical 
insight into the neurobiological mechanisms underlying these complex disorders (Figure 1.3; Greenwood et 
al., 2019; Iacono et al., 2014). Overall, this research aims to improve the understanding of psychiatric disorders 
in terms of symptoms and aetiology, to prognosis and treatment, with the goal of identifying reliable biomarkers 
and improving diagnostic assessments and treatment strategies (Mufford et al., 2017).  
 
 
Figure 1.3. Two applications of imaging genetics in the context of psychiatric disorder research (Hashimoto et al., 2015). 
Reproduced from Hashimoto et al. (2015), as per the following license:  
https://creativecommons.org/licenses/by-nc/3.0/legalcode. 
 
The field of imaging genetics was first introduced approximately 20 years ago with twin and family studies 
aiming to calculate the heritability estimates for neuroimaging-based measurements such as brain volume 
(Bartley et al., 1997), shape (Ge et al., 2016; Roshchupkin et al., 2016), activity (Glahn et al., 2010), 
connectivity (Jahanshad et al., 2013), and white matter microstructure (Patel et al., 2010). These studies 
confirmed that certain brain measures derived from non-invasive scans have a moderate to strong genetic 
basis, which is an important property in the selection of appropriate endophenotypes (Gottesman and Gould, 
2003). Early imaging genetics studies of psychiatric disorders made use of hypothesis-driven, candidate gene 
approaches to investigate associations between well-characterised genetic variants and brain structural or 
functional phenotypes (Mufford et al., 2017). Toward the end of the first decade of imaging genetics research 
in psychiatric disorders, methodologies expanded from candidate gene approaches to investigations of gene-
gene interactions (Figure 1.4; Mufford et al., 2017). From 2011, imaging genetics studies started to incorporate 
GxE and epigenetic effects. During the first 10 years, hypothesis-free approaches, i.e. GWAS, were 
implemented, along with the emergence of large-scale collaborations and consortia (Mufford et al., 2017). 
Examples of such consortia include the Enhancing NeuroImaging Genetics through Meta-analysis (ENIGMA) 
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consortium (Thompson et al., 2014; http://enigma.ini.usc.edu/), Cohorts for Heart and Aging Research in 
Genomic Epidemiology (CHARGE) consortium (Psaty et al., 2009; http://web.chargeconsortium.com/), and 
the IMAGEN study (Schumann et al., 2010; https://imagen-europe.com/). With the advent of big data came 
the development of multivariate approaches to account for arising statistical challenges. Additionally, GWAS 
of neuropsychiatric disorders revealed significant variants with previously uncharacterised biological roles, 
which therefore warranted investigation using candidate imaging genetics approaches. The most recent 
developments in the imaging genetics field include the expansion of hypothesis-free approaches to alternative 
genetic models such as gene-gene interactions (Mufford et al., 2017). 
 
 
Figure 1.4. A timeline of methodological approaches implemented in imaging genetics studies of neuropsychiatric 
disorders (Mufford et al., 2017). Reproduced from Mufford et al. (2017), as per the following license:  
https://creativecommons.org/licenses/by-nc/3.0/legalcode. 
 
1.5.2. Imaging genetics in schizophrenia and antipsychotic response 
 
A multitude of studies over the last two decades has been dedicated to investigating the imaging genetics of 
schizophrenia (Greenwood et al., 2019). These studies have revealed promising findings in terms of the 
genetic contributions to certain brain structural and functional correlates of the disorder (Greenwood et al., 
2019). Numerous widely studied genes implicated in schizophrenia, such as AKT1, BDNF, COMT, DISC1, 
DTNBP1, and NRG1, have been investigated in imaging genetics studies (Hashimoto et al., 2015). The COMT 
gene has been the most frequently studied of these genes in both structural and functional imaging genetics 
studies of schizophrenia (Meyer-Lindenberg, 2010). A meta-analysis of all the functional neuroimaging studies 
of COMT rs4680 that were done before 2008 found that this variant has a significant impact on prefrontal 
activation (Mier et al., 2010). Findings relating to the effects of COMT variation on brain structure have been 
less consistent than functional findings (Meyer-Lindenberg, 2010), but one example is a study of COMT rs4680 
that found significant volumetric reductions in the bilateral anterior cingulate cortex (ACC), left amygdala-
uncus, right middle temporal gyrus (MTG) and left thalamus, in schizophrenia patients with the homozygous 
Val/Val COMT genotype compared to COMT Met carriers (Ohnishi et al., 2006). No significant genotype effects 
on brain morphology were found in the control group, which suggests that COMT rs4680 might contribute to 
morphological abnormalities in schizophrenia (Ohnishi et al., 2006). In terms of schizophrenia imaging genetics 
studies in the post-GWAS era, significant variants identified in schizophrenia GWAS have been found to impact 
various structural phenotypes (reviewed by Gurung and Prata, 2015). These include grey matter volume 
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(variants in CACNA1C, NRGN, TCF4 and ZNF804A), ventricular volume (TCF4), cortical folding (NCAN) and 
thickness (ZNF804A), white matter integrity (ANK3 and ZNF804A), white matter volume (CACNA1C and 
ZNF804A) and white matter density (ZNF804A; Gurung and Prata, 2015). 
 
Despite the extensive imaging genetics research in schizophrenia, studies of this nature investigating 
antipsychotic treatment outcomes remain scarce. Furthermore, to our knowledge, all of the imaging genetics 
studies of antipsychotic response thus far have only focussed on fMRI measurements, and no studies have 
investigated the genetic underpinnings of structural brain measurements in antipsychotic response. In a study 
by Blasi et al. (2011), the interaction between specific DRD2 and AKT1 variants was associated with altered 
cingulate response and reduced behavioural accuracy during attentional processing in healthy individuals, and 
with greater PANSS score improvement in patients treated with olanzapine. In a later study by Blasi et al. 
(2015), it was found that combined effects of DRD2 and HTR2A variants may influence working memory 
processing reflected by prefrontal activity in healthy individuals, as well as response to antipsychotic treatment 
in patients with schizophrenia. Lastly, in a group of patients with schizophrenia, variants in GRM3 were 
associated with a reduction in negative symptoms as well as a worsening of working memory deficits after 
antipsychotic treatment (Bishop et al., 2015). Therefore, despite apparent symptom improvement, these 
results suggested that GRM3 variants may influence the risk for adverse cognitive effects of antipsychotic 
treatment (Bishop et al., 2015). 
 
Overall, these studies highlight the potential utility of imaging genetics to improve our understanding of the 
underlying mechanisms relating to antipsychotic treatment and response. However, two of the three studies 
investigated the genetics of neuroimaging phenotypes in healthy individuals, and compared these findings to 
treatment response measurements in schizophrenia patients (Blasi et al., 2011; 2015). This highlights a clear 
deficit in research addressing the genetic components of neuroimaging phenotypes in direct relation to 
antipsychotic response, i.e. conducting both the imaging genetics analysis and the pharmacogenetics analysis 
in the patient cohort. Even though the third study identified a potential genetic subgroup of patients that may 
have a greater risk for adverse cognitive effects in relation to antipsychotic treatment (Bishop et al., 2015), of 
potentially greater value would be the use of imaging genetics approaches for the identification of baseline 
(pre-treatment) neuroimaging phenotypes that have the capacity to reliably predict treatment outcome in 
certain patients based on genetic profiles (Kempton and McGuire, 2015). This would enable the 
implementation of more guided treatment strategies based on predictive response profiles derived from 
individual-level genetic data combined with neuroimaging data. In order to address this, imaging genetics 
studies of antipsychotic response should be done with both MRI and fMRI correlates, as both structural and 
functional brain measurements would be valuable in the search for robust and reliable biomarkers of treatment 
response. In fact, it is surprising that none of the existing imaging genetics studies of antipsychotic response 
have included structural neuroimaging phenotypes, as the existing literature on neuroimaging studies of 
antipsychotic response includes a greater number of studies that focussed on structural neuroimaging 
measures compared to functional modalities (reviewed by Tarcijonas and Sarpal, 2019). These structural 
imaging studies have found correlations between numerous brain regions and response to antipsychotic 
treatment, considering various measurements such as thickness, volume, and density (Tarcijonas and Sarpal, 
2019). For example, increased hippocampal volumes have been associated with favourable response to 
risperidone treatment (Savas et al., 2002), and increased thickness of temporal regions have been associated 
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with more rapid response to antipsychotic treatment (Szeszko et al., 2012). These findings highlight the 
potential for structural brain measurements as useful intermediate phenotypes of antipsychotic response in 
imaging genetics studies moving forward.  
 
1.5.3. Imaging gene-environment interactions (iGxE) 
 
Examining the interplay between genes, experience and the brain is essential to improve our understanding 
of psychopathology. In this regard, both gene-environment interaction studies and imaging genetics studies 
have shown much promise in the study of neuropsychiatric disorders (as discussed in sections 1.4.2, 1.5.1, 
and 1.5.2.). However, these approaches have very rarely been integrated, despite their considerable potential 
to inform each other. Recognising this potential, Hyde et al. (2011) proposed the term imaging gene-
environment interactions (iGxE) to describe an integrative research strategy combining gene-environment 
interactions and imaging genetics. The authors of this review state that “Overall, iGxE can provide a more 
nuanced and complex model of human nature in health and disease by extending beyond nature–nurture 
debates and revealing specific mechanisms through which the constantly interacting environment and genome 
can be understood at the level of brain function and behaviour” (Hyde et al., 2011). Considering an iGxE model 
of a complex neuropsychiatric disorder, there are numerous ways in which genetic, neural, environmental, and 
behavioural factors could interact (Figure 1.5).  
 
Although iGxE approaches have not been implemented for the investigation of antipsychotic treatment 
response, this approach has been used in the context of healthy individuals (Gerritsen et al., 2011), major 
depressive disorder (Carballedo et al., 2013; Frodl et al., 2014), and schizophrenia (Aas et al., 2013). For 
example, Aas et al. (2013) found that BDNF rs6265 modulated the association between childhood trauma and 
brain cognitive and structural abnormalities in psychosis. Specifically, Val/Met individuals exposed to high 
levels of childhood abuse showed poorer cognitive functioning compared to homozygous Val/Val individuals 
(Aas et al., 2013). Additionally, reduced right hippocampal volumes and larger right and left lateral ventricles 
were observed in Val/Met individuals with a history of severe sexual abuse (Aas et al., 2013).  
 
The goals of personalised treatment approaches in psychiatry are to predict the risk of developing a psychiatric 
disorder, obtain an accurate diagnosis, and predetermine the most effective therapeutic strategy for an 
individual (Ozomaro et al., 2013). Despite decades of research in numerous fields (i.e. genetic, neuroimaging, 
and clinical studies) aimed at elucidating the mechanisms contributing to differential antipsychotic treatment 
outcomes with the goal of progressing toward more personalised treatment regimens, the clinical utility of 
research findings thus far remains incredibly limited. It is therefore plausible that embracing more integrated 
research approaches may better inform on the relationships between correlates of treatment response, and 
more effectively disentangle the mediating factors and mechanisms underlying these relationships (Cao et al., 
2014; Domschke and Müller, 2015). Specifically, an iGxE approach considering the interplay between genetic, 
neuroimaging, and environmental factors may be a reasonable starting point. Firstly, not only have genetic 
variants and childhood trauma been associated with differential treatment outcomes in schizophrenia, 
respectively, but a potential role of GxE with childhood trauma in antipsychotic response has also been 
highlighted. Secondly, the same can be said for variations in brain structural and functional phenotypes. Lastly, 
structural and functional brain measurements have been implicated in differential response to antipsychotic 
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treatment. Therefore, the existing literature addressing the various relationships between genetic factors, brain 
imaging phenotypes, childhood trauma, and treatment outcomes in schizophrenia, points to the potential utility 
of integrated iGxE studies of antipsychotic response. 
 
 
Figure 1.5. A conceptual model of iGxE (Hyde et al., 2011). Traditional GxE and imaging genetic paths are highlighted 
among the variables, as well as new potential paths for iGxE studies. The ‘a’ paths (green) demonstrate typical GxE 
relationships; ‘b’ paths (purple) model traditional links in imaging genetics approaches; the ‘c’ path (blue) models the direct 
effect of the environment on neural functioning (as demonstrated in epigenetic studies); the ‘d’ path (yellow) models GxE 
prediction of neural functioning (the iGxE effect); the ‘e’ path (red) represents the possibility of genetic variation or 
environmental variables interacting with neural functioning to predict behaviour. Indirect and mediated pathways can be 
connected between many of the variables (e.g. GxE to behaviour via neural functioning). rGE = gene-environment 
correlation. An ideal iGxE finding would be a GxE interaction term that predicts behaviour through neural functioning. 
Reproduced with permission from Elsevier.  
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1.6. Overview of the current study 
 
1.6.1. Aim and objectives 
 
This study aims to investigate the interplay between genetics, childhood trauma, and brain structure, in the 
context of antipsychotic treatment response, using an integrative research approach. 
 
The aforementioned aim will be achieved by the following objectives: 
 
1. To determine whether volumetric variation in brain regions previously associated with antipsychotic 
response are associated with treatment outcomes in a South African FES cohort. 
a. Survey the literature to identify brain regions that have been previously implicated in antipsychotic 
response. 
b. Conduct association analyses to investigate whether volumetric variation in any of these regions 
is associated with antipsychotic response in a local cohort.  
2. To determine whether candidate genes previously implicated in both brain structure and antipsychotic 
response are associated with brain structure and antipsychotic treatment response in a South African FES 
cohort. 
a. Search the literature for genes shown to influence both brain structure and antipsychotic response. 
b. Make use of publicly available data and bioinformatics tools to identify functionally relevant 
variants within these genes. 
c. Perform association analyses to investigate the involvement of these prioritised variants in brain 
structure and antipsychotic treatment response.  
3. To determine whether childhood trauma severity is associated with brain structure and antipsychotic 
treatment response. 
a. Conduct association analyses to determine the influence of the severity of childhood trauma on 
both brain structure and antipsychotic treatment response. 
4. To determine wther GxE are associated with brain structure and antipsychotic treatment response. 
a. Perform association analyses to determine if any GxE between childhood trauma and prioritised 








1. VARIABLES OF INTEREST 
1.1 GENETIC VARIABLES 
 
Identify candidate genes implicated in 1) 
brain structure and 2) antipsychotic (AP) 
response (literature search) 
 
Extract variants within candidate genes (mine 
available genotype data) 
 
Prioritise variants based on functional 
relevance (QC & bioinformatics pipeline) 
1.2. IMAGING VARIABLES 
 
Identify brain regions implicated in AP 
response (literature search) 
 
Select regions of interest (ROIs) for inclusion 
in the study (mine available MRI data) 
2. ASSOCIATION ANALYSES 
2.1. ROLE OF BASELINE ROI VOLUME IN AP RESPONSE 
 
Perform association analysis between ROI volumes and AP response (linear mixed-effects models) 
2.2. GENETIC ANALYSES 
2.2.1. ROLE OF VARIANTS IN AP RESPONSE 
 
Perform association analyses between variants 
and AP response (linear mixed-effects models) 
2.2.2. ROLE OF VARIANTS IN ROI VOLUMES 
 
Perform association analyses between variants 
and ROI volumes (linear models) 
2.4. GxE ANALYSES 
2.4.1. ROLE OF GxE IN AP RESPONSE 
 
Perform association analyses between variants 
and AP response, with childhood trauma as an 
interaction term (linear mixed-effects models) 
2.4.2. ROLE OF GxE IN ROI VOLUMES 
 
Perform association analyses between variants 
and ROI volumes, with childhood trauma as an 
interaction term (linear models) 
2.3. CHILDHOOD TRAUMA ANALYSES 
2.3.1. ROLE OF CHILDHOOD TRAUMA IN AP 
RESPONSE 
 
Perform association analyses between 
childhood trauma and AP response (linear 
mixed-effects models) 
2.3.2. ROLE OF CHILDHOOD TRAUMA IN ROI 
VOLUMES 
 
Perform association analyses between 
childhood trauma and ROI volumes (linear 
models) 
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Materials and methods 
 
2.1. Role of the incumbent 
 
Clinical interviews, patient treatment, data collection, MRI scans, and blood sampling, were performed by 
trained clinicians. Neuroimaging data was generated by experts in the field at the University of Stellenbosch, 
Tygerberg Medical Campus. DNA extractions were performed by a laboratory technician. Genotyping was 
performed prior to this study by the Department of Psychiatry, Zucker Hillside Hospital, New York, USA. The 
role of the incumbent of this study was therefore to make use of existing literature to select candidate genes 
and brain regions of interest to include in the study. The incumbent then mined existing neuroimaging data 
provided to identify available brain regions of interest, and extracted all of the genetic variants within the 
selected candidate genes from the genome-wide genotype data provided. The incumbent then designed and 
subsequently implemented a novel bioinformatics pipeline to prioritise genetic variants, making use of a 
number of online databases and in silico prediction tools. In addition to this, the incumbent wrote several R 
scripts in RStudio, making use of linear regression and mixed-effects modelling to execute the necessary 
association analyses between all variables of interest, in line with the aim and objectives of the study. Model 
diagnostics were also performed by the incumbent for all analyses in RStudio. The results were then discussed 




The patient cohort comprised 103 unrelated South African individuals (median age 23 ± 7 years; 76 males and 
27 females) who were recruited through Stikland Hospital in the Western Cape, between April 2007 and March 
2011, as described previously (Chiliza et al., 2015; Drögemöller et al., 2014; Emsley et al., 2015; Emsley et 
al., 2017). Of these participants, 82 were South African Mixed-Ancestry, 13 were Xhosa, and 8 were of 
Caucasian descent as per self-reported ancestry. Inclusion criteria for the study were men and women 
between the ages of 16 and 45, experiencing a first episode of psychosis according to the diagnostic criteria 
for schizophrenia, schizophreniform, or schizoaffective disorder as defined by the Diagnostic and Statistical 
Manual of Mental Diseases, Fourth Edition (DSM-IV; American Psychiatric Association, 1994). Exclusion 
criteria were exposure to more than four weeks of antipsychotic medication during participants’ lifetime, any 
previous treatment with a long-acting depot antipsychotic, serious or unstable general medical condition, 
intellectual disability, and overt substance abuse. Clinical and demographic data were obtained for all 
participants at the time of recruitment. Written informed consent was received from the participants or their 
caregivers, and from the legal guardian in the case of minors. Ethical approval was obtained from the Human 
Research and Ethics Committee (HREC), Faculty of Health Sciences, University of Stellenbosch (N06/08/148). 
 
2.3. Clinical assessments 
 
At the time of recuitment, all participants were assessed by means of the Structured Clinical Interview for DSM-
IV (SCID; American Psychiatric Association, 1994). They were also scored in terms of symptom severity 
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according to the Positive and Negative Syndrome Scale (PANSS; Kay et al., 1987) before receiving treatment, 
and then every two weeks for the first six weeks, and every three months thereafter, for a period of 12 months. 
Symptoms were categorised into either positive, negative, or general symptom domains, and participants were 
given a score for each separate symptom category, as well as a total score. The change in positive, negative, 
general, and total PANSS scores over 12 months was used to indicate drug efficacy and response to 
antipsychotic treatment. The Clinical Global Impressions (CGI) Scale (Busner and Targum, 2007) was also 
used to monitor treatment response over time. Extrapyramidal symptoms were examined using an 
Extrapyramidal Symptom Rating Scale (ESRS; Chouinard and Margolese, 2005). The CTQ (Bernstein et al., 
1997) was used to evaluate the type and severity of childhood trauma in 75 of the participants according to 
the five subscales, namely emotional abuse, emotional neglect, physical abuse, physical neglect, and sexual 
abuse. Scores for the five subscales were summed to obtain an overall trauma (CTQ total) score for each 
participant. A minimisation/ denial scale was also incorporated to indicate inaccurate reporting of mistreatment. 




All participants were treated according to a standardised protocol with flupenthixol decanoate (a first-
generation antipsychotic) in the form of a long-acting injectable, thereby ensuring adherence (Chiliza et al., 
2015). A 1-3 mg/day dosage of oral flupenthixol was administered for the first week, followed by fortnightly 
injections of flupenthixol depot, at a starting dose of 10 mg every two weeks, with increments of 10 mg 
permitted every six weeks, to a maximum of 30 mg fortnightly (Chiliza et al., 2015). The lowest possible dose 
of the antipsychotic was maintained, only increased when insufficient response persisted (less than 20% 
reduction in the PANSS total score, and minimal improvement on the CGI Scale), until either remission was 
achieved – as defined by the Remission in Schizophrenia Working Group (Andreasen et al., 2005) - or the 
maximum allowed/ tolerated dose was reached (Chiliza et al., 2015). Early response to treatment was indicated 
by a ≥ 25% reduction in PANSS total scores within the first six weeks. Non-response was defined by either a 
discontinuation of treatment due to poor response, a < 25% reduction in PANSS total scores at end-point, or 
a PANSS total score of > 70 at end-point (Chiliza et al., 2015).  
 
2.5. Neuroimaging variables 
 
2.5.1. Imaging methods 
 
A subset of participants (N = 76) underwent baseline MRI scans prior to antipsychotic treatment, at the time 
of recruitment. The following imaging methods were used, and have been described previously (Emsley et al., 
2015; Emsley et al., 2017). High-resolution T1-weighted data were obtained using a 3T Siemens Allegra MRI 
scanner (Erlangen, Germany) with the following acquisition parameters: MPRAGE sequence, 2080 ms 
repetition time; 4.88 ms echo-time, field of view: 230 mm, 176 slices, voxel size: 0.9 × 0.9 × 1 mm3. All scans 
were screened for intracranial pathology and motion artefacts, and were processed and analysed using 
Freesurfer version 6.0.0. Slices were resampled to a three-dimensional image with 1 mm isotropic voxels. 
Non-uniform intensity normalisation was performed, and images were registered to the Montreal Neurological 
Institute space. A second normalisation step was then performed, where control points were automatically 
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identified and normalised to a standard intensity value. This was followed by an automated skull strip 
procedure. Global brain anatomy was delineated into cortical and subcortical labels. Reconstructions were 
performed with custom batching scripts, on the Centre for High Performance Computing, Cape Town, Lengau 
cluster. All data were visually inspected for errors in Talairach transformation, skull strip, final segmentations 
and within subject-registrations. Detailed quality-checking was done, whereby errors were manually corrected 
and re-inspected. This resulted in 74 participants with usable baseline MRI data, which was available prior to 
the current study. 
 
2.5.2. Brain regions of interest (ROIs) 
 
A literature search was performed via PubMed (https://www.ncbi.nlm.nih.gov/pubmed/) and the Stellenbosch 
University Library to identify brain regions of interest (ROIs) that had been previously implicated in variable 
response to antipsychotic treatment. This search was conducted between March and May 2018, using 
combinations of the following search terms: “brain”, “imaging”, “morphology”, “morphometry”, “MRI”, 
“neuroanatomical”, “neuroimaging”, “region”, “structural”, “structure”, “variation”, “volume”, “volumetric”, 
“voxel”, “antipsychotic”, “first episode”, “outcome”, “psychosis”, “psychotic”, “resistant”, “response”, 
“schizophrenia”, “treatment”. Only measures of volume were considered for the study, as volumetric 
measurements were the most abundant in both the literature and the available structural MRI data. The 
available MRI data was mined for the ROIs that were identified in the literature search (i.e. previously 
associated with antipsychotic treatment response). Eight ROIs were identified in the available MRI data, and 
were thus included in the study. The volumetric measurements for the ROIs were expressed as percentages 
of total intracranial volume. 
 
2.6. Genetic variables 
 
2.6.1. DNA extraction and genotyping 
 
Whole blood samples were previously obtained from all 103 participants using venepuncture, from which 
genomic DNA (gDNA) was isolated using the Miller et al. (1988) protocol. Prior to this study, the entire cohort 
was genotyped using the Infinium OmniExpressExome-8 Kit (Illumina, California, USA), that includes 958,497 
SNP markers. 
 
2.6.2. Candidate gene selection 
 
A literature search was performed via PubMed (https://www.ncbi.nlm.nih.gov/pubmed/) and the Stellenbosch 
University Library to identify genes that had been previously implicated in both brain structure and antipsychotic 
treatment response. This search was conducted between March and May 2018, using combinations of the 
following search terms: “gene”, “genetic”, “genome-wide association study”, “GWAS”, “pharmacogenetic”, 
“pharmacogenomic”, “polymorphism”, “SNP”, “variation”, “brain”, “imaging”, “morphology”, “morphometry”, 
“MRI”, “neuroanatomical”, “neurodevelopment”, “neuroimaging”, “region”, “structural”, “structure”, “variation”, 
“volume”, “volumetric”, “voxel”, “antipsychotic”, “first episode”, “outcome”, “psychosis”, “psychotic”, “resistant”, 
“response”, “schizophrenia”, “treatment”. Inclusion criteria for genes implicated in brain structure required that 
Stellenbosch University https://scholar.sun.ac.za
CHAPTER 2                                                                                                         MATERIALS AND METHODS 
23 
 
the studies involved neuroimaging measures of volume only, in either healthy individuals, or individuals with 
schizophrenia (no other disorders); and inclusion criteria for genes implicated in antipsychotic treatment 
response required that the studies involved any measure of response to any antipsychotic in individuals with 
schizophrenia (no other neuropsychiatric disorders), excluding measurements of any antipsychotic-induced 
adverse drug reactions. Following the literature search, the NHGRI-EBI GWAS Catalog (MacArthur et al., 
2017), which is a curated collection of all published genome-wide association studies, was searched for GWAS 
of brain structure and antipsychotic treatment response, in May 2018. The term “brain volume measurement” 
was used to identify studies of brain structure, and the term “response to antipsychotic drug” was used to 
identify studies of antipsychotic treatment response. Inclusion criteria for GWAS were the same as for studies 
identified in the literature search, outlined above. No studies that considered the genetics of brain structure in 
the context of antipsychotic treatment response were identified, therefore two separate gene lists were 
compiled for 1) implication in brain structure and 2) implication in antipsychotic response. Each of the genes 
in these two lists were then cross searched with the other trait, to ensure no relevant studies were missed. 
Genes identified in both lists were selected as candidate genes for the study. 
 
2.6.3. Variant prioritisation 
 
PLINK v1.9 (Purcell et al., 2007) was used to mine the available genome-wide genotype data for variants 
within the identified candidate genes, using the positions documented on each gene page of the National 
Center for Biotechnology Information (https://www.ncbi.nlm.nih.gov/gene/) for the GRCh37.p13 genome 
assembly. Variants 1000 bp up- and downstream from each gene were also extracted to account for additional 
non-coding variation for these genes. Allele frequencies for each variant were extracted using PLINK v1.9 
(Purcell et al., 2007). Choosing to focus on the effects of common variants, all variants were then filtered 
according to minor allele frequency (MAF) in order to eliminate rare variants. Variants with an MAF of ≥ 0.1 
were considered as “common” and were selected for further analyses. In order to further prioritise variants for 
inclusion in the study, these variants were investigated for previously reported implication in antipsychotic 
treatment response and brain structure, and predicted functional consequences or regulatory effects, with the 
use of various online databases and in silico prediction tools. The databases and tools used are summarised 
in Table 2.1, along with the type of prediction for each, and the dates accessed.  
 
The following describes the prioritisation process and criteria for inclusion of variants in the study: Variants 
that had been previously associated with either brain structure or antipsychotic treatment response in the 
literature were included for further analyses. The NHGRI-EBI GWAS Catalog (MacArthur et al., 2017) was 
used to investigate whether any of the variants had been significantly associated with either brain structure or 
antipsychotic treatment response in relevant GWAS. PharmGKB (Whirl-Carrillo et al., 2012) is a resource that 
curates knowledge about the effects of genetic variation on drug response. Variants that were shown to have 
an effect on antipsychotic efficacy, toxicity or response (including adverse drug reactions) according to the 
clinical and variant annotations on PharmGKB were included. In order to investigate predicted functional 
consequences of all variants, Ensembl (Zerbino et al., 2018), SNPnexus (SIFT and Polyphen options, for 
assembly GRCh38/hg38; Chelala et al., 2009), SIFT (Sim et al., 2012) and Polyphen-2 (Adzhubei et al., 2010) 
were used. Variants reported to be missense, nonsynonymous, deleterious, damaging, probably damaging, 
or possibly damaging, according to any of these databases/ tools were included. The potential regulatory 
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impact of variants was also investigated with the use of SNPnexus (TarBase option, for assembly 
GRCh38/hg38; Chelala et al., 2009), PolymiRTS (Bhattacharya et al., 2014), SNP2TFBS (Kumar et al., 2017), 
RegulomeDB (Boyle et al., 2012), and rSNPBase (Guo et al., 2014). Any variants reported as having a 
potential impact on a miRNA target site according to SNPnexus (TarBase option), or on miRNA binding 
according PolymiRTS, were included. Variants shown to affect transcription factor binding according to 
SNP2TFBS were included for downstream analyses. Lastly, variants with scores ranging from ‘1a’ to ‘3b’ as 
per the RegulomeDB scoring system (outlined in Table S1) were included. As almost all variants were reported 
as rSNPs (regulatory single nucleotide polymorphisms) according to rSNPBase, this information was not used 
in the prioritisation process, as very few variants would have been eliminated. However, rSNPBase was still 
used in the annotation of all variants for future reference. This informs on the role of each variant in regulation 
of a proximal, distal, miRNA and/ or RNA binding protein mediated nature, as well as reported eQTL 
(expression quantitative trait loci) status. This pipeline resulted in 192 variants that were prioritised for inclusion 
in the study. 
 
2.6.4. Variant descriptive statistics  
 
PLINK v1.9 (Purcell et al., 2007) was used to assess Hardy-Weinberg equilibrium (HWE) for the prioritised 
variants (significance threshold of P ≤ 0.01). SNPStats (Sole et al., 2006) was used to determine genotype 
frequencies, and to assess levels of LD between the prioritised variants for each gene. This was based on the 
D’ statistic, where values above 0.8 were indicative of strong LD.  
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Table 2.1. Summary of online databases and tools used for variant prioritisation. 
TF = Transcription factor 
1Using annotation categories for GRCh38/hg38 
 
  
Online database/tool Option/tool used Variant prediction type Link Reference 
Date 
accessed 
Ensembl Variant Effect Predictor Functional impact https://www.ensembl.org/ (Zerbino et al., 2018) June 2018 
PolyPhen-2 NA Functional impact 
http://genetics.bwh.harvard.e
du/pph2/ 
(Adzhubei et al., 2010) May 2018 
SIFT SIFT dbSNP Functional impact https://sift.bii.a-star.edu.sg/ (Sim et al., 2012) May 2018 
SNPnexus1 
SIFT Functional impact 
https://snp-nexus.org/ 
(Chelala et al., 2009; Ullah et 
al., 2012, 2013, 2018) 
May 2018 PolyPhen Functional impact 
TarBase Impact on miRNA target site 
PolymiRTS NA Impact on miRNA binding 
http://compbio.uthsc.edu/miR
SNP/ 
(Bhattacharya et al., 2014) June 2018 
SNP2TFBS SNPViewer Impact on TF binding https://ccg.epfl.ch/snp2tfbs/ (Kumar et al., 2017) June 2018 
RegulomeDB NA Regulatory impact http://regulome.stanford.edu/ (Boyle et al., 2012) May 2018 
rSNPBase NA Regulatory impact http://rsnp.psych.ac.cn/ (Guo et al., 2014) May 2018 




Implication in brain structure/ 
antipsychotic response 
https://www.ebi.ac.uk/gwas/ (MacArthur et al., 2017) August 2018 
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2.7. Association analyses 
 
All association analyses that were done for this study are summarised in Table 2.2. These analyses are 
outlined in more detail in sections 2.6.1 to 2.6.4.2 below. All linear regression modelling was done in RStudio 
(RStudio Team, 2015), using R (R Core Team, 2018) packages lme4 (Bates et al., 2015) and lmerTest 
(Kuznetsova et al., 2017). 
 
Table 2.2. Summary of all association analyses done in this study.  
PANSS = Positive and Negative Syndrome Scale; ROI = brain region of interest; SNP = single nucleotide polymorphism; CTQ = 
Childhood Trauma Questionnaire; Additive = Additive allelic model 
1Corresponding written section below; 2The number of tests performed in the model; 3Adjusted significance threshold (⍺) after 
Bonferroni correction for multiple testing 
 
2.7.1. Associations between baseline ROI volumes and antipsychotic treatment response 
 
Linear mixed-effects models were used to investigate the associations between baseline volumes of the eight 
brain regions of interest (ROIs) and antipsychotic treatment response as determined by the change in PANSS 
scores over 12 months. Model diagnostics were done to assess whether the fitted models were in compliance 
with the assumptions for linear models, i.e. linearity, homoscedasticity, and normality, as follows: residual plots 
were generated for the models to visually inspect linearity and homoscedasticity; and as statistical 
assessments for normality are sensitive to sample size, visual methods (density and Q-Q plots) were used in 
combination with the Shapiro-Wilk’s statistical significance test to assess normality of the residuals. Although 
the distribution of the residuals was satisfactory, the residual plots revealed violation of the linearity and 
homoscedasticity assumptions. Log-transformation of the PANSS scores improved the linearity and 
homoscedasticity of the residual plots, and the models were then considered suitable for the analysis. The 
four different log-transformed PANSS scores (positive, negative, general and total) were modelled as functions 






























Genotypic 528 9.470 × 10-5 
103 








Genotypic 1056 4.735 × 10-5 
74 


























Genotypic 3168 1.578 × 10-5 
75 









Genotypic 6336 7.891 × 10-6 
55 
Additive 8928 5.600 × 10-6 
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effects, for each of the eight ROIs. A random effect was included to correct for the presence of multiple 
measures (PANSS scores) per individual over time. As the South African Mixed-Ancestry population is highly 
admixed, a panel of ancestry informative markers (AIMs) was previously developed specifically for this 
population group, in order to correct for differences in ancestry that may contribute to population stratification, 
and possibly result in spurious associations (Daya et al., 2013). All 103 patients were previously genotyped 
for the 96 AIMs, and for each individual, ancestral proportions were estimated in ADMIXTURE (Alexander et 
al., 2009) for the five base population groups (African San, African non-San, European, South and East Asian). 
To account for differences in ancestry, each model was adjusted for these five ancestral proportions. In 
addition to this, all models were adjusted for age, gender, baseline PANSS scores (log-transformed), and 
substance use (any substance use ever versus no substance use ever). In order to correct for multiple testing, 
Bonferroni correction was used, therefore the significance threshold of 0.05 was divided by the total number 
of tests performed. Bonferroni correction was applied separately to each family of tests as shown in Table 2.2. 
The number of tests was calculated as follows: (number of tests [n = 32]) = (number of ROIs [n = 8]) × (number 
of PANSS domains [n = 4]); resulting in an adjusted significance threshold of ⍺ = 1.563 × 10-3 (0.05/32). 
 
2.7.2. Genetic analyses 
 
2.7.2.1. Associations between genetic variants and antipsychotic treatment response 
 
Linear mixed-effects models were used to investigate associations between the prioritised genetic variants 
and antipsychotic treatment response. Model diagnostics were done as outlined in section 2.6.1 and PANSS 
scores were once again log-transformed to improve linearity and homoscedasticity. The four different log-
transformed PANSS scores were modelled as functions of the interaction between time of observation and 
genetic factor as fixed effects. Genotypic and additive allelic models of inheritance were considered for the 
analyses, thus genotypes and number of minor alleles (0, 1, or 2) were the genetic predictors in the models, 
respectively. A random effect was included to account for the multiple measures (PANSS scores) per individual 
over time. All models were adjusted for age, gender, ancestry (as described in 2.6.1) and log-transformed 
baseline PANSS scores. For these analyses, all variants for which the cohort included less than five minor 
genotypes were removed due to failure of the regression models to converge. A total of 132 and 186 variants 
were therefore included in the genotypic and additive allelic association analyses, respectively. In order to 
correct for multiple testing, Bonferroni correction was applied as described in 2.6.1. For the genotypic model, 
the number of tests was 528, resulting in an adjusted significance threshold of ⍺ = 9.470 × 10-5. The number 
of tests for the additive allelic model was 744, therefore ⍺ = 6.720 × 10-5 (Table 2.2). 
 
2.7.2.2. Associations between genetic variants and baseline ROI volumes 
 
Linear models were used to investigate the associations between prioritised genetic variants and baseline ROI 
volumes. Model diagnostics were done as described in section 2.6.1, and all model assumptions were 
satisfied. Volumetric measures for the eight ROIs were modelled as functions of the respective genetic factors 
as fixed effects, adjusting for age, gender, substance use, and ancestry (as described in section 2.6.1). The 
genetic predictors in the models were genotypes for association analyses under the genotypic model, and 
number of minor alleles (0, 1 or 2) for association analyses under the additive allelic model of inheritance. Due 
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to the model errors described in section 2.6.2.1, once again 132 variants were included for analyses under the 
genotypic model, and 186 variants were included for the additive allelic model. Bonferroni correction was 
applied to account for multiple testing as described above. For the genotypic model, the number of tests was 
1056, therefore ⍺ = 4.735 × 10-5. For the additive allelic model, the number of tests was 1488 and ⍺ = 3.360 × 
10-5 (Table 2.2).  
 
2.7.3. Childhood trauma analyses 
 
2.7.3.1. Associations between childhood trauma and antipsychotic treatment response 
 
Linear mixed-effects models were used to investigate the association between childhood trauma severity and 
antipsychotic treatment response. Model diagnostics were done as outlined in section 2.6.1 and PANSS 
scores were once again log-transformed to improve linearity and homoscedasticity. The four different log-
transformed PANSS scores (positive, negative, general and total) were modelled as functions of the interaction 
between time of observation and CTQ scores as fixed effects, for each of the six CTQ scoring domains, namely 
emotional abuse and neglect, physical abuse and neglect, sexual abuse, and total trauma score. A random 
effect was included to correct for the presence of multiple measures (PANSS scores) per individual over time. 
All models were adjusted for age, gender, ancestry, and baseline PANSS scores (log-transformed). In order 
to correct for multiple testing, Bonferroni correction was used, as described above. The number of tests was 
24, therefore ⍺ = 2.083 × 10-3 (Table 2.2).  
 
2.7.3.2. Associations between childhood trauma and baseline ROI volumes 
 
Linear models were used to investigate the associations between childhood trauma severity and baseline ROI 
volumes. Model diagnostics were done as described in section 2.6.1 and all model assumptions were satisfied. 
Volumetric measures for the eight ROIs were modelled as functions of the six CTQ scoring domains (described 
in 2.6.3.1) respectively as fixed effects, adjusting for age, gender, ancestry and substance use. Bonferroni 
correction was used to correct for multiple testing, as described above. The number of tests was 48, therefore 
⍺ = 1.042 × 10-3 (Table 2.2).  
 
2.7.4. Gene-environment interaction (GxE) analyses with childhood trauma 
 
2.7.4.1. Associations between GxE and antipsychotic treatment response 
 
To investigate the associations between GxE and antipsychotic treatment response, with childhood trauma as 
the environmental influence of interest, all analyses and model diagnostics were done as described in section 
2.6.2.1, but CTQ scores were included as an interacting variable with the genetic predictors in the models. 
This was done for each of the six scoring domains for CTQ, as outlined in 2.6.3.1. Bonferroni correction was 
applied to account for multiple testing as described above. The number of tests for the genotypic model was 
3168, therefore ⍺ = 1.578 × 10-5. The number of tests for the additive allelic model was 4644, therefore ⍺ = 
1.120 × 10-5 (Table 2.2).  
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2.7.4.2. Associations between GxE and baseline ROI volumes 
 
To investigate the associations between GxE with childhood trauma, and baseline ROI volumes, all analyses 
were done as described in section 2.6.2.2, but with the inclusion of CTQ scores as an interacting variable with 
the genetic predictors in the models. This was done for each of the six scoring domains for CTQ, as outlined 
in section 2.6.3.1. Bonferroni correction was used to correct for multiple testing as described above. The 
number of tests for the genotypic model was 6336, therefore ⍺ = 7.891 × 10-6. For the additive allelic model, 
the number of tests was 8928, therefore ⍺ = 5.600 × 10-6 (Table 2.2). 
 
2.8. Pathway analysis  
 
The KEGG Human database option on Enrichr (Chen et al., 2013; Kuleshov et al., 2016; 
https://amp.pharm.mssm.edu/Enrichr/) was used to identify pathways of interest that were enriched for genes 
significantly associated with antipsychotic treatment response or ROI volume in this study, either without 
childhood trauma interaction, or for the GxE analyses with childhood trauma.
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3.1. Clinical outcomes 
 
After 12 months of antipsychotic treatment, the patient cohort was assessed for various measures of treatment 
outcome, as previously reported by Chiliza et al. (2015). Considering the change in PANSS scores over time, 
77 of the participants (74.8%) experienced a ≥ 25% reduction in their PANSS scores by week six, thereby 
achieving early response. By the end of month 12, 58 participants (56.3%) had achieved full remission 
according to the Remission in Schizophrenia Working Group criteria (Andreasen et al., 2005), and nine 
participants (8.7%) were classified as non-responders (treatment refractory). 
 
3.2. Brain regions of interest (ROIs) 
 
Twenty-six ROIs (volumetric measures) were identified in the literature search and are listed in Table S2. Eight 
of the 26 ROIs were identified in the available structural MRI data (highlighted in red and in bold in Table S2). 
The eight ROIs (volumetric measures) included in the study were the caudate, cortex, hippocampal tail, 
hippocampus, pallidum, putamen, subcortical grey matter, and total grey matter.  
 
3.3. Candidate genes 
 
As shown in Table S3, 134 genes linked to variation in regional brain volume were identified, 48 of which were 
identified through the literature search (coloured in white), and 86 of which were identified in GWAS via the 
NHGRI-EBI GWAS Catalog (coloured in blue). Ninety-seven genes previously associated with antipsychotic 
treatment response were identified, 52 from the literature search only (coloured in white), 44 from the NHGRI-
EBI GWAS Catalog only (coloured in blue), and one (ANKS1B) identified via both the literature search and the 
NHGRI-EBI GWAS Catalog (coloured in purple). Fifteen genes were identified in both lists, i.e. implicated in 
both brain structure and antipsychotic response (coloured red and in bold), all of which were identified through 
the literature search only. These genes were AKT1, BDNF, CACNA1C, CNR1, COMT, DISC1, DRD2, DRD3, 
DTNBP1, IL1RN, NRG1, OXTR, RGS4, TNFα, and ZNF804A. The cannabinoid receptor 1 gene (CNR1) was 
excluded due to possible confounding effects of cannabis use in potential associations between CNR1 variants 
and antipsychotic treatment response or brain structure; thus 14 genes were included as candidates for the 
study. 
 
3.4. Genetic variants 
 
From the available genome-wide genotype data, 1132 variants within the 14 candidate genes were extracted. 
From these variants, 192 were prioritised for inclusion in the study based on an MAF of ≥ 0.1, functional 
relevance, and previous implication in either brain structure or antipsychotic treatment response. The number 
of variants that were included for each gene is shown in Table 3.1. No variants within AKT1 met the criteria for 
inclusion in the study, and so this gene was not further investigated. All prioritised variants are listed in Tables 
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S4 – S6, along with the reasons for inclusion and the annotations from each database or tool that was used in 
the prioritisation process. As shown in Table S4, 18 variants fulfilled inclusion criteria based on functional 
impact, as they were reported to be either missense, nonsynonymous, deleterious, damaging, probably 
damaging, or possibly damaging according to Ensembl (Zerbino et al., 2018) SNPnexus (SIFT and Polyphen 
options; Chelala et al., 2009), SIFT (Sim et al., 2012), and Polyphen-2 (Adzhubei et al., 2010). As shown in 
Table S5, the literature search revealed a total of 42 variants that had been previously associated with either 
brain structure (11 variants), antipsychotic response (21 variants), or both of these traits (10 variants). Six 
variants were found in the NHGRI-EBI GWAS Catalog (MacArthur et al., 2017) for association with brain 
structure, and none for antipsychotic treatment response. Twenty-six variants were reported to have an effect 
on antipsychotic efficacy, toxicity or response (including adverse drug reactions) according to the clinical and 
variant annotations on PharmGKB (Whirl-Carrillo et al., 2012). As shown in Table S6, 62 variants had scores 
ranging from ‘1a’ to ‘3b’ on RegulomeDB (Boyle et al., 2012). Seven variants were reported to impact miRNA 
binding according to PolymiRTS (Bhattacharya et al., 2014), and no variants were identified from the TarBase 
option on SNPnexus (not included in the table), which shows potential impact on a miRNA target site. Lastly, 
94 variants were shown to affect transcription factor binding according to SNP2TFBS (Kumar et al., 2017).  
 
Table 3.1. The number of variants per gene that were prioritised for inclusion in the study.  


















3.5. Variant descriptive statistics 
 
All but three of the prioritised variants were in Hardy-Weinberg equilibrium (HWE). The three variants that 
deviated from HWE were CACNA1C rs2238096 (P = 2.661 × 10-4), DISC1 rs2356606 (P = 6.761 × 10-3), and 
NRG1 rs1623372 (P = 7.085 × 10-3). These variants were included in downstream analyses. Cases of LD 
between significant variants are mentioned in following sections, and the corresponding LD plots for these 
variants are shown in Tables S7a - e. 
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3.6. Association analyses  
 
In all of the following sections, results are reported as significant if associations surpassed a Bonferroni 
corrected significance threshold. In cases where no significant associations were identified, an uncorrected 
significance threshold of ⍺ = 0.05 was considered for the observation of trends.  
 
3.6.1. Associations between baseline ROI volumes and antipsychotic treatment response 
 
No significant associations were identified between the eight brain regions of interest (volumetric measures) 
and the four PANSS domains (positive, negative, general and total scores), after Bonferroni correction for 
multiple testing (⍺ = 1.563 × 10-3). No trends were observed when considering an uncorrected significance 
threshold (⍺ = 0.05). Results are not shown. 
 
3.6.2. Genetic analyses 
 
3.6.2.1. Associations between genetic variants and antipsychotic treatment response 
 
Ten variants in CACNA1C, NRG1, and OXTR were significantly associated with antipsychotic treatment 
response as determined by the change in log-transformed PANSS scores over 12 months (Table 3.2). Two of 
these variants (NRG1 rs1481728 and rs7005124) were significantly associated with treatment response under 
the genotypic model of inheritance only (P < 9.470 × 10-5), four of the variants (CACNA1C rs215976, NRG1 
rs16879304 and rs2439312, and OXTR rs4686301) under the additive allelic model of inheritance only (P < 
6.720 × 10-5), and the remaining four variants (CACNA1C rs10161032, NRG1 rs6987996 and rs17645417, 
and OXTR rs237884) were significantly associated with treatment response for both the genotypic and additive 
allelic inheritance models (P < 9.470 × 10-5, and P < 6.720 × 10-5, respectively).  
 
Eleven significant associations (involving five different variants) showed poorer response to antipsychotic 
treatment for either negative, general, or total symptoms, as per the positive values of the effect estimates 
(relative increase in log-transformed PANSS scores). These associations were for CACNA1C rs10161032, 
OXTR rs4686301, and NRG1 rs6987996, rs17645417, and rs16879304. Six associations were for improved 
response to treatment as per the negative effect estimate values (relative decrease in log-transformed PANSS 
scores). Variants associated with improved treatment response (for negative symptoms) were CACNA1C 
rs215976, OXTR rs237884, and NRG1 rs1481728, rs7005124, and rs2439312. The most significant result 
was the association between NRG1 rs17645417 and poorer treatment response for negative symptoms with 
each additional C allele (P = 5.25 × 10-7). Two of the variants in NRG1 (rs17645417 and rs2439312) were in 
LD, the plot for which is shown in Table S7a. The specific genotypes, alleles, and PANSS scoring domains 
involved in the associations are displayed in Table 3.2, along with the estimated effect sizes, 95% confidence 
intervals, and P values for each association.  
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Table 3.2. Genetic variants significantly associated with antipsychotic treatment response (ATR) as defined by the change in log-transformed PANSS 
scores over 12 months, considering the genotypic and additive allelic models of inheritance. 




Contrast ATRa Effect estimate 95% CI P value 
CACNA1C 
rs10161032 General CC vs TT × 6.12 × 10-3 3.14 × 10-3 to 9.10 × 10-3 6.14 × 10-5 
rs10161032 Negative CC vs TT × 6.30 × 10-3 3.26 × 10-3 to 9.35 × 10-3 5.40 × 10-5 
NRG1 
rs6987996 Negative TT vs CC × 5.49 × 10-3 3.18 × 10-3 to 7.80 × 10-3 3.69 × 10-6 
rs1481728 Negative TT vs GG ✓ -7.81 × 10-3 -1.15 × 10-2 to -4.10 × 10-3 4.00 × 10-5 
rs7005124 Negative GT vs TT ✓ -4.43 × 10-3 -6.35 × 10-3 to -2.50 × 10-3 7.59 × 10-6 
rs17645417 Negative CT vs TT × 4.49 × 10-3 2.49 × 10-3 to 6.49 × 10-3 1.16 × 10-5 
rs17645417 Negative CC vs TT × 6.53 × 10-3 3.68 × 10-3 to 9.38 × 10-3 8.13 × 10-6 
OXTR rs237884 Negative GG vs AA ✓ -5.03 × 10-3 -7.42 × 10-3 to -2.64 × 10-3 4.15 × 10-5 




Contrast ATRa Effect estimate 95% CI P value 
CACNA1C 
rs10161032 General each C × 2.78 × 10-3 1.43 × 10-3 to 4.14 × 10-3 6.00 × 10-5 
rs215976 Negative each T ✓ -4.13 × 10-3 -6.05 × 10-3 to -2.18 × 10-3 3.42 × 10-5 
NRG1 
rs6987996 Negative each T × 2.83 × 10-3 1.69 × 10-3 to 3.97 × 10-3 1.48 × 10-6 
rs16879304 Negative each C × 4.43 × 10-3 2.54 × 10-3 to 6.32 × 10-3 5.02 × 10-6 
rs17645417 Negative each C × 3.53 × 10-3 2.16 × 10-3 to 4.90 × 10-3 5.25 × 10-7 
rs17645417 Total each C × 2.68 × 10-3 1.39 × 10-3 to 3.96 × 10-3 4.91 × 10-5 
rs2439312 Negative each T ✓ -3.50 × 10-3 -5.14 × 10-3 to -1.86 × 10-3 3.14 × 10-5 
OXTR 
rs237884 Negative each G ✓ -2.58 × 10-3 -3.76 × 10-3 to -1.39 × 10-3 2.46 × 10-5 
rs4686301 Negative each T × 3.64 × 10-3 2.17 × 10-3 to 5.11 × 10-3 1.42 × 10-6 
PANSS domain = Positive and Negative Syndrome Scale scoring domain (positive, negative, general, or total); ATR = Antipsychotic treatment response; Effect estimate = Difference in log-transformed PANSS 
scores between the different genotypes/ with each additional minor allele, multiplied by time; 95% CI = 95% confidence interval; P value = unadjusted P value.  
aIndicates relative response to treatment over time between genotypes (genotypic model) or with each additional minor allele (additive model); × = worse treatment trajectory; ✓ = improved treatment trajectory. 
Variants in bold typeset were significant under both the genotypic and additive inheritance models. Variants highlighted in yellow are in LD with another yellow variant within that gene. 
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3.6.2.2. Associations between genetic variants and baseline ROI volumes 
 
No variants were significantly associated with any of the eight ROI volumes. An uncorrected significance 
threshold (⍺ = 0.05) was therefore considered in order to observe imaging genetics trends of interest with 
respect to antipsychotic treatment response. Three of the variants that were significantly associated with 
antipsychotic treatment response in this study (Table 3.2), showed tentative trends of interest (P < 0.05) for 
ROI volumes, and are shown in Table 3.3, along with the ROIs, estimated effect sizes, 95% confidence 
intervals, P values, and associated treatment outcomes which were taken from Table 3.2. 
 
CACNA1C rs10161032, that was significantly associated with poorer response to treatment (Table 3.2), 
showed trend-level increases in caudate and subcortical grey matter volumes under both the genotypic and 
additive inheritance models (Table 3.3). OXTR rs237884, that was significantly associated with improved 
treatment response, showed trend-level reductions in putamen volumes under both inheritance models. Lastly, 
NRG1 rs2439312, that was significantly associated with improved treatment response, showed trend-level 
increases in cortex and total grey matter volumes under the additive model of inheritance. 
 
Table 3.3. Genetic variants of interest for ROI volumes (uncorrected P < 0.05), that were significantly 
associated with antipsychotic response (Table 3.2). 
Genotypic model of inheritance 
Gene SNP Contrast ATRa Brain ROI Volumeb 
Effect 
estimatec 




Caudate  6.79 × 10-2 












Putamen  -5.64 × 10-2 
-0.11 to -
4.25 × 10-3 
0.0345 
Additive allelic model of inheritance 
Gene SNP Contrast ATRa Brain ROI Volumeb 
Effect 
estimatec 
95% CIc P valuec 
CACNA1C rs10161032 each C × 
Caudate  3.34 × 10-2 
1.02 × 10-2 






8.29 × 10-3 
to 0.25 
0.0367 
NRG1 rs2439312 each T ✓ 










OXTR rs237884 each G ✓ Putamen  -2.99 × 10
-2 
-5.53 × 10-2 
to -4.39 × 
10-3 
0.0223 
ATR = Antipsychotic treatment response; Brain ROI = Brain region of interest; Effect estimate = Percentage increase or reduction in ROI 
volume between different genotypes/ with each additional minor allele; 95% CI = 95% confidence interval; P value = unadjusted P value. 
aIndicates relative response to treatment over time between genotypes (genotypic model) or with each additional minor allele (additive 
model); × = worse treatment trajectory; ✓ = improved treatment trajectory (taken from Table 3.2). bIndicates the overall difference in brain 
volume ( = smaller volume;  = larger volume). cIndicates association statistics from Brain ROI analyses. 
Variants in bold typeset occur under both the genotypic and additive inheritance models. 
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3.6.3. Childhood trauma analyses 
 
3.6.3.1. Associations between childhood trauma and antipsychotic treatment response 
 
No significant associations were identified between the six childhood trauma domains (emotional abuse and 
neglect, physical abuse and neglect, sexual abuse, and total trauma scores) and the four PANSS domains 
(positive, negative, general and total scores). However, when considering an uncorrected significance 
threshold (⍺ = 0.05), a trend was observed between the severity of emotional neglect and the change in log-
transformed PANSS positive scores over time (P = 0.010). This trend suggests that increased severity of 
emotional neglect may result in a poorer treatment trajectory in the positive symptom domain (effect estimate 
= 2.991 × 10-4; 95% CI = 7.166 × 10-5 to 5.269 × 10-4). Other results are not shown. 
 
3.6.3.2. Associations between childhood trauma and baseline ROI volumes 
 
No significant associations were identified between the six childhood trauma domains and the eight brain 
regions of interest (volumetric measures), and no trends of interest were observed when considering an 
uncorrected threshold (⍺ = 0.05). Results are not shown. 
 
3.6.4. Gene-environment interaction (GxE) analyses with childhood trauma 
 
3.6.4.1. Associations between GxE and antipsychotic treatment response 
 
Thirty-one unique GxE (between 27 different variants and varying childhood trauma scores), were significantly 
associated with antipsychotic treatment response under the genotypic model of inheritance. The specific 
associations are listed in Table 3.4, showing the variants and genotypes involved, the categories of childhood 
trauma with which the variants interacted, the PANSS scoring domains affected, along with the estimated 
effect sizes, 95% confidence intervals and unadjusted P values. The 27 variants highlighted in these analyses 
were within CACNA1C, COMT, DISC1, DRD3, NRG1, and OXTR. These variants were found to influence 
treatment trajectory based on the interaction between childhood trauma severity and specific genotypes. One 
of these variants (CACNA1C rs2238096) deviated from Hardy-Weinberg equilibrium. All of the variants in 
COMT, DRD3, and OXTR were found to be in LD with at least one other significant variant within the same 
gene (highlighted in yellow in Table 3.4), and the LD plots for these are displayed in Tables S7b – d. Sixteen 
associations were for improved treatment response, and fifteen associations were for poorer treatment 
response. Significantly influenced treatment response outcomes were evident for negative, general, and total 
symptoms, but not for positive symptoms. Each of the six childhood trauma scoring domains were involved in 
the significant GxE.  
 
Considering the additive model of inheritance, 34 unique GxE between 18 different variants and varying 
childhood trauma scores, were significantly associated with antipsychotic treatment response (Table 3.5). 
These variants were found to influence treatment trajectory based on the interaction between childhood trauma 
severity and the number of minor alleles present. The 18 significant variants were within CACNA1C, COMT, 
DISC1, DRD3, and NRG1, and are shown in Table 3.5, with the categories of childhood trauma involved, the 
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PANSS scoring domains affected, the estimated effect sizes, 95% confidence intervals and unadjusted P 
values. Eleven of these variants were also significant under the genotypic model of inheritance (Table 3.4). All 
of the variants in DRD3 were in LD with another DRD3 variant (highlighted in yellow in Table 3.5), and the LD 
plot for DRD3 is shown in Table S7c. All but one of the variants in DISC1, and all but two of the variants in 
NRG1, were in LD with at least one other significant variant within the same gene (LD plots displayed in Table 
S7e, and Table S7a, respectively), and are highlighted in yellow in Table 3.5. Fifteen associations were for 
improved treatment response, and 19 associations were for poorer treatment response. As observed for the 
genotypic model, these associations involved either negative, general, or total symptoms, but not positive 
symptoms, and each of the six childhood trauma scoring domains were involved in the significant associations. 
 
3.6.4.2. Associations between GxE and baseline ROI volumes 
 
No variants were significantly associated with any of the eight ROI volumes, when interacting with childhood 
trauma. In order to observe exploratory trends of interest for imaging gene-environment interactions (iGxE) of 
antipsychotic treatment response, an uncorrected significance threshold (⍺ = 0.05) was considered. Ten of 
the GxE that were significantly associated with antipsychotic treatment response in this study (Tables 3.4 and 
3.5), showed tentative trends of interest (P < 0.05) for ROI volumes. These 10 GxE are displayed in Table 3.6, 
along with the childhood trauma domain involved, specific ROIs, estimated effect sizes, 95% confidence 
intervals, P values, and associated treatment outcomes that were taken from Tables 3.4 and 3.5. All of the 
variants in DISC1 and NRG1, were in LD with at least one other significant variant within the same gene (LD 
plots displayed in Table S7e, and Table S7a, respectively), and are highlighted in yellow in Table 3.6. Six GxE 
with childhood trauma that were significantly associated with poorer response to antipsychotic treatment, 
showed trend-level reductions in several ROIs (caudate, cortex, pallidum, putamen, subcortical grey matter, 
and total grey matter). Conversely, five GxE that were significantly associated with improved response to 
antipsychotic treatment showed trend-level increases in putamen and hippocampal volumes.  
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Table 3.4. Genetic variants significantly associated with antipsychotic treatment response when interacting with childhood trauma, under the genotypic 
model of inheritance (P < 1.578 × 10-5). 
Gene SNP CTQ domain PANSS domain Contrast Responsea Effect estimate 95% CI P value 
CACNA1C 
rs2238096 EN Negative CC vs AA × 1.51 × 10-3 8.25 × 10-4 to 2.20 × 10-3 1.84 × 10-5 
rs2429127 EN General CT vs TT ✓ -7.92 × 10-4 -1.15 × 10-3 to -4.40 × 10-4 1.23 × 10-5 
rs4126711 SA Negative TC vs CC × 1.17 × 10-3 7.385 × 10-4 to 1.59 × 10-3 1.22 × 10-7 
rs4765687 PN Negative AG vs GG ✓ -1.50 × 10-3 -2.14 × 10-3 to -8.65 × 10-4 4.79 × 10-6 
COMT 
rs2020917 SA Negative TC vs CC × 1.44 × 10-3 8.51 × 10-4 to 2.02 × 10-3 1.81 × 10-6 
rs2075507 PN Negative AG vs GG ✓ -1.55 × 10-3 -2.13 × 10-3 to -9.65 × 10-4 2.62 × 10-7 
rs2239393 SA Negative GA vs AA × 1.32 × 10-3 7.61 × 10-4 to 1.88 × 10-3 4.67 × 10-6 
rs4818 SA Negative CG vs GG × 1.14 × 10-3 6.47 × 10-4 to 1.64 × 10-3 7.77 × 10-6 
rs737865 SA Negative CT vs TT × 1.50 × 10-3 9.91 × 10-4 to 2.01 × 10-3 1.33 × 10-8 
rs737866 SA Negative GA vs AA × 1.50 × 10-3 9.91 × 10-4 to 2.01 × 10-3 1.33 × 10-8 
rs933271 SA General CT vs TT × 9.87 × 10-4 5.40 × 10-4 to 1.43 × 10-3 1.73 × 10-5 
DISC1 
rs12757857 PA Negative TC vs CC ✓ -9.83 × 10-4 -1.40 × 10-3 to -5.64 × 10-4 5.07 × 10-6 
rs2487453 SA Negative GA vs AA ✓ -1.19 × 10-3 -1.69 × 10-3 to -6.83 × 10-4 4.93 × 10-6 




EA General GG vs AA × 1.85 × 10-3 1.01 × 10-3 to 2.69 × 10-3 1.70 × 10-5 
SA Negative GA vs AA × 1.53 × 10-3 1.00 × 10-3 to 2.06 × 10-3 2.46 × 10-8 
rs167771 SA General AA vs GG × 2.68 × 10-3 1.55 × 10-3 to 3.80 × 10-3 3.93 × 10-6 
rs6280 SA Negative TC vs CC × 1.10 × 10-3 6.82 × 10-4 to 1.52 × 10-3 3.53 × 10-7 
rs9825563 SA General GG vs AA ✓ -1.67 × 10-3 -2.35 × 10-3 to -9.90 × 10-4 1.89 × 10-6 
rs9825563 SA Negative GG vs AA ✓ -1.94 × 10-3 -2.63 × 10-3 to -1.25 × 10-3 5.56 × 10-8 
rs9825563 SA Total GG vs AA ✓ -1.56 × 10-3 -2.21 × 10-3 to -9.04 × 10-4 3.68 × 10-6 
NRG1 
rs2919392 EN Negative CC vs TT × 1.63 × 10-3 8.94 × 10-4 to 2.36 × 10-3 1.56 × 10-5 
rs10503901 SA Negative TT vs CC ✓ -1.23 × 10-3 -1.77 × 10-3 to -6.91 × 10-4 8.87 × 10-6 
rs3847131 SA Negative TC vs CC ✓ -1.04 × 10-3 -1.48 × 10-3 to -5.89 × 10-4 6.77 × 10-6 
rs3924999 PN Negative AA vs GG ✓ -1.87 × 10-3 -2.69 × 10-3 to -1.05 × 10-3 8.89 × 10-6 
rs6987996 PN Negative TT vs CC ✓ -1.74 × 10-3 -2.51 × 10-3 to -9.66 × 10-4 1.19 × 10-5 
rs6987996 Total Negative TT vs CC ✓ -3.96 × 10-4 -5.62 × 10-4 to -2.31 × 10-4 3.14 × 10-6 
rs796549 EN Negative AG vs GG × 1.13 × 10-3 7.21 × 10-4 to 1.53 × 10-3 7.76 × 10-8 
OXTR 
rs11706648 SA Negative CA vs AA ✓ -9.95 × 10-4 -1.44 × 10-3 to -5.52 × 10-4 1.23 × 10-5 
rs237885 SA Negative TG vs GG ✓ -1.00 × 10-3 -1.44 × 10-3 to -5.60 × 10-4 1.05 × 10-5 
rs237888 SA Negative CC vs TT × 2.00 × 10-3 1.26 × 10-3 to 2.73 × 10-3 1.49 × 10-7 
CTQ domain = Childhood Trauma Questionnaire scoring domain (EN = emotional neglect, EA = emotional abuse, PN = physical neglect, PA = physical abuse, SA = sexual abuse, Total = overall trauma 
score); PANSS domain = Positive and Negative Syndrome Scale scoring domain (positive, negative, general, or total scores); Effect estimate = Difference in log-transformed PANSS scores between the 
different genotypes, multiplied by time and CTQ score; 95% CI = 95% confidence interval; P value = unadjusted P value.  
aIndicates relative response to treatment over time between genotypes (× = worse treatment trajectory; ✓ = improved treatment trajectory). 
Variants in bold typeset were significant under both the genotypic and additive inheritance models. Variants in red font deviate from HWE. Variants highlighted in yellow are in LD with another yellow variant 
within that gene.  
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Table 3.5. Genetic variants significantly associated with antipsychotic treatment response when interacting with childhood trauma, under the additive 
allelic model of inheritance (P < 1.120 × 10-5). 
Gene SNP CTQ domain PANSS domain Contrast Responsea Effect estimate 95% CI P value 
CACNA1C 
rs2239084 SA General each A × 1.83 × 10-3 1.16 × 10-3 to 2.50 × 10-3 1.36 × 10-7 
rs2239084 SA Total each A × 1.68 × 10-3 1.03 × 10-3 to 2.33 × 10-3 4.57 × 10-7 
rs4126711 SA Negative each T × 8.98 × 10-4 5.70 × 10-4 to 1.23 × 10-3 1.16 × 10-7 
COMT rs2075507 PN Negative each G ✓ -1.28 × 10-3 -1.79 × 10-3 to -7.63 × 10-4 1.51 × 10-6 
DISC1 
rs12757857 PA Negative each T ✓ -6.36 × 10-4 -9.01 × 10-4 to -3.72 × 10-4 2.97 × 10-6 
rs1407601 EN Negative each C × 1.25 × 10-3 8.72 × 10-4 to 1.63 × 10-3 2.44 × 10-10 
rs1407601 PN Negative each C × 1.64 × 10-3 1.07 × 10-3 to 2.20 × 10-3 2.07 × 10-8 
rs701160 SA Negative each A ✓ -7.34 × 10-4 -1.02 × 10-3 to -4.48 × 10-4 6.36 × 10-7 
rs7552697 Total Negative each C × 2.65 × 10-4 1.49 × 10-4 to 3.80 × 10-4 8.96 × 10-6 
DRD3 
rs1394016 SA General each G × 1.25 × 10-3 7.63 × 10-4 to 1.73 × 10-3 5.99 × 10-7 
rs1394016 SA Negative each G × 1.44 × 10-3 9.46 × 10-4 to 1.94 × 10-3 2.03 × 10-8 
rs1394016 SA Total each G × 1.20 × 10-3 7.40 × 10-4 to 1.67 × 10-3 4.96 × 10-7 
rs167771 SA General each A × 9.21 × 10-4 5.32 × 10-4 to 1.31 × 10-3 4.32 × 10-6 
rs167771 SA Negative each A × 9.96 × 10-4 5.96 × 10-4 to 1.40 × 10-3 1.38 × 10-6 
rs167771 SA Total each A × 8.61 × 10-4 4.88 × 10-4 to 1.23 × 10-3 7.14 × 10-6 
rs6280 SA General each T × 9.23 × 10-4 5.63 × 10-4 to 1.28 × 10-3 6.47 × 10-7 
rs6280 SA Negative each T × 9.30 × 10-4 5.56 × 10-4 to 1.30 × 10-3 1.36 × 10-6 
rs6280 SA Total each T × 8.03 × 10-4 4.57 × 10-4 to 1.15 × 10-3 6.59 × 10-6 
rs9825563 SA General each G ✓ -8.51 × 10-4 -1.15 × 10-3 to -5.55 × 10-4 2.65 × 10-8 
rs9825563 SA Negative each G ✓ -1.04 × 10-3 -1.34 × 10-3 to -7.38 × 10-4 3.84 × 10-11 
rs9825563 SA Total each G ✓ -8.01 × 10-4 -1.09 × 10-3 to -5.17 × 10-4 5.04 × 10-8 
NRG1 
rs10503901 SA Negative each T ✓ -6.16 × 10-4 -8.85 × 10-4 to -3.46 × 10-4 8.81 × 10-6 
rs11778887 EA Negative each G ✓ -7.57 × 10-4 -1.05 × 10-3 to -4.64 × 10-4 5.32 × 10-7 
rs11778887 EN Negative each G ✓ -6.76 × 10-4 -9.65 × 10-4 to -3.87 × 10-4 5.54 × 10-6 
rs11778887 PN Negative each G ✓ -1.04 × 10-3 -1.50 × 10-3 to -5.92 × 10-4 7.34 × 10-6 
rs11778887 Total Negative each G ✓ -2.46 × 10-4 -3.34 × 10-4 to -1.58 × 10-4 6.93 × 10-8 
rs16879067 EA Negative each T ✓ -7.56 × 10-4 -1.06 × 10-3 to -4.55 × 10-4 1.05 × 10-6 
rs16879067 Total Negative each T ✓ -2.44 × 10-4 -3.34 × 10-4 to -1.54 × 10-4 1.63 × 10-7 
rs2466049 EN Negative each T × 1.00 × 10-3 5.65 × 10-4 to 1.44 × 10-3 8.09 × 10-6 
rs2466049 PN Negative each T × 1.85 × 10-3 1.09 × 10-3 to 2.60 × 10-3 2.20 × 10-6 
rs3847131 EN General each T × 5.65 × 10-4 3.21 × 10-4 to 8.09 × 10-4 6.57 × 10-6 
rs3847131 EN Total each T × 5.23 × 10-4 2.90 × 10-4 to 7.56 × 10-4 1.27 × 10-5 
rs3924999 PN Negative each A ✓ -1.07 × 10-3 -1.45 × 10-3 to -6.76 × 10-4 1.14 × 10-7 
rs4733094 PN Negative each A ✓ -1.06 × 10-3 -1.52 × 10-3 to -6.03 × 10-4 7.29 × 10-6 
CTQ domain = Childhood Trauma Questionnaire scoring domain (EN = emotional neglect, EA = emotional abuse, PN = physical neglect, PA = physical abuse, SA = sexual abuse, Total = overall trauma 
score); PANSS domain = Positive and Negative Syndrome Scale scoring domain (positive, negative, general, or total scores); Effect estimate = Difference in log-transformed PANSS scores with each additional 
minor allele, multiplied by time and CTQ score; 95% CI = 95% confidence interval; P value = unadjusted P value.  
aIndicates relative response to treatment over time with each additional minor allele (× = worse treatment trajectory; ✓ = improved treatment trajectory). 
Variants in bold typeset were significant under both the genotypic and additive inheritance models. Variants highlighted in yellow are in LD with another yellow variant within that gene. 
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Table 3.6. Genetic variants of interest for ROI volumes (P < 0.05), that were significantly associated with antipsychotic response (Tables 3.4 and 3.5) 
when interacting with childhood trauma. 
Genotypic model of inheritance 
Gene SNP CTQ domain Contrast ATRa Brain ROI Volumeb Effect estimatec 95% CIc P valuec 
CACNA1C rs4126711 SA TC vs CC × Putamen  -1.05 × 10-2 -1.91 × 10-2 to -1.87 × 10-3 0.0183 
DISC1 rs701160 SA AA vs GG ✓ Putamen  1.08 × 10
-2 6.23 × 10-5 to 2.16 × 10-2 0.0487 
NRG1 rs796549 EN AG vs GG × 
Cortex  -0.39 -0.74 to -0.05 0.0265 
Total grey matter  -0.42 -0.83 to -1.18 × 10-2 0.0441 
Additive allelic model of inheritance 
Gene SNP CTQ domain Contrast ATRa Brain ROI Volumeb Effect estimatec  95% CIc P valuec 
CACNA1C rs4126711 SA each T × 
Pallidum  -2.79 × 10-3 -5.39 × 10-3 to -1.98 × 10-4 0.0355 
Putamen  -9.15 × 10-3 -1.56 × 10-2 to -2.71 × 10-3 0.0065 
DISC1 
rs1407601 EN each C × 
Pallidum  -3.44 × 10-3 -6.63 × 10-3 to -2.42 × 10-4 0.0357 
Putamen  -1.05 × 10-2 -1.86 × 10-2 to -2.36 × 10-3 0.0127 
rs12757857 PA each T ✓ Hippocampus  4.02 × 10
-3 6.89 × 10-4 to 7.36 × 10-3 0.0191 
rs7552697 Total each C × Subcortical grey matter  -1.01 × 10-2 -2.00 × 10-2 to -1.88 × 10-4 0.0460 
NRG1 
rs11778887 EN each G ✓ Hippocampus  4.39 × 10
-3 6.54 × 10-4 to 8.13 × 10-3 0.0223 
rs11778887 PN each G ✓ Hippocampus  6.93 × 10
-3 8.32 × 10-4 to 1.30 × 10-2 0.0268 
rs2466049 PN each T × Caudate  -1.37 × 10-2 -2.65 × 10-2 to -9.64 × 10-4 0.0357 
rs4733094 PN each A ✓ Hippocampus  6.65 × 10
-3 1.47 × 10-4 to 1.31 × 10-2 0.0452 
CTQ domain = Childhood Trauma Questionnaire scoring domain (EN = emotional neglect, EA = emotional abuse, PN = physical neglect, PA = physical abuse, SA = sexual abuse, Total = overall trauma 
score); ATR = Antipsychotic treatment response; Brain ROI = Brain region of interest; Effect estimate = Percentage increase or reduction in ROI volume between different genotypes/ with each additional minor 
allele, multiplied by CTQ score; 95% CI = 95% confidence interval; P value = unadjusted P value.  
aIndicates relative response to treatment over time between genotypes (genotypic model) or with each additional minor allele (additive model); × = worse treatment trajectory; ✓ = improved treatment trajectory 
(taken from Tables 3.4 and 3.5). bIndicates the overall difference in brain volume ( = smaller volume;  = larger volume). cIndicates association statistics from Brain ROI analyses. 
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3.7. Pathway analysis 
  
No variants were significantly associated with ROI volumes in the genetic analyses nor in the GxE analyses. 
Enrichment analysis was therefore done for all of the genes that were significantly associated with 
antipsychotic treatment response in this study, with and without childhood trauma interaction, i.e. CACNA1C, 
COMT, DISC1, DRD3, NRG1, and OXTR. A total of 33 pathways were identified involving CACNA1C, COMT, 
DRD3, NRG1, and OXTR, shown in Table 3.7. Five of these pathways involved more than one gene of interest, 
and were the top five most significant pathways (ordered by P value). These were the “Dopaminergic synapse” 
(involving CACNA1C, COMT, DRD3), “Oxytocin signalling pathway” (OXTR and CACNA1C), “Calcium 
signalling pathway” (OXTR and CACNA1C), “cAMP signalling pathway” (OXTR and CACNA1C), and 
“Neuroactive ligand-receptor interaction” (OXTR and DRD3). CACNA1C was involved in 29 of the pathways. 
 
Table 3.7. Enrichr output showing KEGG Human pathways involving genes significantly associated 
with antipsychotic treatment response in this study (with and without childhood trauma interaction). 
aPathway according to the KEGG 2019 Human database. bGenes from input list involved in pathway. cFrom Enrichr output, computed 
from the Fisher exact test, which is a proportion test that assumes a binomial distribution and independence for probability of any gene 
belonging to any set.
KEGG 2019 Human Pathwaya Genesb P valuec 
Dopaminergic synapse CACNA1C, COMT, DRD3 5.41 x 10-6 
Oxytocin signalling pathway OXTR, CACNA1C 8.55 x 10-4 
Calcium signalling pathway OXTR, CACNA1C 0.001 
cAMP signalling pathway OXTR, CACNA1C 0.002 
Neuroactive ligand-receptor interaction OXTR, DRD3 0.004 
Tyrosine metabolism COMT 0.011 
Type II diabetes mellitus CACNA1C 0.014 
Steroid hormone biosynthesis COMT 0.018 
Cortisol synthesis and secretion CACNA1C 0.019 
Long-term potentiation CACNA1C 0.020 
Amphetamine addiction CACNA1C 0.020 
Renin secretion CACNA1C 0.021 
Arrhythmogenic right ventricular cardiomyopathy CACNA1C 0.021 
Cardiac muscle contraction CACNA1C 0.023 
Taste transduction CACNA1C 0.025 
Hypertrophic cardiomyopathy CACNA1C 0.025 
ErbB signalling pathway NRG1 0.025 
Insulin secretion CACNA1C 0.026 
GABAergic synapse CACNA1C 0.026 
Dilated cardiomyopathy CACNA1C 0.027 
GnRH signalling pathway CACNA1C 0.028 
Circadian entrainment CACNA1C 0.029 
Aldosterone synthesis and secretion CACNA1C 0.029 
Cholinergic synapse CACNA1C 0.033 
Serotonergic synapse CACNA1C 0.033 
Glutamatergic synapse CACNA1C 0.034 
Vascular smooth muscle contraction CACNA1C 0.039 
Adrenergic signalling in cardiomyocytes CACNA1C 0.043 
Retrograde endocannabinoid signalling CACNA1C 0.044 
Cushing syndrome CACNA1C 0.046 
cGMP-PKG signalling pathway CACNA1C 0.049 
Alzheimer disease CACNA1C 0.050 
MAPK signalling pathway CACNA1C 0.085 
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This study made use of an integrative research approach to explore the interplay between genetics, brain 
structure, and childhood trauma, in the context of differential antipsychotic treatment outcomes in 
schizophrenia. This was done by conducting a number of different association analyses, in an attempt to reveal 
trends that may contribute to the understanding of various underlying mechanisms involved in antipsychotic 
treatment response. 
 
4.1. Candidate genes and variants 
 
To our knowledge, aside from the current study, there have been no studies investigating imaging genetics in 
antipsychotic treatment response considering structural neuroimaging measurements. The candidate genes 
included in this study, based on previous implication in both brain structure and antipsychotic treatment 
response, were therefore selected if they were identified in 1) genetic studies of brain structure, and 2) genetic 
studies of antipsychotic response, respectively. Fourteen genes were identified in the two lists, which provides 
evidence for a genetic overlap between the two traits (brain structure and treatment response). This is further 
supported when considering specific variants identified in these studies. Ten of the variants prioritised for this 
study were found to influence both brain structure and antipsychotic treatment response in previous studies 
(Table S5). These were: BDNF rs6265 (Ho et al., 2006; Zhang et al., 2013), CACNA1C rs1006737 (Porcelli et 
al., 2015; Wang et al., 2011), COMT rs4680 (Gupta et al., 2009; Ohnishi et al., 2005), DISC1 rs6675281 
(Mouaffak et al., 2011; Trost et al., 2013), DRD2 rs1800497 (Li et al., 2018; Zhang et al., 2010), DRD3 rs6280 
(Takahashi et al., 2008; Vehof et al., 2012), NRG1 rs35753505 (Mostaid et al., 2017; Suárez-Pinilla et al., 
2015), RGS4 rs2661319 (Lane et al., 2008; Prasad et al., 2005), TNFα rs1800629 (Baune et al., 2012; Zai et 
al., 2006), and ZNF804A rs1344706 (Mössner et al., 2012; Wassink et al., 2012). These findings warrant 
further investigation of the genetic overlap between brain structure and antipsychotic response. Although very 
few fMRI imaging genetics studies of antipsychotic treatment response have been performed, one of these 
studies found that the interaction between DRD2 rs1076560 and AKT1 rs1030233 was associated with 
differing cingulate response and reduced behavioural accuracy during attentional processing in healthy 
individuals, and with improved antipsychotic treatment response in schizophrenia patients (Blasi et al., 2011). 
Both DRD2 and AKT1 were selected as candidate genes for this study, which supports a potential role of these 
genes in both brain structure and antipsychotic treatment response, in addition to the suggested role in brain 
function as per the study by Blasi et al. (2011). This warrants future exploration of the potential links between 
these three traits (brain structure, function, and antipsychotic response) in the context of DRD2 and AKT1 
variation. As no variants within AKT1 met the criteria for inclusion in the current study, this gene was not 
investigated for associations with either ROI volume or antipsychotic treatment response. 
 
4.2. Brain structure in antipsychotic response 
 
Structural variation in the brains of individuals with schizophrenia is undoubtedly correlated with differential 
response to antipsychotic treatment. Although the exact role that specific brain regions may have in 
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antipsychotic response remains unclear, this link has been supported by numerous imaging studies (reviewed 
by Tarcijonas and Sarpal, 2019). It is therefore surprising that no significant associations, nor trends of interest 
(P < 0.05) were identified between antipsychotic response and the brain regions of interest explored in this 
study, all of which have been previously implicated in varied response to antipsychotic treatment. As with any 
association studies in a trait of such a complex nature, there are a multitude of reasons for this. Firstly, the 
participants in this study were first-episode, and treatment-naïve. Neuroimaging studies of antipsychotic 
response in treatment-naïve patients are incredibly limited, and as antipsychotic treatment results in structural 
brain changes over time, the effects of prior antipsychotic exposure on brain structure cannot be ruled out in 
previously treated patients, when making comparisons between studies (Emsley et al., 2017). Furthermore, 
several studies considered the changes in brain volume between start and endpoint in relation to antipsychotic 
response (Altamura et al., 2017; Li et al., 2012; Mitelman et al., 2009), whereas this study only included 
volumetric measures of brain regions at baseline (pre-treatment). Importantly, there are major inconsistencies 
among studies with regard to the specific antipsychotic administered, the clinical measurements of symptoms, 
and the criteria for response to treatment, all of which present a massive challenge with respect to study 
comparison. Additionally, differences in neuroimaging methodologies may also account for inconsistencies 
between studies. These include differences in instruments used, and data processing methods (i.e. software 
packages and versions, and parameters used), which contribute to the reliability of structural MRI measures 
(Gronenschild et al., 2012; Senjem et al., 2005). Lastly, most of the previous studies classified patients as 
either responders or non-responders, and assessed structural brain differences between the two groups; 
examples include the studies by Buchsbaum et al. (2003), Mitelman et al. (2009), and Quarantelli et al. (2014). 
This approach was not feasible for this study, as the majority of participants (~75%) achieved early response, 
approximately half achieved full remission (~56%), and only nine participants (~9%) were classified as non-
responders. The entire patient cohort was therefore assessed together, where response to treatment was 
based on the treatment trajectory over 12 months, thus taking into consideration all nine of the PANSS score 
assessments done over this time period. Assessing antipsychotic response in terms of treatment trajectory 
allows observation of relative differences in response over time between all patients. However, this could 
possibly explain the lack of significant associations identified here, as differences in brain structure between 
individuals can be minor and subtle, potentially necessitating the comparison of patients with phenotypic 
extremes for antipsychotic response, in order to reveal trends in small sample sizes. 
 
4.3. Genetic predictors of antipsychotic response 
 
This study revealed 17 unique significant associations between 10 genetic variants in CACNA1C, NRG1, and 
OXTR, and different antipsychotic treatment outcomes (Table 3.2). The majority of associations were for the 
negative symptom domain, and no variants were found to significantly effect changes in positive symptoms 
over time. Two associations were for changes in general symptoms, and one association was for changes in 
total symptoms over time. Four of the 10 genetic variants were associated with treatment response across 
more than one PANSS symptom domain (negative, general, or total), or under both the genotypic and additive 
allelic models of inheritance. Nine of the variants were novel with respect to antipsychotic treatment response, 
and the remaining variant (OXTR rs4686301) has been previously associated with treatment outcome (Souza 
et al., 2010) 
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The abundance of associations pertaining to the negative symptoms of schizophrenia was interesting, as these 
symptoms are particularly complex and difficult to treat (Millan et al., 2014). The results presented here may 
therefore have specific links to the pathophysiology and manifestation of negative symptoms such as avolition 
and blunted emotion, and could potentially be considered as drug targets for the specific improvement of 
persistent negative symptoms. Considering that 31 of the variants prioritised for investigation in this study had 
been previously implicated in antipsychotic response (Table S5), it may seem unexpected that only one of 
these variants was significantly associated with antipsychotic treatment outcome in our study. However, this 
did not come as a surprise when taking into account the previously discussed clinical and methodological 
inconsistencies between studies, which render study comparison difficult, and create a massive challenge with 
respect to the reproducibility of findings. In addition to these factors, another important consideration warrants 
attention in the context of genetic association studies: that of population stratification (Daya et al., 2013). The 
current study cohort predominantly comprised South African Mixed-Ancestry individuals, who are highly 
admixed, yet the vast majority of previous genetic studies of treatment response identified were done in non-
African populations. When comparing genetic associations across different population groups, one needs to 
consider the fluctuations in allele frequencies between populations that lead to differences in LD. This is 
demonstrated in particular with the extensive variation in LD patterns between individuals of European and 
African descent (Gurdasani et al., 2019; Sirugo et al., 2019). This contributes to the inconsistencies observed 
among genetic association studies, as variants associated with a certain phenotype in a specific population 
group, could just be proxies for the biologically relevant variants due to LD (Sirugo et al., 2019). This 
phenomenon emphasises the importance of conducting genetic association studies in more genetically diverse 
population groups, as 1) variants associated with certain outcomes in European individuals may not be 
applicable in African individuals (Gurdasani et al., 2019; Sirugo et al., 2019), and 2) populations with high 
levels of genetic diversity present an untapped recourse with regard to the discovery of potential biologically 
relevant variants, due to the low levels of linkage disequilibrium (Gurdasani et al., 2019). 
 
4.3.1. Calcium channel signalling and CACNA1C variation 
 
Two novel significant associations between CACNA1C variants and antipsychotic treatment response were 
identified (rs10161032 and rs215976; Table 3.2). Considering the critical role of ionic calcium in neuronal 
function and neurotoxicity (Harrison et al., 2019), calcium channel signalling, modulated by voltage-gated 
calcium channels, is gaining increasing recognition for its implication in the pathophysiology of 
neuropsychiatric disorders including schizophrenia (Bhat et al., 2012; Kabir et al., 2017), as well as its excellent 
potential for therapeutic intervention (O’Connell et al., 2019; Zamponi, 2016). Calcium channel blockers have 
been used in the treatment of cardiovascular conditions for 40 years, and are emerging as potential therapies 
for a number of neuropsychiatric disorders including schizophrenia (Grebb et al., 1986; Harrison et al., 2019; 
Price, 1987; Yamada et al., 1996). These drugs primarily target L-type voltage-gated calcium channels 
(Harrison et al., 2019), of which subunit alpha-1C (encoded by CACNA1C) is one of the main subtypes 
expressed in the brain (Kabir et al., 2017). Additionally, the alpha-1C subunit is essential for normal brain 
development and plasticity (Kabir et al., 2017), and for these reasons, CACNA1C has been the most widely 
documented with regard to psychiatric disorders (Bhat et al., 2012; Kabir et al., 2017), as well as for association 
with antipsychotic treatment response (O’Connell et al., 2019; Porcelli et al., 2015; Yu et al., 2018). 
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With respect to the first significant variant, rs10161032, the CC genotype was associated with worse response 
to treatment compared to TT, considering the trajectory of both general and negative symptoms over time. 
This was further supported by the association of each additional C allele conferring a worse general symptom 
trajectory over time, under the additive model (Table 3.2). This variant was predicted to be involved in both 
proximal and distal regulation according to rSNPbase, and is also within a transcription factor binding motif for 
EHF (ETS homologous factor). Interestingly, a variant in EHF (rs286913) was the most significant variant in a 
genome-wide pharmacogenomic study looking at neurocognitive phenotypes as indicators of antipsychotic 
response, where it was found to significantly mediate the effects of ziprasidone on vigilance (McClay et al., 
2011). EHF is known to be a transcriptional repressor downstream of mitogen-activated protein kinase (MAPK) 
signalling cascades (Tugores et al., 2001). Abnormal activity of MAPK-associated signalling pathways has 
been found in frontal cortical areas of the post-mortem brain in schizophrenia (Funk et al., 2012). EHF could 
therefore be a relevant transcription factor to explore further in the context of antipsychotic response, as in 
addition to its role in MAPK signalling, and its potential contribution to neurocognition, our findings suggest an 
additional role for EHF in antipsychotic response via the regulation of calcium channel signalling through 
CACNA1C binding. 
 
The second CACNA1C variant, rs215976, was found to be associated with an improved trajectory for negative 
symptoms with each additional T allele. This variant was predicted to be missense/ synonymous according to 
the Ensembl variant effect predictor, resulting in a predicted amino acid change (aspartic acid to glutamic acid) 
as per the SIFT and Polyphen results from SNPnexus. However, the consequences of this amino acid change 
are inconclusive, as it was predicted by SIFT to be tolerated, and a number of results were returned for 
Polyphen, with predictions ranging from benign (scores from 0 to 0.084), to probably damaging (scores from 
0.919 to 0.997). Further investigation is required to confirm whether this variant has a damaging functional 
consequence, as such alterations to the protein structure may potentially be beneficial in the context of 
antipsychotic mechanism of action, thus contributing to improved response to treatment. 
 
Although in silico prediction tools provide a useful platform to predict the potential consequences of variants, 
the suggested mechanisms by which the aforementioned variants may contribute to alterations in calcium 
channel signalling are by no means indisputable. These findings require validation in other cohorts, and 
predicted consequences of variants should be functionally validated in situ or in vivo. That said, these results 
lend further evidence to the involvement of CACNA1C, and calcium channel signalling, in antipsychotic efficacy 
and response. The novel associations warrant further investigation in research pertaining to antipsychotic 
response, especially considering the recognised potential for calcium channels as therapeutic targets. 
 
4.3.2. NRG1-ErbB4 signalling and NRG1 variation 
 
Of the variants significantly associated with treatment outcome in this study, the majority (six of the 10) were 
NRG1 variants (Table 3.2). NRG1 (encoding neuregulin 1) is a pleiotropic growth factor with multiple isoforms, 
that plays a role in neurodevelopment and synaptic plasticity, and is also one of the leading schizophrenia 
susceptibility genes (Deng et al., 2013; Harrison and Law, 2006). ErbB4 is the receptor for NRG1, and NRG1-
ErbB4 signalling has been shown to closely interact with several neurotransmitter pathways that are critical in 
schizophrenia pathophysiology and antipsychotic efficacy, namely glutamatergic, GABAergic, and 
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dopaminergic pathways (Deng et al., 2013). The NRG1-ErbB4 signalling pathway may therefore present an 
opportunity for the discovery of novel therapeutic targets for schizophrenia treatment (Deng et al., 2013; Hahn, 
2011; Karam et al., 2010).  
 
All of the NRG1 variants significantly associated with treatment response had predicted roles in gene regulation 
according to RegulomeDB, rSNPBase, or SNP2TFBS. The abundance of variants with regulatory 
consequences does not come as a surprise, as it has become increasingly apparent that significant 
associations in GWAS of complex disorders such as schizophrenia, as well as antipsychotic response, are 
enriched for variants in noncoding regions of the genome (Ovenden et al., 2017; Roussos et al., 2014). 
Noncoding variants involved in regulatory pathways have implications in altered gene expression and may 
contribute larger effects than variants in coding regions, considering their influence on global transcription and 
translation (Georgitsi et al., 2011). The variant with the lowest RegulomeDB score of 1f (likely to affect binding 
and linked to expression of a gene target) was predicted to be a cis-eQTL according to RegulomeDB and 
rSNPBase, thus directly influencing NRG1 expression. This variant (rs2439312) therefore had the most 
evidence for regulatory impact and was significantly associated with improved negative symptomology over 
time. Interestingly, this variant was found to be in LD with rs17645417 (predicted to be less likely to affect 
binding according to RegulomeDB), which was the variant with the highest number of significant associations 
with antipsychotic response. These associations showed that both the CC and CT genotypes had significantly 
worse treatment trajectories for negative symptoms, than the TT genotype. Furthermore, under the additive 
allelic model, it was found that each additional C allele conferred significantly worse treatment trajectories for 
both negative and total symptom scores over time. It was unexpected to see such different associations for 
two variants in LD, yet not unjustifiable, as these two variants had a D’ value of 0.84 and were therefore not in 
perfect LD, which could explain the differences between the associations. 
 
Collectively, these results give an indication that dysregulation of neuregulin 1 signalling, that may arise from 
multiple rSNPs in NRG1, could contribute toward phenotypic variation in antipsychotic treatment response. 
These findings therefore support the existing evidence for the role of NRG1-ErbB4 signalling in variable 
response to antipsychotics (Kampman et al., 2004). Furthermore, the novel associations discovered here 
warrant further investigation, as this could provide additional insight into the role of NRG1-ErbB4 signalling in 
treatment response, and as a potential target for novel therapeutic intervention. 
 
4.3.3. Oxytocin signalling and OXTR variation 
 
Two significant associations between OXTR variants and antipsychotic response were identified (Table 3.2), 
one novel association (rs237884) and one that had been previously reported in literature (rs4686301; Souza 
et al., 2010). The OXTR gene encodes the oxytocin receptor protein (OXTR) in humans which functions as a 
receptor for the neurohormone oxytocin (Chatterjee et al., 2016). Although only one previous study of OXTR 
variants in antipsychotic response was identified (Souza et al., 2010), the oxytocin system has received 
considerable attention in the context of psychiatric disorders (Rich and Caldwell, 2015; Quintana et al., 2019). 
Of particular relevance here, is the traction that is being gained for the oxytocin system as a promising 
therapeutic target in schizophrenia (Bujanow, 1972; MacDonald and Feifel, 2012; Rich and Caldwell, 2015). 
This has been explored in animal studies (Keebaugh et al., 2015; Lee et al., 2005; 2008), as well as several 
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small clinical trials in humans (Feifel et al., 2010; Lee et al., 2013; Modabbernia et al., 2013; Pedersen et al., 
2011). Oxytocin signalling serves as an attractive candidate for drug targeting because of its diverse range of 
actions (Chatterjee et al., 2016). 
 
In the study of OXT (encoding oxytocin) and OXTR variants in antipsychotic response by Souza and 
colleagues in 2010, the TT genotype of OXTR rs4686301 was found to be nominally associated with 
improvement of positive symptoms (Souza et al., 2010). Conversely, an association between a worse 
treatment trajectory for negative symptoms with each additional T allele of rs4686301 was identified in the 
current study (Table 3.2). There are a number of explanations for the contrasting associations between the 
two studies. Firstly, the difference between positive and negative symptoms must be acknowledged when 
considering response to antipsychotic treatment. Regardless of the varying clinical assessment tools used to 
measure and categorise the symptoms of schizophrenia, the negative symptoms (i.e. avolition and anhedonia) 
tend to persist even when positive symptoms have been alleviated. Considering the inconsistent effects of 
antipsychotics between distinct symptom domains, contrasting directionality of response observed for a 
particular variant in positive and negative symptom domains in different studies is therefore not unjustifiable. 
Secondly, the study by Souza et al. (2010) was done in a cohort comprising mostly individuals of Caucasian 
descent (82%), whereas 80% of the individuals in the current study were South African Mixed-Ancestry. As 
discussed in section 4.3, population stratification may account for some of the observed inconsistencies 
between studies considering different population groups. Lastly, the study by Souza et al. (2010) was 
investigating clozapine response, therefore almost all patients in the study had been classified as treatment 
refractory or intolerant of FGA treatment. This is in contrast to the current study of flupenthixol treatment 
response (an FGA) in FES patients. This is particularly notable here, as treatment refractoriness may represent 
a distinct subtype of schizophrenia, with clozapine used for antipsychotic therapy in these patients when other 
drugs fail. This could, in part, explain how the T allele of rs4686301 conferred worse response to treatment in 
a first-episode cohort, yet the TT genotype conferred improved clozapine response in the treatment refractory 
cohort. 
 
A second variant within OXTR, rs237884, was significantly associated with treatment response in our study 
under both the genotypic and additive inheritance models. Here, individuals with the GG genotype for this 
variant had a significantly improved treatment trajectory in the negative symptom domain, compared to 
individuals with the AA genotype. This was in accordance with the additive model, which showed that each G 
allele of rs237884 conferred an improvement in treatment trajectory for the negative symptoms. Interestingly, 
this variant was predicted to alter miRNA binding (according to PolymiRTS), where it was shown to be located 
within the target site for hsa-miR-4786-3p. Here, the presence of the G allele predicted binding of hsa-miR-
4786-3p, whereas the A allele could abolish this target site. The predicted regulatory impact of rs237884 lends 
evidence to the potential role of miRNA-mediated regulation in antipsychotic treatment response. 
 
These findings therefore provide support for the implication of rs4686301 in antipsychotic response, although 
this variant could contribute varying effects with different antipsychotics, or with different subtypes of 
schizophrenia. A novel OXTR association was also identified which warrants further investigation, but could 
potentially corroborate the potential for miRNA-mediated regulation as a mechanism contributing to the 
functioning of the oxytocin system, and by extension, to antipsychotic response. These results should be 
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investigated further, as this could contribute to our understanding of the oxytocin signalling as a potential drug 
target for schizophrenia treatment. 
 
4.3.4. Imaging genetics of antipsychotic response 
 
The lack of significant associations between genetic variants and ROI volumes prevented the identification of 
significant imaging genetic correlates of antipsychotic treatment response in this study. This can most likely 
be attributed to insufficient statistical power, considering the limited sample size in this study. However, this 
study was exploratory in nature, therefore an uncorrected significance threshold (⍺ = 0.05) was considered in 
order to examine imaging genetic trends of interest for antipsychotic response. Three of the genetic variants 
found to be significantly associated with antipsychotic response in this study, showed trends of interest for ROI 
volume (P < 0.05; Table 3.3). These variants were CACNA1C rs10161032, OXTR rs237884, and NRG1 
rs2439312. The CC genotype and number of C alleles for CACNA1C rs10161032, which were significantly 
associated with worse response to antipsychotic treatment under the genotypic and additive inheritance 
models (respectively), revealed potential trends for larger caudate and subcortical grey matter volumes. The 
GG genotype and number of G alleles for OXTR rs237884 were associated with improved response to 
treatment in this study, and also showed trend-level reductions in putamen volumes under both inheritance 
models. Lastly, NRG1 rs2439312 showed a potential trend for larger cortex and total grey matter volumes with 
each additional T allele, for which there was a significant association with improved treatment outcome.  
 
As all previous imaging genetics studies of antipsychotic response involved the investigation of functional 
magnetic resonance imaging (fMRI) measures, no comparisons could be made with these studies (Bishop et 
al., 2015; Blasi et al., 2011; 2015). Furthermore, none of the three variants discussed here have been 
previously associated with volumetric variation in any of the brain regions of interest. Despite the lack of 
significant associations, these results suggest that at least three of the variants implicated in differential 
response to antipsychotics in this study, may potentially influence brain structure as well, and should be further 
investigated for potential associations with volumetric variation in brain ROIs. Considering that to the best of 
our knowledge, this was the first study to investigate the genetic overlap between structural neuroimaging 
measures and antipsychotic response in schizophrenia, these findings could provide a starting point for future 
structural imaging genetics studies of antipsychotic treatment outcome. 
 
4.4. Childhood trauma in antipsychotic response and brain structure 
 
Although the severity of childhood trauma was not significantly associated with differential treatment response 
in our study, when considering an uncorrected significance threshold (⍺ = 0.05), a trend of interest was 
observed. This suggested that more severe experiences of emotional neglect during childhood may contribute 
to a poorer treatment trajectory for positive symptoms. In a previous study of treatment-resistant schizophrenia, 
it was reported that more frequent experiences of emotional neglect and abuse, as well as sexual abuse, were 
evident among the treatment-resistant patients compared to the patients who responded to antipsychotics 
(Hassan and De Luca, 2015). It has also been shown that childhood trauma, and emotional abuse in particular, 
may contribute to early non-response to antipsychotic treatment in FES patients (Misiak and Frydecka, 2016). 
The paucity of studies addressing the link between childhood adversities and treatment outcome makes it 
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difficult to draw unequivocal conclusions, however there is an apparent trend among the existing literature for 
less favourable response to antipsychotic treatment in patients with a self-reported history of childhood trauma. 
Although our findings were not statistically significant, the trend identified does support previous findings. 
 
In terms of childhood trauma and brain structure, no significant associations, nor trends of interest were 
identified in this study for the eight ROIs. Potential trends between antipsychotic response and ROI volumes 
in the context of childhood trauma could therefore not be explored in our cohort. The majority of previous 
studies investigating the link between brain volume and childhood trauma have focussed on the hippocampal 
and amygdalar brain regions (Calem et al., 2017; Misiak et al., 2017). It has been suggested that these regions 
in particular could mediate associations between early trauma and schizophrenia due to their implication in 
hypothalamic-pituitary-adrenal (HPA) axis regulation, which is the body’s core stress response system (Misiak 
et al., 2017). As the amygdala was not found to be previously associated with antipsychotic response, it was 
not included as an ROI for this study. However, an association with the hippocampus was expected, as 
reduced hippocampal volume is one of the most consistently reported neuroimaging correlates of childhood 
trauma (Calem et al., 2017; Teicher and Samson, 2016). In addition to this, sexual abuse has been previously 
associated with reduced total grey matter volume (Sheffield et al., 2013), which was also included in this study, 
yet no associations were identified here. The numerous clinical and methodological inconsistencies among 
studies that could explain either contrasting associations, or lack of associations in our study, have already 
been discussed. One additional clinical inconsistency that has not yet been mentioned is that of childhood 
trauma assessment. Differences in the measurement tools used to assess the severity of different types of 
childhood trauma range from structured and semi-structured interviews to self-report questionnaires, thereby 
potentially hindering the reproducibility of findings (Popovic et al., 2019). 
 
4.5. Toward a unified view of antipsychotic treatment outcome 
 
4.5.1. Gene-environment interactions (GxE) in antipsychotic response 
 
When considering GxE, thirty-four variants in CACNA1C, COMT, DISC1, DRD3, NRG1, and OXTR were 
significantly associated with antipsychotic response when interacting with childhood trauma (Tables 3.4 and 
3.5). These associations show that childhood trauma can influence response to antipsychotic treatment via 
interactions with certain genetic variants. In other words, the way an individual responds to treatment based 
on the presence of specific genotypes, can be altered if certain types and severities of trauma are experienced 
during childhood. Most of these associations were for changes in negative symptoms over time, and no 
significant associations were identified in the positive symptom domain. Several associations were evident for 
the general symptom domain, as well as for changes in total symptom severity scores over time. This is the 
same as what was observed in the genetic association analyses, when childhood trauma was not factored in. 
Each of the five CTQ subscales, namely emotional abuse and neglect, physical abuse and neglect, and sexual 
abuse, as well as overall trauma, were involved in these significant GxE. However, predominantly sexual abuse 
was found to significantly influence patients’ response to treatment based on genotypic differences.  
 
With regard to the genetic variants significantly associated with antipsychotic treatment response when 
childhood trauma was not factored in (Table 3.2), it was interesting to see that only one of these variants 
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remained significant in the GxE analysis (NRG1 rs6987996), even though many more variants were 
significantly associated with treatment response when interacting with childhood trauma (Tables 3.4 and 3.5). 
This observation also highlights the fact that all, but one, of the significant variants in the GxE analysis were 
not found to significantly influence treatment response when childhood trauma was not considered. Four of 
the seven COMT variants in the significant GxE, have been associated with antipsychotic response in previous 
studies (rs737865 and rs4818; Gupta et al., 2009), or according to the PharmGKB database (rs2020917 and 
rs933271). Interestingly, these variants were only significantly associated with treatment response in our 
cohort when the severity of childhood trauma was factored in. The same was observed for OXTR rs11706648 
(Souza et al., 2010), DRD3 rs6280 (Escamilla et al., 2018) and DRD3 rs167771, which was not implicated in 
antipsychotic response, but in antipsychotic toxicity (extrapyramidal symptoms), according to PharmGKB. The 
number of previously reported variants here was particularly notable, considering that in the genetic analyses 
(without childhood trauma), only one of the significant variants had been previously associated with 
antipsychotic response in literature (OXTR rs4686301). This emphasises the importance of childhood trauma 
as a relevant modifier to include in analyses of antipsychotic response. In terms of predicted consequences of 
the variants involved in the significant GxE, NRG1 rs3924999 was predicted to be missense according to 
Ensembl, with inconsistent effect predictions across SNPnexus, SIFT, and Polyphen-2 ranging from “tolerated/ 
benign” to “possibly damaging/ deleterious”. DRD3 rs6280 was also predicted to be missense according to 
Ensembl, yet reported as “tolerated/ benign” across all aforementioned prediction tools. The remainder of the 
variants had predicted regulatory effects, which provides support for the consideration of regulatory variants 
in future GxE studies of antipsychotic response, as well as complex disorders and neuroimaging phenotypes, 
seeing as the majority of existing GxE studies only consider coding variants. 
 
Upon overall inspection of the results, it is apparent that many of the variants in the GxE are in LD with another 
variant in the same gene (Tables 3.4 and 3.5). There are many more cases of LD between these variants than 
the variants that were significantly associated with antipsychotic response before childhood trauma was 
factored into the analyses (Table 3.2). However, the LD reported for the GxE variants is based on the initial 
LD analysis that was done for the entire cohort (N = 103), whereas the GxE analyses were done using the 
subset of participants for which CTQ data was available (N = 75). Because of the small cohort size, fluctuations 
in sample sizes between the various analyses will result in variation in allele frequencies and LD patterns. 
These variants may therefore not be in LD (or not strong enough LD) with one another, when only considering 
these 75 patients, which would explain the observed differences between associations involving these 
variants. An example of two variants in very strong LD, resulting in identical effect sizes and P values for the 
respective associations, can be seen with the COMT variants rs737865 and rs737866. No other cases like 
this were evident. Considering that the probability of strong LD being calculated between two variants 
increases with a decrease in sample size, our limited sample size means that variants found to be in LD based 
on D’ values may not be biologically linked. For this reason, and due to the fluctuating sample numbers 
between different analyses, no variants were initially eliminated based on LD, as biologically relevant variants 
may have been overlooked in downstream analyses. 
 
Considering Hardy-Weinberg equilibrium, CACNA1C rs2238096 was the only significant variant found to 
deviate from HWE principles. It is generally accepted that a deviation in HWE could confer association with a 
trait, disease, or disorder being investigated (Wittke-Thompson et al., 2005). A common observation in case-
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control association analyses is the occurrence of variants that deviate from HWE in the case group, but meet 
HWE assumptions in controls, or vice versa. This suggests either increased susceptibility, or resilience to the 
disorder, respectively (Wittke-Thompson et al., 2005). It is therefore possible that the observed deviation of 
rs2238096 from HWE could be attributed to increased risk for schizophrenia, however the lack of a control 
group in this study prevents evidence-based speculation in this regard. Furthermore, common trends of HWE 
and deviation thereof, are not as well characterised in complex disorders such as schizophrenia, as opposed 
to more common disease models (Wittke-Thompson et al., 2005). This observed significant association should 
therefore be regarded tentatively, as other reasons for the HWE deviation include possible genotyping error, 
gene-gene interactions, age, gender, and population stratification (Wigginton et al., 2005). However, all of our 
association analyses were adjusted for differences in age, gender, and ancestry. 
 
Noticeably, there are more than three times the number of significant associations here, than in the analyses 
where only genetic variants (without factoring in childhood trauma) were considered, even with a significance 
threshold that was six times more stringent to account for additional testing across the different CTQ scoring 
domains. From a statistical standpoint, this suggests that incorporating relevant environmental influences into 
genetic analyses of complex traits may increase power to find associations. Moreover, not taking into account 
these environmental factors may put into question the biological validity of findings, given the tendency of 
childhood trauma to modulate the effects of genetic variants associated with disorder risk/ manifestation 
(Alemany et al., 2015; Collip et al., 2013; Green et al., 2014; 2015; Modinos et al., 2013), or response to 
antipsychotic treatment (McGregor et al., 2018). This was demonstrated in this study with one variant, NRG1 
rs6987996. This variant was found to be significantly associated with a worsened negative symptom trajectory 
for patients with a TT genotype compared to CC patients, or for each additional T allele. However, when 
considering the severity of childhood trauma, the directionality of this effect was altered, where it was found 
that TT individuals show improved response to treatment compared to CC individuals (also for negative 
symptoms), specifically with increased severity of physical neglect, and overall trauma experienced during 
childhood. This implies that the TT genotype of this variant could contribute to protective mechanisms in the 
context of the negative biological consequences induced by childhood trauma. This phenomenon was 
observed in a study by McGregor et al. (2018), with a haplotype in MMP9. Here, it was suggested that this 
could possibly be explained by the process of synaptic scaling, which is a form of homeostatic plasticity 
(McGregor et al., 2018).  
 
Hebbian synaptic plasticity includes long-term potentiation (LTP) and long-term depression (LTD), which are 
forms of long-lasting activity-dependent alterations in synaptic strength (Cooke and Bliss, 2006; Malenka and 
Bear, 2004). However, the occurrence of positive feedback loops brought about by these activity-dependent 
changes in synaptic strength can provoke destabilisation of neural networks (Fernandes and Carvalho, 2016). 
In order to counteract this, negative feedback control of excitatory synapse strength is triggered, thereby 
stabilising the rate of neuron firing (Citri and Malenka, 2008; Fernandes and Carvalho, 2016). This mechanism 
is known as homeostatic plasticity, or synaptic scaling, and is essential in maintaining neuronal activity within 
appropriate ranges for normal brain functioning (Fernandes and Carvalho, 2016). There is emerging evidence 
to support the potential role of disrupted synaptic scaling in the development of neuropsychiatric disorders 
such as schizophrenia (Sellgren et al., 2019), yet the potential link to antipsychotic response remains relatively 
unexplored. In the context of a link to childhood trauma, it has been hypothesised that early trauma exposure 
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triggers gene expression promoting a form of synaptic modelling that is less responsive with following exposure 
to traumatic events (McGregor, 2014). However, this is believed to depend on the age at which trauma is 
experienced (McGregor, 2014).  
 
With this in mind, considering GxE, the results of this study suggest that some genetic profiles may confer 
more resilience to early-life traumatic experiences than others, and this could be due to the involvement of 
certain genes in pathways essential to synaptic plasticity. Conversely, variants contributing to aberrant 
expression of genes central to synaptic plasticity mechanisms, could result in insufficient stabilisation of 
neuronal activity in the context of provocation by traumatic events, thereby contributing to unfavourable 
response to antipsychotic treatment. This hypothesis is supported when considering the specific GxE 
associations highlighted in this study, as all of the genes involved in these associations (CACNA1C, COMT, 
DISC1, DRD3, NRG1, and OXTR) have shown evidence for potential involvement in mechanisms of synaptic 
plasticity (Forero et al., 2006; Guma et al., 2019; Moon et al., 2018; Lin and Hsu, 2018; Shamir et al., 2012; 
Tropea et al., 2018), as well as differential antipsychotic response (Bourgon et al., 2016; Gupta et al., 2009; 
Jajodia et al., 2016; O’Connell et al., 2019; Souza et al., 2010; Vehof et al., 2012).  
 
4.5.2. Pathway involvement in antipsychotic response 
 
All of the genes that were significantly associated with antipsychotic treatment response without childhood 
trauma (CACNA1C, NRG1, and OXTR; Table 3.2) were also implicated in antipsychotic response in the GxE 
analyses with childhood trauma, along with COMT, DISC1, and DRD3 (Tables 3.4 and 3.5). These genes 
(CACNA1C, COMT, DISC1, DRD3, NRG1, and OXTR) were therefore considered as the most notable genes 
with respect to antipsychotic treatment response in this study and were used to identify potential pathways of 
interest. Of the 33 pathways identified via Enrichr analysis, no pathways involving DISC1 were returned, but 
each of the remaining genes was involved in at least one pathway (Table 3.7). The five most significant 
pathways according to P value (involving more than one gene) were the “Dopaminergic synapse” (CACNA1C, 
COMT, DRD3), “Oxytocin signalling pathway” (OXTR and CACNA1C), “Calcium signalling pathway” (OXTR 
and CACNA1C), “cAMP signalling pathway” (OXTR and CACNA1C), and “Neuroactive ligand-receptor 
interaction” (OXTR and DRD3). Notably, 29 of the pathways involved CACNA1C, and each of the top five 
pathways either involved CACNA1C, OXTR, or both of these genes.  
 
Calcium channel alpha-1C subunit, encoded by CACNA1C, is involved in modulating the activation of 
intracellular signalling pathway activity, gene transcription, and synaptic plasticity (Moon et al., 2018). This 
arises from cell membrane depolarisation coupled to an increase in membrane permeability, resulting in 
calcium influx (Moon et al., 2018). Furthermore, L-type calcium channel antagonists have been shown to 
decrease induction of LTP in the CA1 of the hippocampus in rats (Freir and Herron, 2003), and alpha-1C 
knockdown models have shown reduced hippocampal LTP (Moosmang et al., 2005), emphasising the 
importance of calcium channel signalling in synaptic plasticity. With regard to OXTR, early-life exposure to 
trauma has been found to dysregulate the developing oxytocin system, which adversely affects many of the 
functions that are central to oxytocin regulation, including the regulation of emotion and stress (Nylander & 
Roman, 2012). Furthermore, OXT (encoding oxytocin) has been repeatedly shown to modify synaptic 
properties and plasticity both in vitro and in vivo (Rajamani et al., 2018). Overall, these findings highlight OXTR 
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and CACNA1C as genes of particular interest with respect to the link between antipsychotic response and 
GxE with childhood trauma. As these two genes are common to both the oxytocin and calcium signalling 
pathways, among other pathways, future studies could potentially investigate OXTR and CACNA1C together 
with respect further exploration of these genes in synaptic plasticity, stress-response mechanisms, and 
antipsychotic response. This could provide further insight into the mechanistic links between GxE and 
differential response to antipsychotics, and possibly highlight relevant pathways to investigate for novel 
therapeutic targets. 
 
4.5.3.  Imaging gene-environment interactions (iGxE) in antipsychotic response 
 
As there were no significant associations between GxE and ROI volumes, no significant iGxE of antipsychotic 
response were idetified. However, when considering an uncorrected significance threshold (⍺ = 0.05), 
numerous trends of interest were identified between GxE and ROI volumes. Fourteen of these involved GxE 
interactions that were found to be significantly associated with antipsychotic response in this study, which 
allowed us to draw tentative comparisons between the results (Table 3.6). Upon first inspection of these 
results, it was immediately noticeable that there was a consistent trend between antipsychotic treatment 
response and ROI volumes, in the context of GxE with childhood trauma. Here, where trends for larger ROI 
volumes were observed with specific GxE, significantly improved treatment response would be evident for the 
same GxE, and vice versa. For example, considering the interaction between increased severity of sexual 
abuse and CACNA1C rs4126711, the TC genotype showed a trend for reduced putamen volume, and was 
significantly associated with worse treatment response for negative symptoms. This was supported in the 
opposite direction, where the AA genotype of DISC1 rs701160 showed a trend for larger putamen volume, 
and was significantly associated with improved treatment response for negative symptoms, when increased 
severity of sexual abuse was evident. These results therefore highlighted a positive correlation between 
baseline ROI volumes and antipsychotic response, when considering associations with common GxE. 
Interestingly, when childhood trauma was not factored in, no such trends were apparent, and inconsistent 
directionality was observed between ROI volumes and treatment response in the context of genetic 
associations. 
 
Considering the association analyses between ROI volumes and antipsychotic treatment response in this 
study, no significant associations, nor trends of interest, were identified (section 3.6.1). The positive correlation 
between ROI volumes and antipsychotic response that was highlighted in the context of GxE, was therefore 
not comparable with direct associations between the two. However, when considering previous imaging 
analyses of antipsychotic response, this correlation has been observed in many studies, showing evidence 
among the literature for increased ROI volumes conferring improvement in antipsychotic response. 
Furthermore,  there is supporting evidence for this correlation in each of the regions of interest highlighted in 
this study, namely the caudate (Hutcheson et al., 2014), cortex (Zipursky et al., 1998a), hippocampus (Savas 
et al., 2002), pallidum (Hutcheson et al., 2014), putamen (Buchsbaum et al., 2003; Hutcheson et al., 2014), 
subcortical grey matter (Molina et al., 2010), and total grey matter (Altamura et al., 2017). For example, it was 
found that with a decrease in hippocampal volume, worse response to risperidone was observed (Savas et 
al., 2002). Here, the authors mentioned a previous study suggesting that risperidone mechanism of action 
involved reduced hippocampal activity along with decreased feedback via cortico-striato-thalamic loops (Liddle 
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et al., 2000; Savas et al., 2002). The authors suggested that this finding could indicate that the hippocampus 
should be large enough to be receptive to the mechanisms of risperidone (an SGA), conferring proper 
response to this treatment (Savas et al., 2002). No similar mechanisms could be identified for flupenthixol (an 
FGA) in our study. Interestingly, reduced hippocampal volume is the most consistently reported neuroimaging 
correlate of schizophrenia (Ebdrup et al., 2010), as well as of childhood trauma (Calem et al., 2017; Teicher 
and Samson, 2016). These findings suggest that the manifestation of schizophrenia symptoms, and 
subsequent poor response to antipsychotic treatment, may arise from decreases in hippocampal 
neuromediators and their receptors (Savas et al., 2002). Furthermore, treatment with antipsychotics can lead 
to increases in the volume of several brain regions over time, indicating response to treatment (Chakos et al., 
1994; Emsley et al., 2017; Gur et al., 1998). However, these affects appear to be region-specific, as reductions 
in total brain volume have also been observed for medicated patients compared to antipsychotic naïve patients, 
with further discrepancies reported for typical compared to atypical antipsychotics (Haijma et al., 2013). 
Considering findings of antipsychotic-induced volume increases, it was found that volume expansion in the 
putamen was correlated with PANSS score reduction ratio, suggesting that increased expansions in putamen 
volume over treatment periods may be indicative of improved response to treatment (Li et al., 2012). Overall, 
imaging studies have found reduced brain volume in schizophrenia patients compared to healthy individuals 
(Krause and Pogarell, 2017), believed to be developmental in origin. Studies have also found that greater 
deficits in grey matter volumes are related to worse cognitive performance (Sullivan et al., 1996; Zipursky et 
al., 1998b). The links between more severe patterns of atrophy in schizophrenia, impaired brain functions, and 
more severe disorder pathogenesis, may therefore represent a fixed deficit that could confer reduced 
responsivity to antipsychotics (Molina et al., 2010; Zipursky et al., 1998a).  
 
Another interesting consideration here, is the link between childhood trauma and reductions in specific ROI 
volumes in some studies (Calem et al., 2017; Misiak et al., 2017; Teicher and Samson, 2016), as well as worse 
treatment outcome in schizophrenia (Misiak and Frydecka, 2016; Hassan and De Luca, 2015). Even though 
this was not reflected in the results of this study, these previously identified relationships lend evidence to the 
potential involvement of childhood trauma in the correlation between ROI volumes and antipsychotic response. 
Moreover, previous studies have shown that the relationships between early trauma and ROI volumes/ 
antipsychotic response can be modulated by genotypic differences for certain variants (Aas et al., 2013; Frodl 
et al., 2014; McGregor et al., 2018). Therefore, despite the lack of statistical significance between GxE and 
ROI volumes in this study, the novel GxE identified here suggest a mechanism through which the relationship 
between baseline ROI volumes and antipsychotic response may be mediated. In other words, it can be 
postulated that in some cases, increases in early life trauma may lead to decreases in ROI volumes, which 
could contribute to less favourable response to antipsychotic treatment, and that this process could be 
modulated by genotypic variation that confers either vulnerability or resilience to stress. If this is true, when 
considering brain structure as an intermediate phenotype of antipsychotic response, then the same (relevant) 
GxE that contribute to variation in brain structure, should predict the corresponding differences in antipsychotic 
response, which was observed in this study. Importantly, this is not an attempt to oversimplify an incredibly 
complex system, but rather a depiction of at least one of the processes taking place in the path from genetic 
architecture to variable antipsychotic treatment response (Figure 4.1). There are numerous other known, and 
unknown, mechanisms involved here that were not explored in this study. For example, in a comprehensive 
review of epidemiological, clinical, neuropsychological, and biological findings focussing on the link between 
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childhood trauma and psychosis, a simplified overview of trajectories leading from childhood trauma to 
psychosis was presented (Figure 4.2; Misiak et al., 2017). Although this was not specifically focussed on 
treatment response in schizophrenia, many of the factors presented here, including biological alterations that 
arise from GxE with childhood trauma, may also contribute to poor outcome in patients, and are therefore 




Figure 4.1. A simplified depiction of one potential biological course from GxE to differential antipsychotic treatment 
response, where there is evidence for a positive correlation between structural brain alterations and antipsychotic 
response, i.e. increased ROI volumes conferring improved response to treatment, and vice versa. 
 
In the future, the accurate prediction of antipsychotic treatment response will most likely rely on multi-faceted 
patient profiles. Better characterisation of the relationships between multiple correlates of antipsychotic 
response, and the biological mechanisms underlying these relationships, is therefore crucial for the 
progression toward more personalised treatment strategies in schizophrenia. To this end, the significant 
associations and novel exploratory trends identified in this study provide support for the utility of integrative 
research approaches to more effectively disentangle some of the underlying mechanisms at play. That said, 
there is still a tremendous amount of research to be done in order to unpack the complex systems contributing 
to treatment outcomes. However, considering a more unified view of antipsychotic treatment response, and 
utilising integrative research approaches to more effectively capture this view, may contribute to the progress 
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Figure 4.2. A simplified overview of trajectories leading from childhood trauma to psychosis (Misiak et al., 2017). Childhood 
trauma and other environmental factors, including substance abuse, low socioeconomic status (SES) or high urbanicity, 
may contribute to psychosis risk via interactions with genetic vulnerability. Furthermore, childhood trauma may increase 
psychosis risk via distinct biological alterations, including aberrant DNA methylation, hypothalamic-pituitary-adrenal (HPA) 
axis dysregulation, decreased levels of brain-derived neurotrophic factor (BDNF) or subclinical pro-inflammatory states 
observed in parallel to structural brain alterations. Experiences of child maltreatment might also increase the risk for 
developing psychosis via psychological mechanisms, such as dysfunctional cognitive schemas, affective dysregulation, 












The aim of this study was to better characterise the interplay between multiple known correlates of 
antipsychotic response, namely genetics, brain structure, and childhood trauma. This was done by performing 
association analyses in a stepwise fashion, ending with GxE analyses of antipsychotic response and ROI 
volumes. Although each separate component of this study had been investigated to some extent in existing 
literature, to our knowledge this was the first study to incorporate all correlates in an attempt to explore a more 
holistic view of antipsychotic treatment response. 
 
This study provided support for the involvement of several candidate genes in antipsychotic response, and 
identified numerous novel associations for variants within these genes. Additional support was also provided 
for the implication of GxE in antipsychotic response, and many novel GxE were identified, emphasising the 
importance of considering childhood trauma in these types of studies. The tendency of childhood trauma to 
modify directionality of variant effects and alter overall patterns of significant associations was also 
demonstrated. This suggests that not accounting for the effects of childhood trauma may contribute toward 
some of the inconsistencies observed among the literature. This should be kept in mind for future studies of 
antipsychotic response, including large-scale hypothesis-free studies, as relevant confounders and modifiers 
are essential to consider in order to increase the biological validity of results.  
 
Aside from the significant findings for antipsychotic response with variants and GxE with childhood trauma, no 
results from any of the other association analyses survived correction for multiple testing. In the case of 
antipsychotic response, it is possible that longitudinal treatment response data may allow for the detection of 
more subtle or relative differences in response over time between individuals (Schober and Vetter, 2018), 
thereby increasing power to find associations in smaller cohorts. However, this may only be the case when 
the predictors are categorical, i.e. variants, for which there are clearly defined genotypes. The opposite may 
be true for predictors that are continuous in nature and have minimal range in values, such as the variation in 
ROI volumes between individuals. Here, categorical outcome variables demonstrating phenotypic extremes 
(i.e. responders vs non-responders) may be preferable over the treatment trajectories derived from longitudinal 
response data, for the identification of significant associations in smaller cohorts. Of course, this may not apply 
in studies with large sample sizes where the statistical power can overcome complications relating to 
phenotypic nuances. However, for the innumerable research groups around the globe where limited sample 
sizes remain the only current option, these observations emphasise the importance of study design, and 
careful selection and definitions of phenotypes for investigating complex heterogeneous traits.  
 
Despite the lack of statistical significance for findings relating to ROI volumes, the trend-level associations 
allowed the tentative exploration of relationships. This led to the identification of consistent trends between 
ROI volumes and antipsychotic response in the context of GxE with childhood trauma. Important to note here 
is the lack of consistency in the directionality of effects that was observed between ROI volumes and 
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antipsychotic response when only genetic variants were factored in. In other words, these findings suggest 
that the relationship between ROI volumes and antipsychotic response may be mediated through GxE with 
childhood trauma and variants conferring vulnerability or resilience to stress. Specifically, from these findings 
and from existing literature, it appears that severe experiences of childhood trauma may act as an insult to the 
developing brain, and that the extent of damage could be modulated by genotype in variants involved in 
neurodevelopment, neurotransmission, and synaptic plasticity (i.e. variants in CACNA1C, COMT, DISC1, 
DRD3, NRG1, and OXTR). Resulting reductions in brain volume could impair brain function, leading to deficits 
in the mechanisms involved in achieving responsiveness to antipsychotics. However, extensive research is 
required to support this hypothesis, and it is important to note that this is one of many processes potentially 
involved in a very complex system of underlying mechanisms contributing to antipsychotic treatment response. 
 
All of the novel findings and trends identified in this study suggest that aside from increasing sample sizes as 
much as possible (as with the movement toward large-scale collaborative consortia), perhaps more effectively 
combining and assessing data may assist in revealing biologically relevant trends, even in smaller cohorts. 
However, considering the complexity and heterogeneity of antipsychotic response, clinically homogeneous 
cohorts are of the utmost importance here. Overall, this study identified promising new approaches and 
avenues to explore with respect to identifying underlying mechanisms of antipsychotic response, and provides 




The greatest limitation of this study was the incomplete data for the cohort, as only 55 of the 103 participants 
had complete data for all variables, i.e. antipsychotic response (PANSS scores), genetics (variant genotypes), 
childhood trauma (CTQ scores), and brain structure (volumetric ROI measures). All 103 participants had 
treatment response and genotypic data, 75 participants had CTQ scores available, and 74 participants had 
structural MRI data. The sample sizes were therefore inconsistent among the various different association 
analyses, which hindered the reliability of cross-analysis comparisons and restricted the statistical power for 
several analyses, especially those incorporating both CTQ and MRI data (N = 55). Large, clinically 
homogeneous cohorts are necessary to achieve the power required to detect true associations in complex 
disorders and traits such as antipsychotic response. Novel trends reported in this study should therefore be 
considered as preliminary findings, which require validation in larger cohorts and other population groups. That 
said, the cohort in this study, albeit limited in size, was extremely well-characterised and homogenised. All 
participants were first-episode and treatment-naïve at the start of the study, and received the same long-acting 
injectable antipsychotic thereby ensuring adherence. Confounders such as illness course, treatment duration, 
differences in drugs, and non-adherence to treatment were therefore eliminated. This is important to note, as 
smaller cohorts of well-characterised patients will have the same power as larger cohorts of less well-
characterised patients (Samuels et al., 2009). Additionally, cohorts of first-episode patients have increased 
power in pharmacogenetic studies (Zhang and Malhotra, 2013). This was demonstrated by the emergence of 
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The limitations of linear regression models should be recognised here, as the PANSS scores had to be log-
transformed to satisfy the model assumptions. Whilst log-transforming the outcome variable to circumvent 
violations of model assumptions is commonly employed in linear regression analyses, most model diagnostics 
are based on visual assessments and can therefore be subjective. As overfitting of data can drastically impair 
the reliability of results, nonparametric statistical models would be more suitable to analyse data of this nature 
and would better capture the variance of PANSS scores (Lever et al., 2016). In terms of the effect sizes 
presented for the genetic associations with antipsychotic response, these were raw effect estimates conveying 
the differences in log-transformed PANSS scores between the different genotypes or number of minor alleles 
multiplied by time. In order to meaningfully interpret the effect of a specific variant, these effect estimates need 
to be back-transformed and expressed as a percentage change in PANSS scores over time. As the effect 
estimates for antipsychotic response were very small in this study, and as interpretations of these effects 
become further complicated with the incorporation of interaction terms (i.e. CTQ scores), emphasis was not 
placed on effect sizes but rather on direction of response for the sake of this exploratory analysis. Furthermore, 
the focus of this study was not on specific variants and their effects but rather on the comparison of trends 
across various analyses in order to assess the relationships between numerous variables in the context of 
antipsychotic response. Emphasis was therefore placed on directionality of effects across all analyses to 
simplify cross-analysis comparisons and provide a simplified overview of relationships between variables, in 
an exploratory manner. Future studies of this nature with larger cohorts and increased statistical power should 
focus more on specific effect sizes to reveal the most biologically relevant variants and pathways for further 
investigation including functional studies. That said, the results presented here may still prove useful in meta-
analyses in the future. 
 
Considering the neuroimaging aspects of this study, fMRI and DTI correlates of antipsychotic response were 
not explored, as only structural MRI data was available for the cohort. Furthermore, ROI volume was selected 
as the structural measurement of choice to investigate, as 1) the majority of previous structural imaging 
correlates of antipsychotic response were for ROI volumes, and 2) there was an abundance of volumetric 
measurements available in the data compared to other measurements such as thickness. However, it has 
been suggested that for genetic studies, cortical thickness and surface area measurements may be 
advantageous over volumetric measurements for gene discovery (Winkler et al., 2010). Although brain volume 
is heritable, volumetric measurements combine aspects of thickness and surface area which have been 
reported to be genetically uncorrelated (Winkler et al., 2010). Using volumetric measurements could therefore 
reduce sensitivity for detecting genetic correlates of brain structure by not discriminating the genetically distinct 
traits that are thickness and surface area (Winkler et al., 2010). In addition to this, only the total volumes were 
considered for the ROIs included in this study. This may have hindered the identification of associations 
relating to ROI volumes, as numerous imaging studies have reported unilateral ROI associations, thereby 
demonstrating differences in associations between left and right ROI volumes (Birur et al., 2017; Shenton et 
al., 2001; Wheeler and Voineskos, 2014). 
 
In terms of the specific genes highlighted in this study, both COMT and OXTR have displayed sexually 
dimorphic effects in brain structure and psychiatric disorders (Carter, 2007; Harrison and Tunbridge, 2008; 
Wang et al., 2017). However, although all models were adjusted for sex, the cohort was not stratified by sex 
in order to perform separate analyses for these genes due to the small sample size. This phenomenon should 
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therefore be explored further in future studies where sample size allows, in case any associations were 
overlooked in our study. Another relevant modifier of genetic associations that was not explored in this study 
is epistasis. Gene-gene interactions have been found between several of the candidate genes in this study, in 
previous studies of both brain structure and antipsychotic response (Blasi et al., 2011; Montag et al., 2010; 
Takahashi et al., 2008; Tan et al., 2008; Tan et al., 2012). This needs to be taken into account when interpreting 
the results in this study, especially results involving the specific genes for which previous cases of epistasis 
have been identified, namely various combinations of AKT1, BDNF, COMT, DRD2, and DRD3 (Blasi et al., 
2011; Montag et al., 2010; Takahashi et al., 2008; Tan et al., 2008; Tan et al., 2012). 
 
Childhood trauma was the only environmental factor that was explored in this study, yet importantly there are 
many other unknown environmental factors that could contribute to differential treatment outcomes via 
interactions with genes. Although environmental correlates of therapeutic response in schizophrenia are not 
well researched or characterised, other environmental contributors to psychosis may be important to 
investigate here, such as low socioeconomic status, urbanicity, and substance abuse (Misiak et al., 2017). 
Considering childhood trauma specifically, a further limitation would be that measures of positive 
environmental factors (i.e. social support) were not considered, which may mitigate the effects of childhood 
trauma thereby influencing treatment outcomes (Huot et al., 2004; Kaufman et al., 2000; van Winkel et al., 
2014). Furthermore, as the CTQ is a self-report instrument, this assessment is subject to recall bias. This 
needs to be taken into account when interpreting results, which should also be validated in replication cohorts. 
However, it has been shown that the relationship between CTQ and clinical outcomes is not moderated by 
bias, as measured by the minimisation/ denial scale (MacDonald et al., 2015). In the context of GxE analyses, 
an assumption of these analyses is that genetic and environmental factors are independent of one another. 
However, gene-environment correlations can confound the detection of true GxE (Jaffee and Price, 2007), 
which was not controlled for in this study. Furthermore, to ensure observed effects are due to the GxE and not 
just one component of the interaction, all terms (G, E, GxE) should be included in the models (Mufford et al., 
2017), which was not done in this study. That said, this study included separate analyses for “G”, “E”, and 
“GxE” for all outcomes allowing comparison of results, which could possibly circumvent this limitation. 
 
5.3. Future prospects 
 
The approach used in this study, along with the novel associations and trends identified, opens up a number 
of avenues to explore in future studies. Novel significant associations with treatment response point to variants 
and pathways of biological relevance for further exploration. Moreover, the novel significant GxE highlight the 
importance of environmental influences of treatment outcome and warrant further investigation of stress-
response systems in relation to antipsychotic efficacy. Lastly, the relevance of considering a more unified view 
of treatment outcome was highlighted, along with the utility of more integrative research approaches. This 
provides a starting point for future studies of this nature, opening doors for the consideration of a multitude of 
factors and correlates to consider for further investigations of treatment response. 
 
With this in mind, the findings from this study firstly require validation in independent cohorts, including those 
of other population groups, and importantly those of larger sample sizes. Not only is there a need for large 
collaborative consortia, such as the Psychiatric Genomics Consortium (PGC) and ENIGMA, to extend their 
Stellenbosch University https://scholar.sun.ac.za
CHAPTER 5                                                     CONCLUSIONS, LIMITATIONS, AND FUTURE PROSPECTS 
60 
 
focus from schizophrenia aetiology to antipsychotic response, but also for large-scale hypothesis-free studies 
of antipsychotic response to incorporate environmental factors such as childhood trauma, given the propensity 
of childhood trauma to modify genetic associations.  
 
Secondly, these findings should be explored in functional studies. The predicted roles of variants significantly 
associated with antipsychotic response were determined with the use of in silico prediction tools. The potential 
functional or regulatory impacts of these variants therefore require in vitro or in vivo validation. This will provide 
further biological insight with respect to the involvement of specific variants or pathways in functional systems, 
with the aim of progressing toward the discovery of clinically actionable biomarkers of antipsychotic response. 
In addition to this, the variants found to significantly modulate the effects of childhood trauma on antipsychotic 
response should be investigated for their potential role in stress vulnerability or resilience, in functional 
systems. The field of translational psychiatry is rapidly progressing, allowing the exploration of numerous 
experimental models for functional validation studies. These approaches include the use of animal models, 
and induced pluripotent stem cells (iPSCs) for the engineering of patient-derived neuronal cell lines. Aside 
from these, an exciting new technology for the in vitro investigation of neurodevelopmental processes and 
brain disorders is that of engineered brain microenvironments (Tate and Munson, 2019). These include brain 
organoids which are produced using three-dimensional cell culture techniques (Koo et al., 2019; Tate and 
Munson, 2019; Wang et al., 2017). It has been suggested that brain organoids could be used as a 
representative model system for the study of the human brain based on recent studies that demonstrated the 
ability of brain organoids to emulate the spatiotemporal dynamicity of neurogenesis, the formation of regional 
neural circuitry, and the integration of glial cells into a neural network (Koo et al., 2019). Engineered brain 
microenvironments can allow for the patient-specific exploration of characteristics of the brain, as well as direct 
examination of drug efficacy (Tate and Munson, 2019). Although in its infancy, this technology holds immense 
potential for the acceleration of research pertaining to personalised medicine in psychiatry.  
 
Although there was a lack of power to identify significant associations across all analyses in this study, the 
approach may be valuable to implement in larger cohorts to assess whether similar trends are identified. 
Furthermore, this approach is transferrable to other complex multifactorial psychiatric disorders of 
uncharacterised aetiology. Using more integrative approaches where multiple correlates are investigated in a 
comparative fashion may accelerate the progress toward identifying underlying mechanisms of disorder 
aetiology and treatment response, which will assist in the long-term with more accurate diagnosis, 
implementations of more personalised treatment strategies, and development of novel therapies. However, in 
smaller cohorts this may only identify preliminary trends of interest for further investigation, as in this study.  
 
Considering only the correlates included in this study (genetics, neuroimaging, and childhood trauma), there 
are several options for variable approaches in future studies. For example, in addition to genetic variants, one 
could consider haploblocks in candidate genes, and polygenic risk scores (PRS) could also be generated for 
schizophrenia cohorts using the PGC schizophrenia summary statistics. PRS and haplotypes could then be 
investigated for associations with antipsychotic response and ROI volumes, with and without interaction with 
childhood trauma. Furthermore, studies could incorporate various neuroimaging measurements besides ROI 
volumes, such as fMRI or DTI measures. The relationships between these measurements would also be of 
interest to evaluate, for example relating brain structure to function in the context of GxE and antipsychotic 
Stellenbosch University https://scholar.sun.ac.za
CHAPTER 5                                                     CONCLUSIONS, LIMITATIONS, AND FUTURE PROSPECTS 
61 
 
response. This type of approach could also be expanded to consider additional potential correlates of 
antipsychotic response. For example, as GxE are said to be mediated by epigenetic mechanisms, epigenetic 
factors such as DNA methylation would be important and relevant to consider in this context. Furthermore, 
gene-gene interactions, and GxE with other environmental contributors such as substance abuse, could be 
explored. Moving forward, multi-omics approaches should also be embraced, combining genomic, 
transcriptomic, proteomic, metabolomic, and autoantibody profiles; the integrative personal omics profile 
(iPOP) is an example of this (Chen et al., 2012). However, it should be kept in mind that the more variables 
included in a study, the greater the statistical power required for analyses. Furthermore, statistical approaches 
will need to be carefully selected in order to conduct the most appropriate and accurate analyses for specific 
combinations of variables. This is an important consideration for future studies of this nature, as statistics and 
biology have become inextricably linked. As an example, linear regression models sometimes recommend the 
rescaling of predictors with vastly different scales. Additionally, various transformations of data may be 
necessary to satisfy the model assumptions, as demonstrated in this study. Therefore, increases in the 
numbers of variables included may increase the amount of data manipulation necessary for analyses with 
specific models. This may decrease the accuracy and reliability of results, and may not be the best way to 
capture the variance of certain variables. With this in mind, a number of different multivariate approaches can 
be explored in future studies, each with their own advantages and limitations. These include methods such as 
independent component analysis (ICA), canonical correlation analysis, sparse partial least squares, and 
sparse reduced-rank regression (Mufford et al., 2017). In addition to these methods, machine learning 
approaches and dimensionality reduction techniques can also be employed, among many others (Bzdok and 
Meyer-Lindenberg, 2018; Durstewitz et al., 2019; Misra et al., 2019; Zeng and Lumley, 2018). This in itself 
presents an opportunity for a multitude of studies, as the advancement and comparison of statistical 
approaches for the reliable analysis of large, mixed datasets is essential for the progress toward personalised 
medicine approaches in psychiatry. 
 
Overall, this study identified a number of significant findings and exploratory trends of interest for future 
consideration. The significant associations between genetic variants and antipsychotic treatment response 
lend evidence to the involvement of a number of candidate genes in differential treatment outcomes, whilst 
contributing novel variants within these genes. Considering all of the different analyses in this study, the vast 
majority of significant findings were for GxE of antipsychotic treatment response. In addition to providing 
support for the involvement of GxE in treatment response, these findings highlighted the propensity of 
childhood trauma to modify both effect directionality and overall patterns of genetic associations with treatment 
response. Not only does this emphasise the importance of including childhood trauma in genetic studies of 
antipsychotic response, but also the relevance of considering additional environmental modifiers in future 
studies. Lastly, with respect to the imaging genetics and iGxE aspects of the study, despite the insufficient 
power to detect significant associations with ROI volumes, an intriguing trend was observed for the iGxE of 
antipsychotic treatment response. Here, for GxE conferring significantly poorer treatment response, trend-level 
reductions in several ROI volumes were observed, and vice versa, highlighting a positive correlation between 
ROI volumes and treatment response in the context of specific GxE. These findings present numerous options 
for future studies, and suggest that integrative research approaches may more effectively disentangle 
underlying mechanisms of complex phenotypes such as treatment response, if implemented in well-powered 
and well-characterised cohorts.
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Table S1. RegulomeDB scoring system (Boyle et al., 2012).  
Category 1 is the most significant and category 6 is the least significant with respect to regulatory effects. 
  
Category Description 
 Likely to affect binding and linked to expression of a gene target  
1a eQTL + TF binding + matched TF motif + matched DNase footprint + DNase peak  
1b eQTL + TF binding + any motif + DNase footprint + DNase peak  
1c eQTL + TF binding + matched TF motif + DNase peak  
1d eQTL + TF binding + any motif + DNase peak  
1e eQTL + TF binding + matched TF motif  
1f eQTL + TF binding/ DNase peak  
  
 Likely to affect binding 
2a TF binding + matched TF motif + matched DNase footprint + DNase peak  
2b TF binding + any motif + DNase footprint + DNase peak  
2c TF binding + matched TF motif + DNase peak  
  
 Less likely to affect binding  
3a TF binding + any motif + DNase peak  
3b TF binding + matched TF motif  
  
 Minimal binding evidence  
4 TF binding + DNase peak  
5 TF binding or DNase peak  
6 Motif hit  
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Table S2. List of all volumetric measures of brain structure implicated in antipsychotic treatment 
response, as reported in the respective studies.  
  
Measures identified in the available structural MRI data are highlighted in red and in bold. 
*These specific subcortical regions were not present in the available structural MRI data, so the available measure of “subcortical grey 
matter” was selected as a proxy for inclusion in the study.  
 
  
Number Volumetric measure Reference/s 
1 Caudate (Hutcheson et al., 2014; Molina et al., 2011) 
2 Corpus callosum (Nakajima et al., 2015) 
3 Cortex (Zipursky et al., 1998) 
4 Cortical sulcus (Honer et al., 1995) 
5 Dorsolateral prefrontal cortex (Nakajima et al., 2015) 
6 Grey matter (Altamura et al., 2017) 
7 Hippocampal tail (Bodnar et al., 2010) 
8 Hippocampus (Nakajima et al., 2015; Savas et al., 2002) 
9 Insula (Molina et al., 2011) 
10 Intracranium (Nakajima et al., 2015) 
11 Middle frontal gyrus (Quarantelli et al., 2014) 
12 Orbital grey matter (Molina et al., 2004) 
13 Pallidum (Hutcheson et al., 2014) 
14 Parahippocampal cortex (Bodnar et al., 2012) 
15 Parahippocampal gyrus (Bodnar et al., 2010) 
16 Pituitary (Garner et al., 2009) 
17 Prefrontal cortex (Nakajima et al., 2015) 
18 Prefrontal grey matter (Nakajima et al., 2015) 
19 Putamen 
(Buchsbaum et al., 2003; Hutcheson et al., 2014; Mitelman et al., 
2009; Molina et al., 2011) 
20 Rectal gyrus (Molina et al., 2011) 
21 Splenium (Nakajima et al., 2015) 
22 Subcortical regions: frontal* (Molina et al., 2010) 
23 Subcortical regions: limbic cortices* (Molina et al., 2010) 
24 Subcortical regions: occipital* (Molina et al., 2010) 
25 Superior gyrus (Quarantelli et al., 2014) 
26 Temporal grey matter (Nakajima et al., 2015) 
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Table S3. Lists of genes implicated in antipsychotic treatment response and brain structure, 
identified via a search of literature and the NHGRI-EBI GWAS Catalog. 
Number Brain structure Antipsychotic response 
1 AKT1 5-HT1A  
2 ANK3 5-HT2A 
3 APOE 5-HT2C  
4 APOOP3 5-HT3A  
5 ARL6IP1P3 5-HT6  
6 ASCC3 5-HTT  
7 ASTN2 AC009562.1 
8 ASTN2  AC025281.1 
9 ATP7BP1 AC026320.2 
10 BCL2L1 AC093913.1 
11 BCL2L1  ADR1A 
12 BDNF AJAP1 
13 C1orf168 AKT1 
14 CACNA1C AL162391.1 
15 CCKAR AL589923.1 
16 CLU ANKK1 
17 CNNM2 ANKS1B 
18 CNR1 AP006295.1 
19 COMT ARID5B 
20 CRHR1 ATP1A2 
21 DCC ATP2B2 
22 DCC  BAG3 
23 DDR2  BDNF 
24 DENND4B CACNA1C 
25 DISC1 CNR1 
26 DLG2 CNTN4 
27 DLG2  CNTNAP5 
28 DPP4 COMT 
29 DPP4  CRCT1 
30 DRD2 CYP2C19  
31 DRD3 CYP2D6  
32 DSCAML1 DAT 
33 DTNBP1  DISC1 
34 DYNC1I2 DRD1  
35 EIF4G3 DRD2 
36 EPB41L2 DRD3 
37 FAM19A2 DTNBP1  
38 FAM86B3P EDN1 
39 FAT3 EIF2AK4 
40 FOXO3  EPHA6 
41 G72 GFRA2  
42 GATAD2B GNB3  
43 GRID1  GRIA4  
44 GRIN2A GRIN2B  
45 GSK3β GRM3 
46 HEATR4 GRM7 
47 HELZ HCG20 
48 HMGA2 HIVEP1 
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49 HOXC4 HS3ST2 
50 HOXC5 HTR2A  
51 HRK HTR3B  
52 HS3ST5 IGSF8 
53 IL-1b  IL-1RN  
54 IL-1RN  KCNH2  
55 ITIH4  KCNH5 
56 KANSL1 LCE3E 
57 KRT18P32 MC2R 
58 KTN1 MCP-1  
59 LEMD3 MDR1 
60 LOC101927768 MEGF10 
61 LOC101929199 MTHFR 
62 LOC101929446 MTRR 
63 LOC102723803 MYO7B 
64 LOC105369409 NEF3  
65 LOC105369860 NPAS3  
66 LOC105369914 NR3C2 
67 LOC105370284 NRG1 
68 LOC105370285 OXT 
69 LOC105370802 OXTR 
70 LOC105371448 PAICS 
71 LOC105371611 PCDH7 
72 LOC105372698 PDE4D 
73 LOC105373592 PDE7B 
74 LOC105374004 PIP5K1B 
75 LOC105374007 PPA2 
76 LOC105375199 PTGFRN 
77 LOC105375951 RF00019 
78 LOC105375976 RF01210 
79 LOC105378986 RGS4  
80 LOC107984373 RNA5SP428 
81 LOC107984425 RNU6-544P 
82 LOC284395 RPL17P44 
83 LOC387820 RTKN2 
84 LOC400794 SLC1A1 
85 MAP2 SLC6A2  
86 MAST4  SPOPL 
87 MCTP2 ST6GAL2 
88 MEAF6P1 TJP1 
89 MGC57346-CRHR1 TNF-a  
90 MIPEPP2 TNFRSF11A 
91 MIR137HG TNIK 
92 MIR492 TNR  
93 MRPL11P3 TRPM1 
94 MSRB3 UNC5C 
95 NCAN XKR4  
96 NOTCH4  ZBTB20 
97 NRG1 ZNF804A  
98 NRGN   
99 NTF3   
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100 OXTR   
101 PARD3B   
102 PCDH12    
103 PCM1   
104 PICALM   
105 PIK3C2G   
106 PRELID1P1   
107 PRODH   
108 RAB3C   
109 RAPGEF4   
110 RASGRF2   
111 RELN   
112 RGS4    
113 RN7SL340P   
114 RPL13AP3   
115 RPL36P15   
116 RPL7AP4   
117 RPS4XP18   
118 SGK223   
119 SLC39A1   
120 SLC4A10    
121 SNTG1   
122 SPATS2L    
123 STIM2   
124 TBC1D19   
125 TBPL2   
126 TBXAS1   
127 TCF4   
128 TGFA   
129 TGFA-IT1   
130 TNF-a    
131 TOMM40   
132 WDR60   
133 YAP1P3  
134 ZNF804A   
 
Genes highlighted in blue were identified via the NHGRI-EBI GWAS Catalog. 
Genes in white were identified in the literature.  
ANKS1B (highlighted in purple) was found in the literature and in the NHGRI-EBI GWAS Catalog. 
Genes highlighted in red and in bold were found in both gene lists, i.e. implicated in both brain structure and antipsychotic response, 
and were thus selected as candidate genes for this study. All of these genes were identified through the literature search only. 
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Table S4. Summary of general information and predicted functional impact of all prioritised variants. 
 
Gene Chr SNP rsID MAF 





























BDNF 11 rs11030104 0.1408 27684517 A G 
Intronic/upstream/down
stream/NMD target 
ND ND ND ND ND 
BDNF 11 rs10835210 0.2313 27695910 C A Intronic ND ND ND ND ND 
BDNF 11 rs988748 0.2451 27724745 G C Intronic/upstream ND ND ND ND ND 
CACNA1C 12 rs11062040 0.4515 2091257 C T Intronic/NMD target ND ND ND ND ND 
CACNA1C 12 rs2429127 0.2767 2116768 T C Intronic/upstream ND ND ND ND ND 
CACNA1C 12 rs10161032 0.3447 2154103 C T Intronic/upstream ND ND ND ND ND 
CACNA1C 12 rs765125 0.2794 2156207 C T Intronic/upstream ND ND ND ND ND 
CACNA1C 12 rs11062093 0.1796 2166479 A G Intronic ND ND ND ND ND 
CACNA1C 12 rs7297992 0.3922 2171649 G A Intronic ND ND ND ND ND 
CACNA1C 12 rs6489348 0.4369 2208215 C A Intronic ND ND ND ND ND 
CACNA1C 12 rs4126711 0.4069 2227311 G A Intronic ND ND ND ND ND 
CACNA1C 12 rs2238034 0.1019 2235628 T C Intronic ND ND ND ND ND 
CACNA1C 12 rs10848635 0.3400 2316195 A T Intronic ND ND ND ND ND 
CACNA1C 12 rs1016388 0.3500 2321868 T A Intronic ND ND ND ND ND 
CACNA1C 12 rs11062162 0.4223 2332104 G A Intronic ND ND ND ND ND 
CACNA1C 12 rs2007044 0.3495 2344960 G A Intronic ND ND ND ND ND 
CACNA1C 12 rs1006737 0.2864 2345295 G A Intronic ND ND ND ND ND 
CACNA1C 12 rs10848645 0.3107 2420244 A G Intronic ND ND ND ND ND 
CACNA1C 12 rs10774037 0.1796 2420526 A G Intronic ND ND ND ND ND 
CACNA1C 12 rs3819536 0.2767 2436998 A G Intronic ND ND ND ND ND 
CACNA1C 12 rs2238070 0.3107 2456115 G T Intronic ND ND ND ND ND 
CACNA1C 12 rs2239056 0.1408 2468195 C T Intronic ND ND ND ND ND 
CACNA1C 12 rs740417 0.3689 2499849 A C Intronic ND ND ND ND ND 
CACNA1C 12 rs10491964 0.1990 2500431 G A Intronic ND ND ND ND ND 
CACNA1C 12 rs2370515 0.1796 2511162 G A Intronic ND ND ND ND ND 
CACNA1C 12 rs4765687 0.4709 2560116 A G Intronic ND ND ND ND ND 
CACNA1C 12 rs4765937 0.3010 2570535 C T Intronic ND ND ND ND ND 
CACNA1C 12 rs2239084 0.1699 2577104 G A Intronic ND ND ND ND ND 
CACNA1C 12 rs1015287 0.4806 2605386 A G Intronic ND ND ND ND ND 
CACNA1C 12 rs10848665 0.1068 2609084 T C Intronic ND ND ND ND ND 
CACNA1C 12 rs2238087 0.1019 2613716 C T Intronic ND ND ND ND ND 
CACNA1C 12 rs11062260 0.1068 2646783 G A Intronic ND ND ND ND ND 
CACNA1C 12 rs4394887 0.1699 2649980 G A Intronic ND ND ND ND ND 
CACNA1C 12 rs2239118 0.4461 2660753 C T Intronic ND ND ND ND ND 
Stellenbosch University https://scholar.sun.ac.za
APPENDIX A                                                                                                                                                                                                      SUPPLEMENTARY DATA
    
82 
 
CACNA1C 12 rs1034936 0.4500 2661160 C T Intronic ND ND ND ND ND 
CACNA1C 12 rs4765961 0.3155 2668472 C T Intronic ND ND ND ND ND 
CACNA1C 12 rs2370602 0.2282 2676683 C T Intronic ND ND ND ND ND 





ND ND ND 
CACNA1C 12 rs2238096 0.2961 2749913 A C Intronic ND ND ND ND ND 
CACNA1C 12 rs2302729 0.4175 2783972 C T Intronic ND ND ND ND ND 





CACNA1C 12 rs4765970 0.2598 2792661 G A Intronic ND ND ND ND ND 
COMT 22 rs9606186 0.3010 19920359 G C Intronic/upstream ND ND ND ND ND 
COMT 22 rs2075507 0.2961 19928092 A G Intronic/upstream ND ND ND ND ND 
COMT 22 rs2020917 0.2376 19928884 C T 
Intronic/upstream/NMD 
target 
ND ND ND ND ND 
COMT 22 rs737866 0.2476 19930109 T C Intronic/upstream ND ND ND ND ND 
COMT 22 rs737865 0.2476 19930121 A G Intronic/upstream ND ND ND ND ND 
COMT 22 rs933271 0.4175 19931407 C T Intronic/upstream ND ND ND ND ND 
COMT 22 rs174674 0.4133 19934025 A G Intronic/upstream ND ND ND ND ND 
COMT 22 rs5993883 0.4660 19937638 G T Intronic/upstream ND ND ND ND ND 
COMT 22 rs740603 0.4752 19945177 G A 
Intronic/upstream/NMD 
target 
ND ND ND ND ND 
COMT 22 rs165656 0.4356 19948863 G C 
Intronic/upstream/NMD 
target 
ND ND ND ND ND 
COMT 22 rs165722 0.4757 19949013 C T 
Intronic/upstream/NMD 
target 
ND ND ND ND ND 





ND ND ND ND ND 




ND ND ND ND ND 
COMT 22 rs2239393 0.3687 19950428 A G 
Intronic/upstream/down
stream/NMD target 
ND ND ND ND ND 





ND ND ND ND ND 





Benign Damaging Tolerated Benign 
COMT 22 rs174697 0.1262 19953832 G A 
Intronic/downstream/N
MD target 
ND ND ND ND ND 
Stellenbosch University https://scholar.sun.ac.za
APPENDIX A                                                                                                                                                                                                      SUPPLEMENTARY DATA
    
83 
 
COMT 22 rs165599 0.3824 19956781 G A Downstream/3' UTR ND ND ND ND ND 
COMT 22 rs165728 0.1456 19957023 T C Downstream/3' UTR ND ND ND ND ND 
COMT 22 rs9265 0.3950 19957631 C A Downstream/3' UTR ND ND ND ND ND 
DISC1 1 rs1417584 0.4903 231819050 C T 
Intronic/upstream/NMD 
target 
ND ND ND ND ND 
DISC1 1 rs2487453 0.4951 231863204 T C 
Intronic/downstream/N
MD target 
ND ND ND ND ND 
DISC1 1 rs4658883 0.1845 231876767 T C Intronic/NMD target ND ND ND ND ND 
DISC1 1 rs12066910 0.3056 231881732 C T Intronic/NMD target ND ND ND ND ND 
DISC1 1 rs10864695 0.2767 231885217 A G Intronic/NMD target ND ND ND ND ND 










ND ND ND 
DISC1 1 rs2812391 0.2767 231911976 C T Intronic/NMD target ND ND ND ND ND 
DISC1 1 rs16854954 0.2961 231912592 C T Intronic/NMD target ND ND ND ND ND 
DISC1 1 rs17766087 0.1359 231917877 T G Intronic/NMD target ND ND ND ND ND 
DISC1 1 rs9803690 0.3883 231923345 G A Intronic/NMD target ND ND ND ND ND 
DISC1 1 rs1322784 0.4951 231928935 G A Intronic/NMD target ND ND ND ND ND 
DISC1 1 rs2255340 0.4608 231936150 C T Intronic/NMD target ND ND ND ND ND 
DISC1 1 rs2738875 0.1602 231945373 G T Intronic/NMD target ND ND ND ND ND 















ND ND ND ND ND 
DISC1 1 rs1000730 0.3835 231963601 C T Intronic/NMD target ND ND ND ND ND 
DISC1 1 rs7552697 0.1893 231997560 C T Intronic/NMD target ND ND ND ND ND 
DISC1 1 rs12757857 0.3932 231998863 C T Intronic/NMD target ND ND ND ND ND 
DISC1 1 rs3082 0.2282 232002392 A G 
Intronic/NMD target/3' 
UTR 
ND ND ND ND ND 
DISC1 1 rs1407601 0.1748 232003412 G T 
Intronic/downstream/N
MD target 
ND ND ND ND ND 
DISC1 1 rs2356606 0.2184 232015040 A G Intronic/NMD target ND ND ND ND ND 
DISC1 1 rs4658889 0.2670 232019810 G A Intronic/NMD target ND ND ND ND ND 
DISC1 1 rs9431714 0.2913 232021248 G A Intronic/NMD target ND ND ND ND ND 
DISC1 1 rs821722 0.4951 232036030 A G Intronic/NMD target ND ND ND ND ND 
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DISC1 1 rs7541019 0.1436 232051185 T G Intronic/NMD target ND ND ND ND ND 
DISC1 1 rs11584798 0.1359 232066277 C T Intronic/NMD target ND ND ND ND ND 
DISC1 1 rs701158 0.2476 232073128 G A Intronic/NMD target ND ND ND ND ND 
DISC1 1 rs701160 0.4175 232092481 T C Intronic/NMD target ND ND ND ND ND 
DISC1 1 rs821615 0.2573 232143946 C T Intronic/NMD target ND ND ND ND ND 









DISC1 1 rs821631 0.3204 232148135 C T Intronic/downstream ND ND ND ND ND 
DISC1 1 rs821639 0.3447 232149843 A G Intronic/downstream ND ND ND ND ND 
DISC1 1 rs9729194 0.3689 232168867 T C Intronic ND ND ND ND ND 
DISC1 1 rs11122396 0.2282 232175268 G A 3' UTR ND ND ND ND ND 
DISC1 1 rs16856322 0.2816 232176987 C T 3' UTR/downstream ND ND ND ND ND 
DRD2 11 rs1800497 0.3186 113270828 A G Missense/downstream Tolerated Benign Tolerated Tolerated Benign 
DRD2 11 rs6278 0.1359 113280724 C A 3' UTR/downstream ND ND ND ND ND 
DRD2 11 rs6277 0.1632 113283459 G A 
Synonymous/downstre
am 
ND ND ND ND ND 
DRD2 11 rs6275 0.4069 113283477 G A 
Synonymous/downstre
am 
ND ND ND ND ND 
DRD2 11 rs1076560 0.1689 113283688 C A Intronic/downstream ND ND ND ND ND 
DRD2 11 rs12363125 0.2282 113285916 T C Intronic/downstream ND ND ND ND ND 
DRD2 11 rs1800498 0.2732 113291588 G A 
Intronic/upstream/down
stream 
ND ND ND ND ND 
DRD2 11 rs1079597 0.1942 113296286 C T Intronic/upstream ND ND ND ND ND 
DRD2 11 rs2471857 0.2816 113298339 C T Intronic/upstream ND ND ND ND ND 
DRD2 11 rs4436578 0.4126 113306765 C T Intronic ND ND ND ND ND 
DRD2 11 rs4245146 0.4029 113317973 T C Intronic/downstream ND ND ND ND ND 
DRD2 11 rs7131056 0.4559 113329774 C A Intronic ND ND ND ND ND 
DRD2 11 rs4630328 0.1505 113334209 G A Intronic ND ND ND ND ND 
DRD2 11 rs1799978 0.1699 113346351 C T Intronic/upstream ND ND ND ND ND 
DRD2 11 rs2514218 0.1942 113392994 C T Intergenic ND ND ND ND ND 
DRD3 3 rs167771 0.3981 113876275 G A Intronic ND ND ND ND ND 





Benign Tolerated Tolerated Benign 
DRD3 3 rs9825563 0.4806 113900220 G A Intronic/upstream ND ND ND ND ND 
DRD3 3 rs1394016 0.2913 113909889 A G Intronic ND ND ND ND ND 




ND ND ND ND ND 
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DTNBP1  6 rs4712253 0.4369 15526417 C T 
Intronic/upstream/down
stream/NMD target 
ND ND ND ND ND 
DTNBP1 6 rs2619522 0.4272 15653649 C A Intronic/NMD target ND ND ND ND ND 
DTNBP1 6 rs2619536 0.1796 15663847 T C Upstream ND ND ND ND ND 
IL1RN  2 rs315920 0.1019 113873018 C T Intronic/upstream ND ND ND ND ND 
IL1RN  2 rs423904 0.1386 113887262 C T 
Intronic/noncoding 
transcript exonic 
ND ND ND ND ND 
IL1RN  2 rs3087266 0.3155 113889100 T C Intronic/downstream ND ND ND ND ND 







ND ND ND 
NRG1 8 rs35753505 0.1553 31474141 T C Intergenic ND ND ND ND ND 
NRG1 8 rs6994992 0.3592 31495581 C T Upstream ND ND ND ND ND 
NRG1 8 rs28401439 0.1845 31496006 G T Upstream ND ND ND ND ND 
NRG1 8 rs6987996 0.4417 31506771 C T Intronic ND ND ND ND ND 
NRG1 8 rs4733094 0.1311 31597593 G A Intronic ND ND ND ND ND 
NRG1 8 rs16878394 0.1893 31727061 G G Intronic ND ND ND ND ND 
NRG1 8 rs796549 0.2670 31768217 T C Intronic ND ND ND ND ND 
NRG1 8 rs7002063 0.3252 31803534 G A Intronic ND ND ND ND ND 
NRG1 8 rs2010243 0.4903 31846380 C T Intronic ND ND ND ND ND 
NRG1 8 rs1462900 0.1845 31927638 A C Intronic ND ND ND ND ND 
NRG1 8 rs1381874 0.2524 31942557 G A Intronic ND ND ND ND ND 
NRG1 8 rs7841220 0.3155 31943664 T C Intronic ND ND ND ND ND 
NRG1 8 rs10503899 0.2039 31947234 A G Intronic ND ND ND ND ND 
NRG1 8 rs11776959 0.2476 31948864 A G Intronic ND ND ND ND ND 
NRG1 8 rs10503901 0.3786 32085171 C T Intronic ND ND ND ND ND 
NRG1 8 rs1481728 0.2767 32116927 T G Intronic/downstream ND ND ND ND ND 
NRG1 8 rs4733313 0.4466 32118416 C T Intronic/downstream ND ND ND ND ND 
NRG1 8 rs900102 0.4223 32120188 A G Intronic ND ND ND ND ND 
NRG1 8 rs16879067 0.1650 32121424 A G Intronic ND ND ND ND ND 
NRG1 8 rs17624592 0.1408 32122424 A G Intronic ND ND ND ND ND 
NRG1 8 rs11778887 0.1942 32156724 A G Intronic ND ND ND ND ND 
NRG1 8 rs7005124 0.2282 32167730 G T Intronic ND ND ND ND ND 
NRG1 8 rs1685117 0.1942 32197182 G T Intronic ND ND ND ND ND 
NRG1 8 rs7841599 0.4653 32199572 C T Intronic ND ND ND ND ND 
NRG1 8 rs970998 0.3689 32201084 G A Intronic ND ND ND ND ND 
NRG1 8 rs1565031 0.1505 32201135 G A Intronic ND ND ND ND ND 
NRG1 8 rs1623372 0.3350 32215602 A G Intronic ND ND ND ND ND 
NRG1 8 rs16879304 0.1408 32240840 T C Intronic ND ND ND ND ND 
NRG1 8 rs939077 0.2913 32245538 G T Intronic ND ND ND ND ND 
NRG1 8 rs4733325 0.3835 32247220 A G Intronic ND ND ND ND ND 
NRG1 8 rs3847131 0.4223 32282019 G A Intronic ND ND ND ND ND 
NRG1 8 rs9297192 0.1117 32283517 G A Intronic ND ND ND ND ND 
NRG1 8 rs17716295 0.1650 32317917 C A Intronic ND ND ND ND ND 
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NRG1 8 rs12216802 0.1214 32340967 A G Intronic ND ND ND ND ND 
NRG1 8 rs17645417 0.4069 32351333 T C Intronic ND ND ND ND ND 
NRG1 8 rs7844425 0.1505 32375617 T G Intronic ND ND ND ND ND 
NRG1 8 rs4733347 0.1765 32376010 G A Intronic ND ND ND ND ND 
NRG1 8 rs4733130 0.2379 32406994 C T Intronic ND ND ND ND ND 
NRG1 8 rs2439312 0.1699 32412359 G A Intronic ND ND ND ND ND 
NRG1 8 rs17721043 0.1505 32436875 G A Intronic ND ND ND ND ND 
NRG1 8 rs2439292 0.3204 32446882 G A Intronic ND ND ND ND ND 








NRG1 8 rs2919370 0.3155 32476816 G A Intronic ND ND ND ND ND 
NRG1 8 rs2466049 0.1262 32514916 G A Intronic ND ND ND ND ND 
NRG1 8 rs2919392 0.4320 32524451 A G Intronic ND ND ND ND ND 
NRG1 8 rs2919390 0.4806 32526955 C A Intronic ND ND ND ND ND 
NRG1 8 rs2976532 0.1845 32594251 G A Intronic ND ND ND ND ND 











OXTR 3 rs237884 0.4563 8793585 G A Intronic/3' UTR ND ND ND ND ND 
OXTR 3 rs237885 0.4608 8795543 G T Intronic ND ND ND ND ND 
OXTR 3 rs11706648 0.2282 8796547 A C Intronic ND ND ND ND ND 
OXTR 3 rs237888 0.2718 8797095 C T Intronic ND ND ND ND ND 
OXTR 3 rs4686301 0.1942 8798586 C T Intronic ND ND ND ND ND 
OXTR 3 rs237889 0.1845 8802483 C T Intronic ND ND ND ND ND 
OXTR 3 rs2268495 0.2621 8807535 A G Intronic/downstream ND ND ND ND ND 
OXTR 3 rs237899 0.2767 8808515 G A Intronic/downstream ND ND ND ND ND 
OXTR 3 rs4686302 0.1350 8809222 C T 
Missense/intronic/down
stream 
Tolerated Benign Tolerated Tolerated Benign 
RGS4 1 rs951439 0.4660 163033691 C T upstream ND ND ND ND ND 
RGS4 1 rs2661319 0.2864 163039777 T C 
Intronic/upstream/regul
atory 
ND ND ND ND ND 
RGS4 1 rs10759 0.2039 163046351 T G 3' UTR/downstream ND ND ND ND ND 
TNF-α 6 rs1800629 0.1262 31543031 G A Upstream/downstream ND ND ND ND ND 
TNF-α 6 rs1800630 0.1042 31542476 C A Downstream ND ND ND ND ND 
ZNF804A 2 rs1344706 0.1748 185778428 A C Intronic ND ND ND ND ND 
ZNF804A 2 rs12476147 0.4709 185800905 T A Missense ND ND Tolerated Tolerated Benign 
ZNF804A 2 rs4667001 0.2816 185801747 G A Missense Tolerated Benign Tolerated Tolerated Benign 
ZNF804A 2 rs1366842 0.2816 185802243 C A Missense Tolerated Benign Tolerated Tolerated Benign 
ZNF804A 2 rs12477430 0.3447 185802363 G A Missense Tolerated Benign Tolerated Tolerated Benign 
Chr = Chromosome; MAF = Minor allele frequency in the study cohort, obtained via PLINK v1.9; Anc = Ancestral allele; Alt = Alternate allele; NMD = Nonsense-mediated mRNA decay; ND = Not 
determined.  
Results coloured in blue fulfilled the defined criteria for prioritisation. 
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Table S5. Summary of prioritised variants showing previously reported associations with brain 
structure and antipsychotic treatment response.  
   








BDNF rs6265 Yes (both) No AP efficacy/toxicity AP response/ADRs 
BDNF rs11030104 Yes (AP response) No AP efficacy AP response 
BDNF rs10835210 No No No No 
BDNF rs988748 No No No No 
CACNA1C rs11062040 No No No No 
CACNA1C rs2429127 No No No No 
CACNA1C rs10161032 No No No No 
CACNA1C rs765125 No No No No 
CACNA1C rs11062093 No No No No 
CACNA1C rs7297992 No No No No 
CACNA1C rs6489348 No No No No 
CACNA1C rs4126711 No No No No 
CACNA1C rs2238034 No No No No 
CACNA1C rs10848635 Yes (AP response) No No No 
CACNA1C rs1016388 Yes (AP response) No No No 
CACNA1C rs11062162 No No No No 
CACNA1C rs2007044 No No No No 
CACNA1C rs1006737 Yes (both) No No No 
CACNA1C rs10848645 No No No No 
CACNA1C rs10774037 No No No No 
CACNA1C rs3819536 No No No No 
CACNA1C rs2238070 No No No No 
CACNA1C rs2239056 No No No No 
CACNA1C rs740417 No No No No 
CACNA1C rs10491964 No No No No 
CACNA1C rs2370515 No No No No 
CACNA1C rs4765687 No No No No 
CACNA1C rs4765937 No No No No 
CACNA1C rs2239084 No No No No 
CACNA1C rs1015287 No No No No 
CACNA1C rs10848665 No No No No 
CACNA1C rs2238087 Yes (AP response) No No No 
CACNA1C rs11062260 No No No No 
CACNA1C rs4394887 No No No No 
CACNA1C rs2239118 No No No No 
CACNA1C rs1034936 Yes (AP response) No No No 
CACNA1C rs4765961 No No No No 
CACNA1C rs2370602 No No No No 
CACNA1C rs215976 No No No No 
CACNA1C rs2238096 No No No No 
CACNA1C rs2302729 No No No No 
CACNA1C rs10848683 No No No No 
CACNA1C rs4765970 No No No No 
COMT rs9606186 No No AP response AP response 
COMT rs2075507 Yes (brain structure) No No No 
COMT rs2020917 No No No AP response 
COMT rs737866 No No No No 
COMT rs737865 Yes (AP response) No No No 
COMT rs933271 No No No AP response 
COMT rs174674 No No No No 
COMT rs5993883 No No AP efficacy AP response 
COMT rs740603 No No No No 
COMT rs165656 No No No No 
COMT rs165722 No No No No 
COMT rs6269 Yes (AP response) No AP efficacy AP response 
COMT rs4633 Yes (AP response) No No AP response 
COMT rs2239393 No No No No 
COMT rs4818 Yes (AP response) No AP efficacy AP response 
COMT rs4680 Yes (both) No AP efficacy/toxicity AP response/ADRs 
COMT rs174697 No No No No 
COMT rs165599 No No AP efficacy AP response 
COMT rs165728 No No No No 
COMT rs9265 No No No No 
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DISC1 rs1417584 No No No No 
DISC1 rs2487453 Yes (brain structure) Brain structure No No 
DISC1 rs4658883 No No No No 
DISC1 rs12066910 No No No No 
DISC1 rs10864695 No No No No 
DISC1 rs2492367 No No No No 
DISC1 rs2812391 No No No No 
DISC1 rs16854954 Yes (brain structure) Brain structure No No 
DISC1 rs17766087 No No No No 
DISC1 rs9803690 No No No No 
DISC1 rs1322784 No No No No 
DISC1 rs2255340 No No No No 
DISC1 rs2738875 No No No No 
DISC1 rs6675281 Yes (both) No No No 
DISC1 rs1535530 Yes (brain structure) No No No 
DISC1 rs1000730 No No No No 
DISC1 rs7552697 No No No No 
DISC1 rs12757857 No No No No 
DISC1 rs3082 No No No No 
DISC1 rs1407601 No No No No 
DISC1 rs2356606 Yes (brain structure) Brain structure No No 
DISC1 rs4658889 No No No No 
DISC1 rs9431714 Yes (brain structure) Brain structure No No 
DISC1 rs821722 No No No No 
DISC1 rs7541019 No No No No 
DISC1 rs11584798 No No No No 
DISC1 rs701158 No No No No 
DISC1 rs701160 No No No No 
DISC1 rs821615 No No No No 
DISC1 rs821616 Yes (brain structure) No No No 
DISC1 rs821631 No No No No 
DISC1 rs821639 Yes (brain structure) Brain structure No No 
DISC1 rs9729194 No No No No 
DISC1 rs11122396 No No No No 
DISC1 rs16856322 Yes (brain structure) Brain structure No No 
DRD2 rs1800497 Yes (both) No AP efficacy/toxicity AP ADR 
DRD2 rs6278 No No No No 
DRD2 rs6277 No No AP efficacy/toxicity AP ADR 
DRD2 rs6275 Yes (AP response) No AP prolactin 
AP ADR and 
prolactin 
DRD2 rs1076560 Yes (AP response) No AP efficacy AP response 
DRD2 rs12363125 No No No No 
DRD2 rs1800498 Yes (AP response) No No No 
DRD2 rs1079597 Yes (AP response) No AP efficacy AP response 
DRD2 rs2471857 No No No No 
DRD2 rs4436578 No No AP toxicity AP ADR 
DRD2 rs4245146 No No No No 
DRD2 rs7131056 No No No AP ADR 
DRD2 rs4630328 No No No No 
DRD2 rs1799978 Yes (AP response) No AP efficacy/toxicity AP response 
DRD2 rs2514218 Yes (AP response) No No AP response 
DRD3 rs167771 No No AP toxicity AP response 
DRD3 rs6280 Yes (both) No AP efficacy AP response 
DRD3 rs9825563 No No No No 
DRD3 rs1394016 No No No No 
DTNBP1 rs1047631 No No No No 
DTNBP1  rs4712253 No No No No 
DTNBP1 rs2619522 Yes (brain structure) No No No 
DTNBP1 rs2619536 No No No No 
IL1RN  rs315920 No No No No 
IL1RN  rs423904 No No No No 
IL1RN  rs3087266 No No No No 
IL1RN  rs315952 No No No No 
NRG1 rs35753505 Yes (both) No No No 
NRG1 rs6994992 Yes (brain structure) No No No 
NRG1 rs28401439 No No No No 
NRG1 rs6987996 No No No No 
NRG1 rs4733094 No No No No 
NRG1 rs16878394 No No No No 
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NRG1 rs796549 No No No No 
NRG1 rs7002063 No No No No 
NRG1 rs2010243 No No No No 
NRG1 rs1462900 No No No No 
NRG1 rs1381874 No No No No 
NRG1 rs7841220 No No No No 
NRG1 rs10503899 No No No No 
NRG1 rs11776959 No No No No 
NRG1 rs10503901 No No No No 
NRG1 rs1481728 No No No No 
NRG1 rs4733313 No No No No 
NRG1 rs900102 No No No No 
NRG1 rs16879067 No No No No 
NRG1 rs17624592 No No No No 
NRG1 rs11778887 No No No No 
NRG1 rs7005124 No No No No 
NRG1 rs1685117 No No No No 
NRG1 rs7841599 No No No No 
NRG1 rs970998 No No No No 
NRG1 rs1565031 No No No No 
NRG1 rs1623372 No No No No 
NRG1 rs16879304 No No No No 
NRG1 rs939077 No No No No 
NRG1 rs4733325 No No No No 
NRG1 rs3847131 No No No No 
NRG1 rs9297192 No No No No 
NRG1 rs17716295 Yes (AP response) No AP efficacy AP response 
NRG1 rs12216802 No No No No 
NRG1 rs17645417 No No No No 
NRG1 rs7844425 No No No No 
NRG1 rs4733347 No No No No 
NRG1 rs4733130 No No No No 
NRG1 rs2439312 No No No No 
NRG1 rs17721043 No No No No 
NRG1 rs2439292 No No No No 
NRG1 rs3924999 No No No No 
NRG1 rs2919370 No No No No 
NRG1 rs2466049 No No No No 
NRG1 rs2919392 No No No No 
NRG1 rs2919390 No No No No 
NRG1 rs2976532 No No No No 
NRG1 rs73672607 No No No No 
OXTR rs237884 No No No No 
OXTR rs237885 No No No No 
OXTR rs11706648 Yes (AP response) No No No 
OXTR rs237888 No No No No 
OXTR rs4686301 Yes (AP response) No No No 
OXTR rs237889 No No No No 
OXTR rs2268495 No No No No 
OXTR rs237899 Yes (AP response) No No No 
OXTR rs4686302 No No No No 
RGS4 rs951439 Yes (AP response) No AP efficacy AP response 
RGS4 rs2661319 Yes (both) No AP efficacy AP response 
RGS4 rs10759 Yes (AP response) No No No 
TNF-α rs1800629 Yes (both) No No No 
TNF-α rs1800630 No No No No 
ZNF804A rs1344706 Yes (both) No AP efficacy AP response 
ZNF804A rs12476147 No No No No 
ZNF804A rs4667001 No No No No 
ZNF804A rs1366842 No No No No 
ZNF804A rs12477430 No No No No 
Yes = Previously associated with brain structure and/or antipsychotic response; No = Not reported in database, or not previously 
associated with brain structure or antipsychotic response in literature; AP = Antipsychotic; Both = Previously associated with both brain 
structure and antipsychotic response in literature; ADRs = Adverse drug reactions; AP prolactin = Antipsychotic-induced 
hyperprolactinemia. 
Results coloured in blue fulfilled the defined criteria for prioritisation. 
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Table S6. Summary of predicted regulatory impact of all prioritised variants.  
 












BDNF rs6265 6 ND No Yes Yes No Yes Yes 
BDNF rs11030104 ND ND No Yes Yes No Yes Yes 
BDNF rs10835210 3a ND No Yes No No Yes No 
BDNF rs988748 4 ND Yes Yes Yes Yes Yes No 
CACNA1C rs11062040 3a ND No Yes No No Yes Yes 
CACNA1C rs2429127 ND ND Yes Yes Yes Yes No No 
CACNA1C rs10161032 5 ND Yes Yes Yes Yes No No 
CACNA1C rs765125 5 ND Yes Yes Yes Yes No No 
CACNA1C rs11062093 2b ND No Yes No Yes Yes Yes 
CACNA1C rs7297992 5 ND Yes Yes No No Yes Yes 
CACNA1C rs6489348 4 ND Yes Yes No No Yes Yes 
CACNA1C rs4126711 4 ND Yes Yes No No Yes Yes 
CACNA1C rs2238034 5 ND Yes Yes No No Yes Yes 
CACNA1C rs10848635 5 ND No Yes No No Yes Yes 
CACNA1C rs1016388 2c ND Yes Yes No No Yes No 
CACNA1C rs11062162 5 ND Yes Yes No No Yes No 
CACNA1C rs2007044 4 ND No Yes No No Yes Yes 
CACNA1C rs1006737 5 ND No Yes No No Yes Yes 
CACNA1C rs10848645 2b ND Yes Yes No No Yes No 
CACNA1C rs10774037 2b ND No Yes No No Yes Yes 
CACNA1C rs3819536 5 ND Yes Yes No No Yes No 
CACNA1C rs2238070 5 ND Yes Yes No No Yes Yes 
CACNA1C rs2239056 4 ND Yes Yes No No Yes No 
CACNA1C rs740417 ND ND Yes Yes No No Yes No 
CACNA1C rs10491964 3a ND No Yes No No Yes Yes 
CACNA1C rs2370515 5 ND Yes Yes No No Yes Yes 
CACNA1C rs4765687 2b ND Yes Yes No No Yes Yes 
CACNA1C rs4765937 1f ND No Yes No No Yes Yes 
CACNA1C rs2239084 ND ND Yes Yes No No Yes No 
CACNA1C rs1015287 3a ND No Yes No No Yes Yes 
CACNA1C rs10848665 ND ND Yes Yes Yes No Yes No 
CACNA1C rs2238087 ND ND No Yes No No Yes No 
CACNA1C rs11062260 5 ND Yes Yes No No Yes No 
CACNA1C rs4394887 5 ND Yes Yes No No Yes No 
CACNA1C rs2239118 5 ND Yes Yes No No Yes Yes 
CACNA1C rs1034936 5 ND No Yes No No Yes Yes 
CACNA1C rs4765961 ND ND Yes Yes No No Yes Yes 
CACNA1C rs2370602 5 ND Yes Yes No No Yes Yes 
CACNA1C rs215976 5 ND No Yes No No Yes No 
CACNA1C rs2238096 2b ND Yes Yes Yes No Yes Yes 
CACNA1C rs2302729 2b ND No Yes Yes Yes Yes Yes 
CACNA1C rs10848683 5 ND No No No No No Yes 
CACNA1C rs4765970 2b ND Yes Yes No No Yes No 
COMT rs9606186 3a ND No Yes Yes Yes Yes Yes 
COMT rs2075507 5 ND No Yes Yes Yes Yes Yes 
COMT rs2020917 4 ND No Yes Yes Yes Yes Yes 
COMT rs737866 2b ND Yes Yes Yes Yes Yes Yes 
COMT rs737865 2b ND No Yes Yes Yes Yes Yes 
COMT rs933271 4 ND No Yes Yes Yes Yes Yes 
COMT rs174674 1f ND No Yes Yes Yes Yes Yes 
COMT rs5993883 ND ND No Yes Yes No Yes Yes 
COMT rs740603 3a ND No Yes Yes Yes Yes No 
COMT rs165656 4 ND Yes Yes Yes Yes Yes No 
COMT rs165722 3a ND No Yes Yes Yes Yes No 
COMT rs6269 1a ND Yes Yes Yes Yes Yes No 
COMT rs4633 2b Yes Yes Yes Yes Yes Yes Yes 
COMT rs2239393 1b ND Yes Yes Yes Yes Yes Yes 
COMT rs4818 4 ND No Yes Yes Yes Yes No 
COMT rs4680 4 ND No Yes Yes Yes Yes Yes 
COMT rs174697 2b ND Yes Yes No Yes Yes No 
COMT rs165599 4 Yes No Yes Yes Yes Yes No 
COMT rs165728 4 Yes No Yes Yes Yes Yes Yes 
COMT rs9265 2b ND No Yes Yes Yes Yes No 
DISC1 rs1417584 ND ND Yes Yes Yes No Yes Yes 
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DISC1 rs2487453 5 ND No Yes No No Yes Yes 
DISC1 rs4658883 3a ND Yes Yes No No Yes Yes 
DISC1 rs12066910 6 ND Yes Yes No No Yes No 
DISC1 rs10864695 ND ND Yes Yes No No Yes Yes 
DISC1 rs2492367 5 ND No Yes Yes No Yes Yes 
DISC1 rs2812391 2b ND No Yes No No Yes Yes 
DISC1 rs16854954 5 ND No Yes No No Yes Yes 
DISC1 rs17766087 2b ND No Yes No No Yes Yes 
DISC1 rs9803690 ND ND Yes Yes No No Yes Yes 
DISC1 rs1322784 2b ND No Yes No No Yes No 
DISC1 rs2255340 2b ND No Yes No No Yes No 
DISC1 rs2738875 5 ND Yes Yes No No Yes Yes 
DISC1 rs6675281 4 ND No Yes Yes No Yes No 
DISC1 rs1535530 4 ND No Yes Yes No Yes Yes 
DISC1 rs1000730 2b ND No Yes No No Yes No 
DISC1 rs7552697 4 ND Yes Yes No No Yes No 
DISC1 rs12757857 6 ND Yes Yes No No Yes Yes 
DISC1 rs3082 4 Yes No Yes Yes No Yes Yes 
DISC1 rs1407601 3a ND No Yes No No Yes Yes 
DISC1 rs2356606 5 ND No Yes No No Yes Yes 
DISC1 rs4658889 6 ND Yes Yes No Yes Yes No 
DISC1 rs9431714 4 ND No Yes No No Yes Yes 
DISC1 rs821722 4 ND Yes Yes No No Yes Yes 
DISC1 rs7541019 6 ND Yes Yes No No Yes No 
DISC1 rs11584798 3a ND No Yes No No Yes Yes 
DISC1 rs701158 2b ND Yes Yes No No Yes Yes 
DISC1 rs701160 1f ND No Yes No No Yes Yes 
DISC1 rs821615 ND ND Yes Yes No No Yes Yes 
DISC1 rs821616 5 ND No Yes Yes No Yes No 
DISC1 rs821631 5 ND Yes Yes No No Yes Yes 
DISC1 rs821639 5 ND No Yes No No Yes No 
DISC1 rs9729194 6 ND Yes Yes No No Yes Yes 
DISC1 rs11122396 3a ND No Yes Yes No Yes No 
DISC1 rs16856322 ND ND No Yes Yes No Yes Yes 
DRD2 rs1800497 4 ND No Yes No No Yes No 
DRD2 rs6278 5 Yes No Yes Yes No Yes No 
DRD2 rs6277 5 ND No Yes No No Yes No 
DRD2 rs6275 5 ND No Yes No No Yes Yes 
DRD2 rs1076560 5 ND Yes Yes No No Yes No 
DRD2 rs12363125 1c ND No Yes No No Yes Yes 
DRD2 rs1800498 5 ND No Yes Yes No Yes No 
DRD2 rs1079597 5 ND No Yes Yes No Yes No 
DRD2 rs2471857 1f ND No Yes Yes Yes Yes Yes 
DRD2 rs4436578 5 ND Yes Yes No No Yes Yes 
DRD2 rs4245146 2b ND No Yes No No Yes No 
DRD2 rs7131056 ND ND No Yes No No Yes Yes 
DRD2 rs4630328 5 ND Yes Yes No No Yes No 
DRD2 rs1799978 5 ND No Yes Yes No No No 
DRD2 rs2514218 6 ND Yes No No No No Yes 
DRD3 rs167771 5 ND No Yes No No Yes No 
DRD3 rs6280 5 ND No Yes No No Yes No 
DRD3 rs9825563 6 ND Yes Yes Yes No No Yes 
DRD3 rs1394016 6 ND Yes No No No No Yes 
DTNBP1 rs1047631 1d Yes No Yes Yes No No Yes 
DTNBP1  rs4712253 2b ND No No No No No Yes 
DTNBP1 rs2619522 6 ND Yes Yes No Yes No No 
DTNBP1 rs2619536 ND ND Yes Yes Yes Yes No No 
IL1RN  rs315920 ND ND Yes Yes Yes No No Yes 
IL1RN  rs423904 3a ND Yes No No No No No 
IL1RN  rs3087266 2c ND Yes No No No No Yes 
IL1RN  rs315952 ND ND No No No No No Yes 
NRG1 rs35753505 6 ND Yes No No No No No 
NRG1 rs6994992 5 ND No Yes Yes No No No 
NRG1 rs28401439 5 ND Yes Yes Yes No No No 
NRG1 rs6987996 6 ND Yes Yes No No Yes Yes 
NRG1 rs4733094 6 ND Yes Yes No No Yes Yes 
NRG1 rs16878394 5 ND Yes Yes No No Yes Yes 
NRG1 rs796549 ND ND Yes Yes No No Yes Yes 
NRG1 rs7002063 5 ND Yes Yes No No Yes Yes 
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NRG1 rs2010243 6 ND Yes Yes No No Yes Yes 
NRG1 rs1462900 6 ND Yes Yes No No Yes Yes 
NRG1 rs1381874 6 ND Yes Yes No No Yes Yes 
NRG1 rs7841220 6 ND Yes Yes No No Yes No 
NRG1 rs10503899 ND ND Yes Yes No No Yes No 
NRG1 rs11776959 6 ND Yes Yes No No Yes Yes 
NRG1 rs10503901 2b ND Yes Yes No No Yes No 
NRG1 rs1481728 ND ND Yes Yes No No Yes Yes 
NRG1 rs4733313 5 ND Yes Yes No No Yes Yes 
NRG1 rs900102 6 ND Yes Yes No No Yes Yes 
NRG1 rs16879067 5 ND Yes Yes No No Yes No 
NRG1 rs17624592 2b ND No Yes No No Yes No 
NRG1 rs11778887 6 ND Yes Yes No No Yes Yes 
NRG1 rs7005124 3a ND No Yes No No Yes No 
NRG1 rs1685117 5 ND Yes Yes No No Yes No 
NRG1 rs7841599 5 ND Yes Yes No No Yes No 
NRG1 rs970998 2b ND No Yes No No Yes Yes 
NRG1 rs1565031 4 ND Yes Yes No No Yes No 
NRG1 rs1623372 1d ND Yes Yes No No Yes Yes 
NRG1 rs16879304 2b ND No Yes No No Yes Yes 
NRG1 rs939077 5 ND Yes Yes No No Yes No 
NRG1 rs4733325 ND ND Yes Yes No No Yes No 
NRG1 rs3847131 6 ND Yes Yes No No Yes No 
NRG1 rs9297192 6 ND Yes Yes No No Yes Yes 
NRG1 rs17716295 6 ND No Yes No No Yes No 
NRG1 rs12216802 1f ND No Yes No No Yes Yes 
NRG1 rs17645417 3b ND No Yes No No Yes No 
NRG1 rs7844425 1f ND No Yes No No Yes Yes 
NRG1 rs4733347 5 ND Yes Yes No No Yes No 
NRG1 rs4733130 2b ND No Yes No No Yes No 
NRG1 rs2439312 1f ND No Yes No No Yes Yes 
NRG1 rs17721043 1f ND No Yes No No Yes Yes 
NRG1 rs2439292 1f ND No Yes No No Yes Yes 
NRG1 rs3924999 ND ND Yes Yes No No Yes No 
NRG1 rs2919370 5 ND Yes Yes No No Yes Yes 
NRG1 rs2466049 5 ND Yes Yes No No Yes Yes 
NRG1 rs2919392 2c ND No Yes No No Yes No 
NRG1 rs2919390 6 ND Yes Yes No No Yes Yes 
NRG1 rs2976532 ND ND Yes Yes No No Yes Yes 
NRG1 rs73672607 6 ND No Yes Yes No Yes No 
OXTR rs237884 ND Yes No Yes Yes No Yes No 
OXTR rs237885 6 ND Yes Yes No No Yes No 
OXTR rs11706648 5 ND No Yes No No Yes No 
OXTR rs237888 3a ND No Yes No No Yes Yes 
OXTR rs4686301 5 ND No Yes No No Yes No 
OXTR rs237889 1f ND No Yes No Yes Yes No 
OXTR rs2268495 2b ND No Yes No No Yes Yes 
OXTR rs237899 5 ND No Yes Yes No Yes No 
OXTR rs4686302 4 ND No Yes Yes Yes Yes Yes 
RGS4 rs951439 3a ND No Yes Yes No No No 
RGS4 rs2661319 4 ND No Yes Yes No Yes Yes 
RGS4 rs10759 5 ND No Yes Yes No Yes Yes 
TNF-α rs1800629 1d ND Yes No No No No Yes 
TNF-α rs1800630 2b ND No No No No No Yes 
ZNF804A rs1344706 ND ND No Yes No No Yes Yes 
ZNF804A rs12476147 ND ND No Yes No No Yes Yes 
ZNF804A rs4667001 5 ND No Yes No No Yes No 
ZNF804A rs1366842 5 ND No Yes No No Yes Yes 
ZNF804A rs12477430 5 ND Yes Yes No No Yes No 
ND = Not determined; rSNP = Regulatory single nucleotide polymorphism; Proximal = Proximal regulation; Distal = Distal regulation; 
RNA BP mediated = RNA binding protein mediated regulation; eQTL = Expression quantitative trait loci; Yes = Involved in regulatory 
category; No = Not involved in regulatory category. 
Results coloured in blue fulfilled the defined criteria for prioritisation. 
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Tables S7a – e. Linkage disequilibrium (LD) plots for genes where two or more variants in LD with one another (as defined by D’ > 0.8) were significantly 
associated with antipsychotic treatment response. 
 
Table S7a. LD plot showing D’ values between all variants in NRG1 that were significantly associated with antipsychotic treatment response in this 
study.   












































































































































rs6987996 . 0.8282 0.1003 0.0017 0.0424 0.1195 0.0950 0.1885 0.4429 0.0687 0.0934 0.0459 0.1295 0.4763 0.1498 
rs4733094 . . 0.9984 0.3509 0.3627 0.2188 0.3809 0.1511 0.9973 0.4014 0.1637 0.1251 0.2112 0.9959 0.4078 
rs796549 . . . 0.3133 0.0719 0.9983 0.6249 0.3717 0.3416 0.2102 0.0066 0.4090 0.5633 0.1409 0.0726 
rs10503901 . . . . 0.2437 0.3195 0.4338 0.6799 0.0020 0.1459 0.0113 0.7161 0.6848 0.4870 0.1658 
rs1481728 . . . . . 0.7039 0.7249 0.6584 0.0486 0.0893 0.1610 0.1911 0.5000 0.1079 0.1879 
rs16879067 . . . . . . 0.8076 0.6213 0.9981 0.2803 0.0851 0.0281 0.1630 0.2183 0.2125 
rs11778887 . . . . . . . 0.4603 0.9977 0.3160 0.2282 0.1779 0.2468 0.7679 0.3177 
rs7005124 . . . . . . . . 0.9983 0.0101 0.1585 0.2566 0.1180 0.1792 0.1910 
rs16879304 . . . . . . . . . 0.4975 0.0744 0.6742 0.8956 0.0826 0.0049 
rs3847131 . . . . . . . . . . 0.3790 0.3348 0.4310 0.1745 0.0080 
rs17645417 . . . . . . . . . . . 0.8415 0.2137 0.4660 0.0191 
rs2439312 . . . . . . . . . . . . 0.2621 0.6841 0.0704 
rs3924999 . . . . . . . . . . . . . 0.9979 0.1465 
rs2466049 . . . . . . . . . . . . . . 0.7987 
rs2919392 . . . . . . . . . . . . . . . 
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Table S7b. LD plot showing D’ values between all variants in COMT that were prioritised for investigation in this study.   
Variants in bold typeset were significantly associated with antipsychotic treatment response in this study.  






























































































































































rs9606186 . 0.9755 0.9991 0.9991 0.9991 0.8433 0.8313 0.8591 0.5868 0.3451 0.4180 0.2383 0.3430 0.3528 0.4250 0.3809 0.6386 0.2806 0.7194 0.3072 
rs2075507 . . 0.9991 0.9991 0.9991 0.9444 0.9399 0.9245 0.6626 0.3130 0.3881 0.2440 0.3486 0.4071 0.3357 0.3787 0.5500 0.2517 0.6532 0.3049 
rs2020917 . . . 0.964 0.964 0.9993 0.9993 0.7909 0.6188 0.5710 0.4949 0.4823 0.5125 0.6747 0.6361 0.7820 0.4918 0.0750 0.0222 0.0523 
rs737866 . . . . 0.9996 0.9347 0.9212 0.8143 0.5369 0.6999 0.4936 0.4856 0.5739 0.7008 0.6759 0.8044 0.2126 0.0660 0.0043 0.0438 
rs737865 . . . . . 0.9347 0.9212 0.8143 0.5369 0.6999 0.4936 0.4856 0.5739 0.7008 0.6759 0.8044 0.2126 0.0660 0.0043 0.0438 
rs933271 . . . . . . 0.9855 0.4608 0.0229 0.0503 0.0225 0.4574 0.0155 0.5188 0.8768 0.0216 0.4358 0.3509 0.1553 0.3090 
rs174674 . . . . . . . 0.5449 0.0700 0.0173 0.0125 0.4446 0.0689 0.4809 0.8487 0.0553 0.2886 0.3305 0.1249 0.2848 
rs5993883 . . . . . . . . 0.5908 0.0403 0.0933 0.2598 0.1187 0.2504 0.1341 0.1463 0.6987 0.2423 0.2710 0.2098 
rs740603 . . . . . . . . . 0.3475 0.3170 0.3039 0.3370 0.3829 0.4976 0.3625 0.6425 0.1812 0.2317 0.2029 
rs165656 . . . . . . . . . . 0.8044 0.5460 0.9513 0.6060 0.9994 0.9997 0.8617 0.3203 0.8848 0.3495 
rs165722 . . . . . . . . . . . 0.9997 0.9481 0.8145 0.7976 0.9997 0.7200 0.3213 0.6711 0.3514 
rs6269 . . . . . . . . . . . . 0.9996 0.9998 0.6807 0.9996 0.9987 0.1327 0.2887 0.1706 
rs4633 . . . . . . . . . . . . . 0.9996 0.8621 0.9997 0.8277 0.3551 0.9988 0.3848 
rs2239393 . . . . . . . . . . . . . . 0.9063 0.9995 0.6375 0.1157 0.2164 0.1464 
rs4818 . . . . . . . . . . . . . . . 0.9992 0.4284 0.1594 0.0001 0.1061 
rs4680 . . . . . . . . . . . . . . . . 0.7859 0.3608 0.9987 0.4158 
rs174697 . . . . . . . . . . . . . . . . . 0.9989 0.5269 0.9990 
rs165599 . . . . . . . . . . . . . . . . . . 0.9988 0.9997 
rs165728 . . . . . . . . . . . . . . . . . . . 0.9989 
rs9265 . . . . . . . . . . . . . . . . . . . . 
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Table S7c. LD plot showing D’ values between all variants in DRD3 that were prioritised for 













Variants in bold typeset were significantly associated with antipsychotic treatment response in this study.  
D’ values > 0.8 are highlighted in red, indicating that the corresponding variants are in pairwise LD. 
 
 
Table S7d. LD plot showing D’ values between all variants in OXTR that were prioritised for 














































































rs237884 . 0.1777 0.7275 0.8425 0.6912 0.6636 0.0471 0.3027 0.2941 
rs237885 . . 0.9994 0.5329 0.9196 0.8174 0.0906 0.1388 0.0239 
rs11706648 . . . 0.8231 0.9664 0.9990 0.0693 0.1068 0.3374 
rs237888 . . . . 0.9991 0.8332 0.1065 0.7739 0.3359 
rs4686301 . . . . . 0.9980 0.0330 0.1172 0.2344 
rs237889 . . . . . . 0.0658 0.2513 0.0741 
rs2268495 . . . . . . . 0.9993 0.9383 
rs237899 . . . . . . . . 0.9984 
rs4686302 . . . . . . . . . 
Variants in bold typeset were significantly associated with antipsychotic treatment response in this study.  
D’ values > 0.8 are highlighted in red, indicating that the corresponding variants are in pairwise LD. 
 
 
Table S7e. LD plot showing D’ values between all variants in DISC1 that were significantly associated 














































rs2487453 . 0.433 0.4241 0.1173 0.1889 
rs7552697 . . 0.9994 0.2695 0.2365 
rs12757857 . . . 0.9988 0.1986 
rs1407601 . . . . 0.3036 
rs701160 . . . . . 




































rs167771 . 0.708 0.4888 0.9697 
rs6280 . . 0.9069 0.9998 
rs9825563 . . . 0.9997 
rs1394016 . . . . 
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